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  Autosomal	  dominant	  polycystic	  kidney	  disease	  AHI1	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Abelson	  helper	  integration	  site	  1	  ANOVA	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Analysis	  of	  variance	  APC	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Adenomatous	  polyposis	  coli,	  Anaphase	  promoting	  complex	  ARL	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ADP-­‐ribosylation	  factor	  (ARF)-­‐like	  ARPKD	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Autosomal	  recessive	  polycystic	  kidney	  disease	  ATCC	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  American	  type	  culture	  collection	  ATP	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Adenosine	  triphosphate	  AURKA	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Aurora	  kinase	  A	  BBS	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Bardet-­‐Biedl	  syndrome	  BCC	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Basal	  cell	  carcinoma	  BHD	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Birt-­‐Hogg-­‐Dube	  syndrome	  	  BrdU	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Bromodeoxyuridine	  BSA	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Bovine	  serum	  albumin	  CALK	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chlamydomonas	  aurora-­‐like	  protein	  kinase	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  Clear	  cell	  renal	  cell	  carcinoma	  cdc20	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cell	  division	  cycle	  20	  CDK	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cyclin-­‐dependent	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  DAMP	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  DAPI	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  Dynein	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  sorting	  FAP	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  and	  WD	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  7	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  Fetal	  calf	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  FGF	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fibroblast	  growth	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  FGFR	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fibroblast	  growth	  factor	  receptor	  FLCN	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Folliculin	  FNIP	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Folliculin	  interacting	  proteins	  FOXJ1	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Forkhead	  box	  J1	  Gli	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  GPCR	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  G	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  GPS	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  synthase	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  3	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  deacetylase	  6	  HEF1	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Human	  enhancer	  of	  filamentation	  1	  	  hESC	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Human	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  stem	  cells	  HSP	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Heat	  shock	  protein	  IFT	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Intra	  flagellar	  transport	  IGF-­‐1R	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Insulin-­‐like	  growth	  factor	  1	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  INPP5E	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Inositol	  polyphosphate-­‐5-­‐phosphatase	  E	  JBTS	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Joubert	  syndrome	  KCTD17	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Potassium	  channel	  tetramerization	  domain	  containing	  17	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1.1.	  CILIA	  Cilia	   are	   microscopic	   hair-­‐like	   organelles	   present	   on	   the	   surface	   of	   most	   mammalian	  cells.	  These	  microtubule-­‐based	  structures	  form	  flexible	  extensions	  of	  the	  cell	  membrane	  and	  play	  a	  vital	  role	  in	  the	  development,	  and	  normal	  functioning	  of	  humans	  and	  animals.	  Cells	  may	  possess	  multiple	   cilia	   or	   a	   single	   cilium	  on	   their	   surface.	  Dysfunction	  of	   the	  cilium	  is	  associated	  with	  many	  different	  pathologies.	  	  	  
1.1.1.	  Types	  of	  Cilia	  There	  are	  several	  kinds	  of	  cilia	  that	  play	  different	  roles	  in	  biological	  processes.	  They	  can	  be	  broadly	  classified	  into	  three	  categories	  -­‐	  motile,	  primary	  and	  nodal	  cilia.	  	  	  
1.1.1.1.	  Motile	  cilia	  are	  generally	  found	  on	  airway	  epithelia,	  cells	  lining	  the	  oviduct	  and	  ependymal	  cells	  in	  the	  brain	  [1].	  Usually,	  these	  cells	  are	  multi-­‐ciliated.	  These	  kind	  of	  cilia	  are	   mechanical	   in	   function	   and	   move	   in	   an	   organized	   wave-­‐like	   pattern,	   which	   is	  necessary	  for	  fluid	  flow	  such	  as	  clearance	  of	  mucus	  in	  the	  lungs,	  movement	  of	  oocytes,	  movement	  of	  cerebrospinal	  fluid	  in	  the	  brain,	  etc.	  [2,	  3].	  	  
1.1.1.2.	  Primary	   cilia	  are	  immotile	  and	  exist	  as	  monocilia	  on	  most	  cells	  of	  the	  human	  body	  [4].	  They	  play	  a	  sensory	  role	  and	  enable	  the	  cells	  to	  communicate	  and	  interact	  with	  the	  surrounding	  environment	  by	  capturing	  and	  transducing	  various	  extracellular	  signals	  like	  chemical,	  mechanical	  and	  visual	  stimuli	  [5].	  Recent	  findings	  show	  that	  primary	  cilia	  play	  an	  important	  role	  in	  a	  number	  of	  signaling	  cascades	  including	  hedgehog,	  wnt,	  and	  PDGFR-­‐α	  [6-­‐9].	  	  
1.1.1.3.	  Nodal	  cilia	  are	  found	  on	  the	  embryonic	  node	  during	  development.	  These	  are	  a	  type	  of	  primary	  cilia	  that	  have	  the	  ability	  to	  move	  with	  rotational	  motion	  along	  a	  vertical	  axis	   in	   a	   propeller-­‐like	   fashion.	   This	   motion	   is	   thought	   to	   aid	   the	   movement	   of	  morphogens	   in	   the	   developing	   tissue.	   Nodal	   cilia	   have	   been	   implicated	   in	   the	  specification	  of	  left-­‐right	  asymmetry	  of	  the	  body	  axis	  [10-­‐12].	  	  
1.1.2.	   Evolution	   of	   cilia:	   sensory	   or	   motile	   cilia,	   which	   came	   first?	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Several	  interesting	  hypotheses	  were	  formulated	  in	  the	  past	  to	  explain	  the	  evolutionary	  origin	   of	   cilium.	   Being	   ancient	   organelles	   present	   in	   almost	   all	   eukaryotes,	   it	   is	   very	  likely	  that	  they	  were	  present	  on	  the	  last	  common	  eukaryotic	  ancestor.	  It	  is	  believed	  that	  the	   cilium	   has	   evolved	   by	   adaptation	   of	   existing	   structures	   that	   are	   involved	   in	  microtubule	   organization	   and	  membrane	   trafficking	   [13-­‐15].	   In	   view	  of	   the	   seemingly	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disparate	   functions	   of	   sensory	   and	  motile	   cilia,	   attempts	   have	   been	  made	   recently	   to	  understand	   the	   evolutionary	   history.	   Despite	   the	   likelihood	   that	   ancestral	   cilium	   did	  have	  sensory	  functions,	  it	  is	  not	  yet	  clear	  whether	  this	  sensory	  function	  emerged	  before,	  or	   after,	   the	   acquisition	   of	   motile	   function.	   Peering	   back	   in	   time,	   it	   appears	   that	   the	  precursor	   of	   ancestral	   cilium	   might	   have	   been	   a	   sensory	   patch	   on	   the	   surface	   of	   a	  polarized	   cell	   that	   ultimately	   extrapolated	   into	   an	   antenna-­‐like	   structure	   that	   was	  efficient	  in	  further	  concentrating	  receptors	  and	  signaling	  components	  (Figure	  1.1).	  The	  apparatus	  necessary	  for	  motility	  is	  likely	  to	  have	  developed	  later	  with	  the	  appearance	  of	  a	  proto-­‐cilium	  [15,	  16].	  It	  is	  believed	  that	  the	  nine-­‐fold	  symmetry	  of	  the	  basal	  body	  and	  axoneme	   evolved	   to	   confer	   motility	   to	   the	   cilium.	   The	   ancestral	   cilium,	   was	   thus	  endowed	  with	  both	  sensory	  and	  motile	  functions.	  Only	  a	  few	  eukaryotic	  lineages	  derived	  from	  the	  ancestral	  eukaryote	  have	  lost	  cilia	  altogether,	  whereas	  motility	  has	  been	  lost	  in	  a	  diverse	  set	  of	  metazoan	  cell-­‐types.	  	  
1.1.3.	  Structure	  of	  the	  cilium	  The	   cilium	   is	   a	   highly	   conserved	   organelle	   that	   consists	   of	   a	   microtubule-­‐based	  axoneme,	  which	  is	  surrounded	  by	  a	  specialized	  membrane	  called	  the	  ciliary	  membrane.	  The	  axoneme	  emerges	  from	  a	  basal	  body,	  which	  is	  essentially	  a	  modified	  centriole.	  The	  	  inner	  space	  of	  the	  cilium	  is	  separated	  from	  the	  cytosol	  by	  the	  transition	  zone.	  Figure1.2	  represents	  the	  basic	  structure	  of	  a	  primary	  cilium.	  
FIGURE	   1.1.	   Possible	   evolutionary	   path	   explaining	   the	   emergence	   of	   the	   ancestral	   ciliated	  
eukaryote,	   and	   subsequent	   cilium-­‐centric	   events	   leading	   to	   extant	   organisms.	   Cells	   are	   shown	  with	   a	  microtubule	   organizing	   centre	   from	   which	  microtubules	   (gray)	   emanate,	   or	   in	   the	   ancestral	  eukaryote	   as	   a	   basal	   body	   from	   which	   a	   ciliary	   axoneme	   emanates.	   The	   microtubule-­‐dependent	  clustering	  of	  sensory	  molecules	  (red)	  was	  likely	  the	  first	  step	  before	  the	  appearance	  of	  a	  proto-­‐cilium	  with	   an	   even	   more	   concentrated	   sensory-­‐signalling	   environment.	   The	   apparatus	   used	   to	   confer	  motility,	   shown	  as	  blue	  decorations	  on	   the	  microtubules/axoneme,	   likely	  evolved	  early	   in	   the	  proto-­‐cilium.	  Both	  ciliary	  motility	  and	  sensory	  functions	  undoubtedly	  conferred	  a	  strong	  selective	  advantage	  to	  the	  ancestral	  eukaryote,	  such	  that	  all	  extant	  eukaryotes	  are	  derived	  from	  it.	  Only	  a	   few	  eukaryotic	  lineages	   have	   lost	   cilia	   altogether,	   whereas	  motility	   has	   been	   lost	   in	   numerous	  metazoan	   cell	   types.	  (Figure	  taken	  from	  [16]).	  




















1.1.3.1.	  Axoneme:	  The	  ciliary	  axoneme	  contains	  a	  cytoskeleton	  of	  microtubule	  doublets	  arranged	   in	   the	   form	   a	   ring.	   The	   ring	   may	   have	   a	   9+0	   or	   9+2	   arrangement	   of	  microtubules	   (Figure	   1.2).	   Motile	   cilia	   display	   the	   9+2	   arrangement	   in	   which	   nine	  microtubule	  doublets	  surround	  a	  central	  pair	  of	  microtubule	  singlets.	  Primary	  cilia	  have	  a	  9+0	  arrangement,	  which	   lacks	   the	   central	  pair	  of	  microtubules.	  Historically,	   the	  9+0	  configuration	   is	   associated	   with	   cilia	   having	   sensory	   function	   whereas	   the	   9+2	  configuration	  is	  associated	  with	  motility.	  Several	  studies	  suggest	  that	  post-­‐translational	  modifications	  (PTMs)	  of	  axonemal	  components	  are	  important	  for	  the	  assembly,	  stability	  and	  function	  of	  the	  cilium.	  Enzymes	  that	  interfere	  with	  PTMs	  of	  axonemal	  components	  are	   known	   to	   either	   promote	   disassembly	   or	   cause	   a	   delay	   in	   the	   assembly	   of	   the	  primary	  cilium	  [17-­‐19].	  Tubulin,	  the	  main	  component	  of	  microtubules	  has	  been	  shown	  
FIGURE	  1.2.	  Structure	  of	  the	  cilium:	  The	  cilium	  is	  a	  hair-­‐like	  structure	  that	  protrudes	  from	  the	  cell	  surface.	   Microtubules	   form	   the	   core	   structure	   of	   the	   cilium,	   the	   axoneme,	  which	   is	   covered	   by	   a	  ciliary	  membrane.	  The	  basal	  body	  anchors	  the	  axoneme	  to	  the	  rest	  of	  the	  cell.	  Near	  the	  base	  of	  the	  cilium	  is	  the	  transition	  zone,	  which	  allows	  selective	  access	  to	  only	  those	  proteins	  that	  are	  destined	  to	  the	  cilium.	  Protein	  cargo	  is	  transported	  up	  and	  down	  the	  cilium	  via	  anterograde	  and	  retrograde	  IFT	  mediated	  by	  kinesin	  and	  dynein	  motor	  proteins,	  respectively,	  which	  travel	  along	  the	  axoneme.	  Right	  hand	  side	  of	  the	  figure	  shows	  two	  distinct	  types	  of	  cilium.	  '9+0'	  cilia,	  also	  known	  as	  primary	  cilia	  or	  monocilia,	   contain	  a	   ring	  of	  nine	  peripheral	   doublets	  of	  microtubules	  but	   lack	   the	   central	  pair,	  whereas	   '9+2'	   cilia,	   also	   known	   as	  motile	   cilia,	   contain	   the	   central	   pair.	   (Figure	   taken	   from	  [115]	  &	  [182]).	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to	  be	  acetylated	  [20],	  detyrosinated	  [21],	  polyglutamylated	  [22]	  and	  polyglycylated	  [23].	  It	   is	   possible	   that	   such	   PTMs	   are	   required	   for	   the	   binding	   of	   specific	   proteins	   that	  interact	  with	  microtubules	  to	  control	  critical	  steps	  in	  the	  cilium	  building	  process	  [24].	  	  
1.1.3.2.	   Basal	   Body:	   The	   basal	   body	   connects	   the	   axoneme	   to	   the	   rest	   of	   the	   cell.	   It	  functions	  as	  a	  microtubule-­‐organizing	  center	  (MTOC),	  which	  anchors	   the	  microtubules	  from	  which	  the	  axoneme	  is	  templated.	  The	  basal	  body	  is	  essentially	  a	  modified	  centriole	  that	   differs	   from	   a	   centriole	   by	   the	   addition	   of	   three	   accessory	   structures	   namely,	  striatal	  rootlets	  [25],	  basal	  feet	  and	  transition	  fibers	  [26].	  The	  rootlets	  extend	  from	  the	  basal	   body	   into	   the	   cytoplasm	   [27]	   and	   are	   essential	   for	   the	   structural	   integrity	   and	  long-­‐term	  survival	  of	  the	  primary	  cilium	  [28].	  Basal	  feet	  emerge	  laterally	  from	  the	  side	  of	   basal	   body	   and	   stabilize	   the	  microtubules	   [29].	   Under	   the	   regulation	   of	   planar	   cell	  polarity	   (PCP)	   proteins,	   the	   basal	   feet	   also	   control	   the	   polarization	   of	   the	   cilium	   [30].	  The	   distal	   appendages	   of	   the	   mother	   centriole	   give	   rise	   to	   transition	   fibres,	   whose	  primary	  role	   is	   to	  anchor	  the	  basal	  body	  to	  the	  ciliary	  membrane	  at	   the	  ciliary	  pocket.	  However,	  recent	  studies	  have	  shown	  that	  transition	  fibres	  are	  also	  required	  for	  docking	  intraflagellar	  transport	  (IFT)	  particles	  [31].	  Other	  proteins	  such	  as	  septin	  2	  (SEPT2)	  are	  also	   known	   to	   be	   targeted	   to	   transition	   fibres	   [32].	   Overall,	   the	   basal	   body	   acts	   as	   an	  interface	  between	  the	  primary	  cilium	  and	  the	  cell	  body.	  It	  also	  provides	  a	  docking	  area	  for	   a	   large	   number	   of	   proteins,	   which	   can	   have	   a	   positive	   or	   negative	   effect	   on	   cilia	  formation	   and	   maintenance	   [33].	   The	   basal	   body	   therefore,	   plays	   a	   key	   role	   in	   the	  assembly	  and	  disassembly	  of	  the	  primary	  cilium.	  	  
1.1.3.3.	   Ciliary	   Membrane:	   The	   ciliary	   cytoskeleton	   is	   enveloped	   by	   a	   ciliary	  membrane,	  which	  is	  continuous	  with	  the	  surrounding	  plasma	  membrane	  but	  distinct	  in	  overall	   composition.	   In	   comparison	   to	   the	  plasma	  membrane,	   the	   ciliary	  membrane	   is	  enriched	   in	   sterols,	   sphingolipids	   and	   glycolipids.	   It	   is	   more	   complex	   and	   specialized	  than	   the	   plasma	  membrane	   [34]	   also	   in	   the	   sense	   that	   it	   has	   a	   high	   concentration	   of	  specific	  receptor	  proteins	  and	  channels	  on	  its	  surface,	  which	  are	  vital	  for	  the	  detection	  of	  particular	   environmental	   signals	   [35].	   A	   large	   number	   of	   membrane	   receptors	   and	  proteins	   including	   morphogenic	   receptors	   like	   Patched1	   (Ptc1),	   mechanosensory	  receptors	   like	   PKD1	   and	   PKD2,	   receptors	   for	   growth	   factors,	   calcium	   channels,	  polycystins	  etc.	  have	  been	  shown	  to	  be	  localized	  to	  the	  ciliary	  membrane	  [34].	  In	  most	  cases,	  the	  functionality	  of	  these	  receptors	  is	  dependent	  on	  their	  localization	  to	  the	  ciliary	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membrane	   [7,	   9,	   36].	   Unraveling	   the	   molecular	   mechanisms	   that	   choreograph	   the	  movement	   of	   these	   receptors	   and	   channels	   to	   the	   ciliary	   membrane	   is	   critical	   to	  understanding	   the	   role	  of	   cilia-­‐generated	   signaling	   in	  health	   and	  disease.	  Discovery	  of	  small	  molecules	  that	  can	  inhibit	  or	  induce	  the	  targeting	  of	  clinically	  significant	  proteins	  to	   the	   ciliary	  membrane	   is	   gaining	   ground	   as	   the	   next	   focus	   of	   translational	   research	  involving	  the	  primary	  cilium.	  	  
1.1.3.4.	   Transition	   Zone:	  At	   the	   base	   of	   ciliary	   axoneme	   is	   a	   region	   called	   transition	  zone	   (TZ),	  where	   the	   triplet	  microtubule	  structure	  of	   the	  basal	  body	  converts	   into	   the	  axonemal	  doublet	  microtubule	  structure.	  The	  TZ	  contains	  Y-­‐shaped	  links,	  which	  connect	  the	  outer	  microtubule	  doublets	  of	  the	  axoneme	  to	  the	  ciliary	  membrane	  [37,	  38].	  The	  TZ	  allows	  only	   a	   subset	   of	   cellular	  proteins	   to	   enter	   the	   cilium.	  Thus,	   it	   forms	  a	   selective	  functional	  barrier	  near	  the	  base	  of	  the	  cilium	  that	  separates	  the	  ciliary	  membrane	  from	  rest	  of	  the	  cell	  membrane	  [34].	  This	  diffusion	  barrier	  is	  composed	  of	  two	  distinct	  regions	  called	   the	  ciliary	  necklace	  and	   the	  ciliary	  pocket.	  Visualization	  by	  electron	  microscopy	  revealed	   that	   the	   ciliary	   necklace	   is	   composed	   of	   several	   parallel	   strands	   of	  intramembrane	  particles	  that	  connect	  the	  proximal	  end	  of	  the	  ciliary	  membrane	  to	  the	  basal	  body	  [39].	  It	  acts	  as	  a	  nuclear	  membrane	  and	  controls	  the	  entry	  or	  exit	  of	  proteins	  to	  or	  from	  the	  ciliary	  axoneme.	  Ciliary	  pocket	  appears	  as	  an	  invagination	  of	  the	  plasma	  membrane	  at	   the	   ciliary	  base	   [40].	   It	   is	   considered	  as	   a	   rate-­‐limiting	   structure	   for	   the	  trafficking	   of	   cilia-­‐related	   proteins	   [41].	   All	   proteins	   that	   enter	   the	   cilium	   must	   pass	  through	   this	   diffusion	   barrier,	   which	   results	   in	   the	   compartmentalization	   of	   ciliary	  signaling	  proteins	  [32,	  37],	  a	  vital	  requirement	  for	  the	  sensory	  function	  of	  the	  primary	  cilium.	   The	  mechanism	  of	   action	   of	   TZ-­‐associated	   proteins	   is	   largely	   unclear	   although	  several	   of	   them	   are	   known	   to	   contain	   membrane-­‐associated	   domains,	   which	   is	  consistent	  with	  their	  role	  as	  a	  diffusion	  barrier	  [37,	  42,	  43].	  
	  
1.1.4.	  Formation	  of	  the	  cilium	  	  Cilia	  are	  post-­‐mitotic	  structures	  that	  are	  typically	  formed	  during	  the	  G0	  phase	  of	  the	  cell	  cycle.	   They	   arise	   only	   from	   the	   mother	   centriole,	   as	   the	   daughter	   centriole	   is	   still	  immature	  [44].	  The	  mother	  centriole	  can	  be	  distinguished	  from	  the	  daughter	  centriole	  	  by	   the	   presence	   of	   distinct	   appendages.	   The	   currently	   accepted	   model	   of	   cilium	  formation	   is	   derived	   from	   electron	   microscopic	   analysis	   of	   organ	   cultures	   and	  fibroblasts	   [45].	   The	   steps	   proposed	   in	   ciliogenesis	   are	   illustrated	   in	   Figure	   1.3.	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Formation	   of	   the	   cilium	   begins	   when	   a	   Golgi-­‐derived	   vesicle	   docks	   near	   the	   distal	  appendages	   of	   the	   mother	   centriole	   migrating	   towards	   the	   apical	   plasma	   membrane	  [46].	  The	  docking	  is	  mediated	  by	  transition	  fibres,	  which	  are	  accessory	  structures	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  derived	   from	  the	  distal	  appendages	  of	   the	  mother	  centriole	   to	  offer	  structural	  support	  [31,	  47].	  The	  mother	  centriole	  converts	  into	  a	  basal	  body	  from	  which	  a	  bud	  emerges	  to	  bend	   the	   membrane	   of	   the	   vesicle	   [48].	   The	   bud	   elongates	   from	   the	   tip	   as	   newly	  assembled	  microtubule	  doublets	  emerge	  from	  the	  basal	  body	  to	  allow	  the	  formation	  of	  an	   axoneme	   [49].	   The	   base	   of	   the	   bud	   becomes	   the	   transition	   zone	   where	   the	   nine	  microtubule	   triplets	   become	   doublets	   and	   each	   doublet	   is	   connected	   to	   the	   ciliary	  membrane	   through	  Y-­‐links	   to	   form	  a	  ciliary	  necklace	   [50,	  51].	  More	  vesicles	   fuse	  with	  the	   migrating	   vesicle-­‐basal	   body	   complex,	   thereby	   providing	   membrane	   material	   to	  form	   a	   sheath	   around	   the	   elongating	   axonemal	   shaft.	   Finally,	   the	   growing	   axoneme	  reaches	   the	   cell	   surface,	   allowing	   the	   membrane	   sheath	   to	   fuse	   with	   the	   plasma	  membrane,	   exposing	   the	   cilium	   to	   extracellular	   space	   [34,	   52].	   The	   newly	   formed	  axoneme	  elongates	  further	  till	  it	  reaches	  a	  stable	  length	  [53].	  	  
FIGURE	  1.3.	  Ciliogenesis:	  Cilium	  formation	  starts	  when	  a	  mother	  centriole	  contacts	  a	  ciliary	  vesicle.	  Axonemes	  elongate	  at	  their	  tips	  and	  so	  are	  constructed	  from	  proximal	  to	  distal,	  with	  the	  most	  proximal	  region	  giving	  rise	  to	  the	  transition	  zone.	  The	  ciliary	  vesicle	  grows	  with	  the	  axoneme	   and	   gives	   rise	   to	   the	   ciliary	   sheath,	   whose	   fusion	   with	   the	   plasma	   membrane	  externalizes	   the	   cilium	   and	   transforms	   the	   outer	   sheath	   into	   the	   periciliary	   membrane.	  (figure	  taken	  from	  [49]).	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1.1.5.	  Regulation	  of	  the	  cilium	  	  
1.1.5.1.	   Assembly	   of	   the	   cilium:	   Since	   the	  cilium	   is	  devoid	  of	   ribosomes	  and	  protein	  biosynthetic	  machinery,	   all	   components	   required	   for	   cilia	   assembly	  are	   synthesized	   in	  the	   cell	   body	   and	   then	   transported	   to	   the	   cilium	   by	   a	   unique	   trafficking	   mechanism	  called	  Intraflagellar	  Transport	  (IFT)	  [54].	  It	  is	  responsible	  for	  the	  maintenance	  of	  ciliary	  structure	  and	  function.	  The	  IFT	  machinery	  consists	  of	  at	  least	  two	  molecular	  motors	  and	  large	   protein	   complexes	   called	   IFT	   particles.	   Microtubule	   motor	   protein	   Kinesin	   2	   is	  directed	   towards	   the	   plus-­‐end	   of	   the	   cilium	   (base-­‐to-­‐tip)	   and	   is	   essential	   for	   the	  transport	  of	  the	  protein	  cargo	  towards	  the	  ciliary	  tip	  (anterograde	  transport),	  whereas	  a	  cytoplasmic	   dyenin2	   carries	   the	   axonemal	   turn-­‐over	   products	   towards	   the	  minus-­‐end	  (tip-­‐to-­‐base)	   direction	   back	   to	   the	   cell	   body	   for	   recycling	   (retrograde	   transport)	   [55].	  Thus,	   IFT	   particles	   resemble	   constantly	   moving	   molecular	   trucks	   that	   run	   along	   the	  microtubule	   doublets	   in	   a	   closed	   loop	  within	   the	   ciliary	  membrane	   [56]	   (Figure	   1.4).	  Addition	  of	  new	  material	  to	  the	  distal	  tip	  continues	  even	  after	  the	  cilium	  reaches	  its	  final	  length.	  The	  balance	  between	  assembly	  and	  continuous	  turn-­‐over	  creates	  a	  steady	  state	  which	  maintains	  a	  fixed	  length	  [57].	  However,	  it	  is	  still	  unclear	  how	  anterograde	  kinesin	  and	  retrograde	  dynein	  motors	  are	  switched	  on	  or	  off	  when	  the	  IFT	  particles	  reach	  the	  tip.	  The	  IFT	  motility	  process	  is	  evolutionarily	  conserved	  in	  ciliated	  eukaryotes.	  The	  IFT	  particles	  consist	  of	  more	  than	  17	  highly	  conserved	  proteins,	  which	  are	  organized	  in	  two	  different	   complexes	   [58].	   Complex	  A	   is	   involved	   in	   the	   trafficking	   of	   retrograde	   cargo	  whereas	   Complex	   B	   is	   responsible	   for	   the	   transport	   of	   anterograde	   cargo	   [59].	   IFT-­‐B	  complex	   is	   composed	  of	  14	  proteins	   important	   for	   the	  biogenesis	   and	  maintenance	  of	  cilium.	   Loss	   of	   any	   component	   of	   the	   IFT-­‐B	   complex	   leads	   to	   the	   disruption	   of	   ciliary	  assembly	  [52,	  60].	  This	  observation	  is	  consistent	  with	  the	  notion	  that	  IFT-­‐B	  complex	  is	  involved	  in	  anterograde	  transport	  responsible	  for	  the	  building	  up	  of	  cilium.	  Knockdown	  or	  knockout	  of	  several	  components	  of	  IFT-­‐B	  complex	  like	  IFT88	  and	  IFT20	  can	  thus	  be	  used	  as	  a	   strategy	   to	   suppress	  ciliogenesis	  or	   ciliary	   function	   [61].	  The	   IFT-­‐A	  complex	  consists	   of	   6	   proteins	   which	   are	   not	   essential	   for	   cilium	   assembly	   [62].	   However,	  mutations	  in	  IFT-­‐A	  proteins	  result	  in	  short,	  stumpy	  cilia	  with	  abnormal	  bulges	  at	  the	  tip	  that	   are	   filled	   with	   IFT	   proteins	   [52,	   63].	   It	   has	   been	   observed	   that	   IFT	   particles	  accumulate	  at	  the	  transition	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  fibers,	   indicating	  that	  docking	  at	  the	  transition	  zone	  might	  be	  a	  critical	  regulatory	  step	  for	  the	  transport	  of	  proteins	  into	  and	  out	  of	  the	  cilium	  [31].	  Interestingly,	  several	  recent	  studies	  have	  shown	  that	  FOXJ1	  and	  RFX	  family	  of	  transcription	  factors	  that	  are	  involved	  in	  cancer,	  are	  also	  involved	  in	  the	  expression	  of	  cilia	  genes	  associated	  with	  intraflagellar	  transport	  [64,	  65].	  	  
1.1.5.2.	  Disassembly	  of	  the	  cilium:	  For	  a	  cell	  to	  proceed	  into	  mitosis,	  the	  cilium	  has	  to	  be	   dismantled	   to	   free	   the	  mother	   centriole	   required	   for	   cell	   division.	   The	   removal	   of	  cilium	   can	   occur	   by	   two	   different	   mechanisms.	   One	   of	   them	   is	   by	   a	   process	   called	  deciliation	   in	   which	   the	   cell	   sheds	   the	   cilium	   by	   katanin-­‐mediated	   cleavage	   of	   the	  complete	  cilium	  from	  the	  basal	  body	  and	  transition	  zone	  [66].	  The	  other	  mechanism	  is	  characterized	  by	  active	  resorption	  of	  cilium	  as	  a	  result	  of	  axonemal	  disassembly	  starting	  from	   the	   ciliary	   tip.	   It	   is	   accompanied	   by	   an	   increase	   in	   the	   number	   of	   empty	   IFT	  particles	   moving	   in	   the	   anterograde	   direction,	   while	   IFT	   particles	   moving	   in	   the	  retrograde	   direction	   continually	   return	   ciliary	   proteins	   to	   the	   cell	   body	   [67].	   The	  cessation	   of	   axonemal	   subunit	   delivery	   to	   the	   distal	   tip,	   coupled	   with	   continuous	  transport	   of	   disassembly	   products	   back	   to	   the	   cell	   body,	   ultimately	   leads	   to	   the	  
FIGURE	  1.4.	  The	  Intraflagellar	  transport	  machinery:	  The	  anterograde	  intraflagellar	  transport	  (IFT)	  motor,	   heterotrimeric	   Kinesin-­‐2,	   transports	   IFT	   complexes	   A	   and	   B,	   axonemal	   proteins	   and	  cytoplasmic	   dynein	   2	   (previously	   known	  as	   cytoplasmic	   dynein	   1b)	   to	   the	   tip	   of	   cilium.	  During	   this	  anterograde	  motion,	  Kinesin-­‐2	  is	  active	  and	  the	  retrograde	  motor,	  cytoplasmic	  dynein	  2,	  is	  somehow	  kept	  inactive	  to	  allow	  smooth	  processive	  anterograde	  movement.	  At	  the	  tip	  of	  cilium,	  anterograde	  IFT	  trains	   release	   axonemal	   proteins	   and	   rearrange	   their	   conformation	   for	   retrograde	   IFT.	   Cytoplasmic	  dynein	  2	   is	   activated	  and	   transports	   retrograde	   IFT	  trains	  to	   the	   cell	  body.	   Subsets	  of	   IFT	   trains	  are	  involved	  in	  transporting	  membrane	  proteins	  and	  the	  BBSome	  (a	  complex	  comprised	  of	  at	  least	  seven	  Bardet–Biedl	  syndrome	  proteins).	  (Figure	  taken	  from	  [53]).	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1.1.5.3.	  Regulation	  of	  cilium	  length:	  Ciliary	  length	  is	  an	  important	  parameter	  as	  it	  can	  critically	  affect	  the	  function	  of	  cilia,	  especially	  of	  cilia	  that	  are	  involved	  in	  the	  generation	  of	   specific	   fluid	  movements.	   It	   is	   important	   for	   cells	   to	   have	   cilia	   of	   normal	   length,	   as	  either	  shortened	  or	  elongated	  cilia	  can	  lead	  to	  developmental	  defects	  or	  diseases.	  It	  has	  been	  proposed	  that	  ciliary	  length	  depends	  on	  the	  balance	  of	  assembly	  and	  disassembly	  at	   the	   ciliary	   tip	   [57].	  An	   inverse	   relationship	  exists	  between	   the	  efficiency	  of	   IFT	  and	  
FIGURE	  1.5.	  Ciliogenesis	  cycle	  and	  cell	  cycle:	  Multiple	  steps	  (a–f)	  of	  primary	  cilia	  formation	  in	  ciliogenesis	  cycle	  are	  shown	  in	  relation	  to	  cell	  cycle.	  (Figure	  taken	  from	  [80]).	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ciliary	   length.	   As	   length	   of	   the	   cilium	   increases,	   the	   frequency	   of	   cargo	   delivery	  decreases	  due	  to	  the	  fact	  that	  it	  has	  to	  traverse	  a	  larger	  distance	  before	  reaching	  the	  tip.	  This	   results	   in	   a	   'Balance-­‐point'	   model	   in	   which	   IFT	   represents	   the	   main	   control	  mechanism	   for	   the	   regulation	   of	   cilium	   length	   through	   changes	   in	   the	   IFT	  machinery,	  such	  as	  cargo	  selection,	  IFT	  particle	  size,	  trafficking	  speed	  and	  frequency	  of	  trafficking.	  This	   IFT	   control	   also	   occurs	   at	   the	   transition	   zone	   [70]	   which	   houses	   a	   number	   of	  structural	  proteins	  like	  NPHP8,	  Tmem67,	  Cc2d2,	  Tctn1	  and	  Tctn2	  that	  are	  essential	  for	  the	   elongation	   of	   cilia	   [71,	   72].	   These	   proteins	   modulate	   ciliary	   length	   by	   possibly	  regulating	  the	  recruitment	  of	  ciliary	  proteins	  from	  the	  cytosol	  to	  the	  cilium.	  Recent	   studies	   propose	   that	   regulation	   of	   the	   cilium	   length	   is	   achieved	   by	   the	  recruitment	   of	   positive	   and	  negative	   regulators	   of	   ciliogenesis	   at	   early	   stages	   of	   basal	  body	   conversion	   [73].	   The	   basal	   body	   acquires	   positive	   regulators	   of	   ciliogenesis	   and	  removes	   the	   negative	   regulators	   before	   docking	   to	   the	   plasma	   membrane	   to	   begin	  axonemal	   extension.	   Several	   proteins	   have	   been	   identified	   as	   key	   regulators	   in	   this	  process.	  CP110,	  a	  negative	  regulator	  of	  cilia	  formation,	  interacts	  with	  Cep290	  to	  restrain	  ciliogenesis	   in	  dividing	  cells	  [74].	   It	  has	  been	  shown	  that	  proteins	  tau	  tubulin	  kinase	  2	  (TTBK2)	  and	  microtubule-­‐	   associated	  protein/microtubule	   affinity	   regulating	  kinase	  4	  (MARK4)	   initiate	   ciliogenesis	   by	   dislocating	   CP110	   from	   the	   mother	   centriole	   [75].	  Besides	   CP110,	   the	   protein	   trichoplein	   acts	   as	   a	   negative	   regulator	   of	   ciliogenesis	   by	  activating	  Aurora-­‐A	  kinase	  in	  the	  cycling	  cells	  [76].	  A	  recent	  study	  shows	  that	  trichoplein	  is	  degraded	  at	  an	  early	  stage	  of	  ciliogenesis	  by	  CRL3-­‐KCTD17	  complex	  of	  the	  Ubiquitin	  proteasome	  system	  (UPS)	  [77].	  Another	  study	  has	  demonstrated	  that	  oral-­‐facial	  digital	  syndrome	  1	  (ofd-­‐1)	  protein	  is	  required	  for	  primary	  cilia	  formation	  [78].	  It	  exerts	  a	  cilia-­‐suppressive	   role	   when	   present	   in	   the	   centriolar	   satellites.	   Induction	   of	   selective	  autophagy	   by	   serum	   starvation	   removes	   ofd1	   from	   centriolar	   satellites	   to	   centrioles	  resulting	  in	  the	  formation	  of	  longer	  cilia	  [79].	  Emerging	  evidence	  has	  revealed	  several	  mechanisms	  that	  are	  involved	  in	  the	  control	  of	  ciliary	  length	  linked	  to	  the	  cell	  cycle	  (Figure	  1.6)	  [80]	  (see	  also	  1.1.6).	  Nde1,	  which	  has	  been	  shown	  to	  suppress	  ciliogenesis	  by	  affecting	  cell	  cycle	  re-­‐entry	  [81],	  controls	  ciliary	  length	   through	   phosphorylation	   by	   CDK5	   that	   primes	   Nde1	   for	   FBW7	   E3	   ubiquitin	  ligase-­‐mediated	   degradation	   by	   the	   Ubiquitin-­‐proteasome	   system	   [82].	   Another	  mechanism	  involves	  Anaphase	  Promoting	  Complex	  (APC),	  which	  interacts	  with	  cdc20	  to	  maintain	   ciliary	   length,	   and	   is	   important	   for	   the	   timely	   resorption	   of	   cilium	   [83].	   The	  APC-­‐cdc20	   complex	   controls	   the	   length	   of	   cilium	   by	   regulating	   the	   stability	   of	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microtubules	  in	  the	  axoneme	  by	  targeting	  Nek1	  for	  proteolysis	  [83].	  Some	  studies	  show	  that	  GTPase	  Arl13b	  localizes	  to	  the	  cilium	  and	  regulates	  ciliary	  length	  [84].	  It	  has	  been	  proposed	   that	   Arl13b	   regulates	   the	   length	   of	   cilium	  by	   recruiting	   proteins	   of	   the	  BBS	  complex	   to	   the	   cilium	   [85].	   Some	   pharmacological	   compounds	   like	   Lithium	   and	  Forskolin,	  an	  activator	  of	  adenylate	  cyclase	  (AC)	  are	  known	  to	  elongate	  cilia	  by	  altering	  the	   intracellular	   levels	   of	   second	   messengers	   like	   calcium	   and	   cAMP	   followed	   by	  activation	  of	  protein	  kinase	  A	  [86-­‐88].	  Ciliary	  length	  increases	  with	  lowering	  of	  Ca2+	  and	  elevation	   of	   cAMP	   levels.	   Under	   fluid	   flow	   conditions,	   the	   cilium	   length	   decreases	   as	  intracellular	  Ca2+	  levels	  rise	  and	  cAMP	  levels	  decrease	  [87].	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  This	  negative	  feedback	  response	  is	  required	  to	  decrease	  the	  mechanosensitivity	  of	  cilia	  to	   fluid	   shear,	   which	   is	   necessary	   for	   the	   normal	   functioning	   of	   cells	   involved	   in	   the	  sensing	   of	   fluid	   movements	   [89].	   Recent	   studies	   show	   that	   Rer1p,	   a	   protein	   quality	  control	  receptor	  is	  involved	  in	  the	  regulation	  of	  ciliary	  length	  and	  function	  by	  increasing	  the	   assembly	   and	   activity	   of	   gamma	   secretase	   complex,	  which	   consequently	   enhances	  Notch	  signaling	  and	  reduces	  Foxj1a	  expression	  [90].	  
FIGURE	   1.6.	   Molecular	   mechanisms	   linking	   ciliary	   length	   and	   cell	   cycle	   regulation:	   Recent	  findings	  to	  uncover	  the	  molecular	  link	  between	  the	  individual	  step	  (a–g)	  of	  ciliogenesis	  and	  cell	  cycle	  are	   depicted.	  Red	   letters	   indicate	   kinases	   and	   blue	   letters	   indicate	  molecules	   related	   to	   ubiquitin–proteasome	  pathway	  or	  autophagy.	  (Figure	  taken	  from	  [80]).	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Also	   several	   environmental	   and	   pharmacological	   factors	   are	   known	   to	   influence	   the	  length	   of	   cilium	   (figure	   1.7).	   For	   example,	   pharmacological	   regulation	   of	   actin	   and	  microtubule	  dynamics	  for	  instance	  by	  treating	  cells	  with	  cytochalasin	  D,	  an	  inhibitor	  of	  actin	  polymerization	  affects	  primary	   cilium	   length	   [91,	  92].	  Environmental	   insults	   like	  renal	  injury	  are	  also	  known	  to	  trigger	  alterations	  in	  ciliary	  length.	  It	  has	  been	  reported	  that	   primary	   cilia	   length	   increases	   in	   injured	   kidneys	   of	   mice	   and	   in	   human	   renal	  transplants	   affected	   with	   acute	   tubular	   necrosis	   [93-­‐95].	   It	   is	   considered	   that	   the	  elongation	  of	  primary	  cilia	  in	  kidneys	  following	  renal	  injury	  leads	  to	  an	  increase	  in	  their	  sensory	  capacity,	  which	  might	  promote	  epithelial	  differentiation	  for	  renal	  repair.	  	  	  
1.1.5.4.	   Selective	   access	   and	   targeting	   of	   proteins	   to	   the	   cilium:	   The	   cilium	   is	   a	  specialized	   cell	   surface	   structure	   whose	   function	   is	   critically	   dependent	   on	   its	  composition.	  Many	  important	  proteins	  are	  highly	  enriched	  in	  the	  cilium.	  To	  concentrate	  
FIGURE	   1.7.	   Proposed	   pathways	   by	   which	   environmental	   and	   pharmacological	   factors	  
influence	   primary	   cilium	   length:	  Treatment	  with	   Gd3+	   or	   forskolin	   evokes	   the	   elongation	   of	  primary	   cilia	   via	   crosstalk	   between	   a	   decrease	   in	   the	   intracellular	   Ca2+	   and	   an	   increase	   in	   the	  cyclic	  AMP	   (cAMP)	   level	  with	   subsequent	  protein	  kinase	  A	  activation.	  The	  deflection	  of	  primary	  cilia	   downregulates	   the	   intracellular	   cAMP	   level,	   resulting	   in	   primary	   cilia	   shortening	   and	   a	  subsequent	  decrease	  in	  the	  mechanosensitivity	  of	  primary	  cilia.	  Increased	  velocity	  of	  anterograde	  IFT	   is	   thought	  to	  underlie	  the	   cAMP/Ca2+-­‐mediated	  elongation	  of	  primary	  cilia.	  Treatment	  with	  cytochalasin	   D	   or	   taxol	   affects	   the	   dynamics	   of	   actin	   filaments	   and	   microtubules,	   respectively,	  leading	   to	   cilia	   length	   alteration	   through	  modulating	   the	   levels	   of	   soluble	   tubulin	   available	   for	  primary	  cilia	  extension.	  Forskolin-­‐induced	  elongation	  of	  primary	  cilia	  is	  attenuated	  by	  treatment	  with	   taxol,	   where	   the	   effects	   on	   cilia	   length	   correlate	   with	   the	   levels	   of	   soluble	   tubulin.	   The	  mechanism	  by	  which	  treatment	  with	  Li+	  or	  K+	  elongates	  primary	  cilia	   is	  uncertain	  but	  might	  be	  related	   to	   certain	   actions	   common	   to	   monovalent	   cations.	   Among	   the	   consequences	   of	   renal	  injury,	  hypoxia	  is	  likely	  to	  contribute	  to	  the	  elongation	  of	  renal	  primary	  cilia	  via	  hypoxia-­‐inducible	  factor	  alpha	  (HIF-­‐1α).	  (Figure	  taken	  from	  [88]).
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these	  proteins	  in	  the	  ciliary	  compartment,	  efficient	  mechanisms	  are	  necessary	  to	  restrict	  their	  movement	  in	  and	  out	  of	  the	  compartment.	  This	  control	  of	  entry	  and	  exit	  is	  tightly	  regulated	  at	  the	  ciliary	  base,	  which	  is	  the	  only	  region	  of	  the	  cilium	  not	  surrounded	  by	  a	  membrane.	   The	   ciliary	   base	   acts	   as	   a	   selective	   diffusion	   barrier,	   which	   is	   similar	   in	  mechanism	  to	  the	  nuclear	  pore	  complex	  that	  regulates	  import/export	  mechanism	  in	  the	  nucleus.	  Ciliary	  proteins	  that	  are	  synthesized	  in	  the	  cytosol,	  are	  trafficked	  to	  the	  ciliary	  base	  for	  selective	  import	  across	  the	  diffusion	  barrier	  prior	  to	  their	  entry	  into	  the	  cilium.	  Microtubular	   transition	   fibers	   that	   separate	   the	   cilium	   from	   the	   cell	   body	  prevent	   the	  free	  diffusion	  of	  cytoplasmic	  proteins	  into	  the	  ciliary	  compartment.	  An	  additional	  barrier	  composed	  of	  condensed	  lipid	  zone	  in	  the	  periciliary	  region	  also	  separates	  the	  cilium.	  Its	  likely	  role	  is	  to	  prevent	  the	  free	  translocation	  of	  membrane	  proteins	  to	  the	  cilium	  [96].	  Recent	  studies	  have	  demonstrated	  the	  existence	  of	  a	  septin	  ring	  at	  the	  base	  of	  the	  cilium.	  It	  is	  composed	  of	  Septin	  2	  (SEPT2)	  and	  has	  been	  shown	  to	  create	  a	  diffusion	  barrier	  to	  limit	   the	   movement	   of	   proteins	   between	   the	   plasma	   membrane	   and	   the	   ciliary	  membrane.	  When	  SEPT2	  was	  depleted	   in	  cells,	   the	  proteins	  of	   ciliary	  membrane	  were	  found	   in	   the	   plasma	   membrane	   surrounding	   the	   cilium	   [32].	   However,	   the	   physical	  connection	   of	   the	   septin	   ring	   with	   other	   structures	   at	   the	   ciliary	   base	   is	   not	   well	  understood.	   Interestingly,	   SEPT2	   is	   has	   been	   reported	   to	   be	   indispensable	   for	   cilium-­‐dependent	  Sonic	  Hedgehog	  (Shh)	  signaling	  [32].	  	  Although	   soluble	   ciliary	   proteins	   can	   reach	   the	   ciliary	   base	   by	   diffusion	   or	   by	  moving	  along	   the	   microtubules,	   membrane	   proteins	   have	   to	   depend	   on	   several	   transport	  pathways:	  (1)	  They	  can	  be	  directly	  targeted	  from	  the	  trans-­‐Golgi	  network	  (TGN)	  to	  the	  ciliary	   base,	   or	   (2)	   they	   can	   be	   targeted	   to	   recycling	   endosomes	  where	   they	   undergo	  sorting	   followed	   by	   transport	   to	   the	   ciliary	   base,	   or	   (3)	   they	   can	   be	   targeted	   to	   the	  plasma	   membrane	   for	   lateral	   diffusion	   into	   the	   ciliary	   membrane.	   All	   these	   ciliary	  transport	  pathways	  are	  closely	  integrated	  with	  the	  gating	  mechanisms	  that	  exist	  at	  the	  ciliary	  base,	  which	  allow	  selective	  access	  to	  only	  those	  proteins	  that	  are	  destined	  to	  the	  cilium.	  Several	  studies	  have	  revealed	  that	  targeting	  of	  proteins	  to	  the	  cilium	  requires	  the	  presence	  of	  specific	  ciliary	  targeting	  motifs	  or	  sequences	  that	  enable	  their	  localization	  to	  the	   cilium	   [97].	   A	   ciliary	   targeting	   sequence	  was	   recently	   identified	   in	   Polycystin-­‐2,	   a	  protein	  that	  localizes	  to	  the	  primary	  cilium	  in	  kidney	  epithelial	  cells.	  Targeting	  of	  some	  proteins	   to	   the	   cilium	   is	   phosphorylation-­‐dependent.	   For	   example,	   phosphorylation	  of	  Nephrocystin-­‐1	  by	  Casein	  Kinase-­‐2	  is	  necessary	  for	  trafficking	  to	  the	  cilium	  [98].	  There	  is	  evidence	  that	  IFT	  proteins	  may	  play	  a	  role	  in	  Golgi	  to	  cilium	  transport.	  IFT20	  has	  been	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shown	   to	   localize	   to	   the	  Golgi	  apparatus	  where	   it	   functions	   in	   sorting	  proteins	   for	   the	  cilium.	  IFT20-­‐containing	  vesicles	  released	  from	  the	  golgi	  fuse	  with	  the	  base	  of	  the	  cilium	  to	  release	  the	  ciliary-­‐targeted	  cargo	  [99,	  100].	  	  
1.1.5.5.	  Regulation	  of	  ciliogenesis	  by	  the	  lipogenic	  factor	  SREBP1c:	  Recent	  research	  by	   our	   team	   has	   revealed	   a	   novel	   mode	   of	   regulation	   of	   ciliogenesis	   involving	   lipid	  metabolism	  [101].	  We	  have	  shown	  that	  increased	  lipogenesis,	  a	  characteristic	  feature	  of	  cancer	   cells,	   was	   accompanied	   with	   the	   loss	   of	   primary	   cilium.	   Further	   research	   has	  pinpointed	   SREBP1c,	   a	   key	   lipogenic	   transcription	   factor,	   as	   the	   mediator	   of	   these	  effects.	  Over-­‐expression	  of	   the	   lipogenic	   transcription	   factor	   SREBP1c	   in	  Xenopus	   and	  mammalian	  cell	   line	  models	  resulted	   in	   the	   loss	  of	   the	  primary	  cilium	  and	  subsequent	  abnormalities	   in	   signaling,	   distrtion	   of	   polarized	   tissue	   structure	   and	   aberrant	   tissue	  morphology.	   One	   of	   the	   downstream	   SREBP1c	   targets	   that	   mediate	   cilium	   loss	   is	   a	  secreted	   phospholipase	   [102]	   that	   releases	   fatty	   acids	   for	   the	   sn-­‐2	   position	   of	  phospholipids	   and	   among	   others	   results	   in	   increased	   lysophospholipid	   levels	   These	  findings	   indicate	   that	   altered	   lipid	   metabolism	   as	   observed	   in	   many	   cancer	   cells	  contributes	   to	   the,	   suppression	   of	   the	   primary	   cilium	   that	   often	   accompanies	   cancer	  development	  (see	  1.3)	  and	  provide	  a	  new	  mechanism	  with	  possible	  therapeutic	  potetial.	  	  
1.1.6.	  Timing	  and	  cell	  cycle	  control	  of	  ciliogenesis	  	  The	  cell	  cycle	  and	  ciliogenesis	  are	  interrelated	  processes.	  Cell	  cycle	  governs	  the	  presence	  of	  cilia	  on	  cells	  and	  the	  timing	  of	  ciliary	  assembly	  and	  disassembly	  is	  linked	  to	  cell	  cycle	  progression	   (figure	   1.8).	   The	   mother	   centriole,	   which	   forms	   the	   basal	   body	   for	  ciliogenesis,	   is	  also	   required	   for	   spindle	   formation	  during	   the	  mitotic	  phase	  of	   the	  cell	  cycle.	  To	  execute	  this	  dual	   function,	   the	  basal	  body	  has	  to	  be	   liberated	  from	  the	  cilium	  before	   it	   becomes	   available	   for	  mitotic	   spindle	   formation	   in	   the	   cell.	   The	   assembly	   of	  cilia	  begins	   in	  G1-­‐phase	  and	   they	  are	  most	  abundant	   in	  G0-­‐phase.	   In	  most	  of	   the	  cells,	  cilia	  are	  resorbed	  as	  they	  enter	  into	  mitosis	  [102].	  However,	  resorption	  of	  the	  cilium	  can	  also	  occur	  prior	   to	  S-­‐phase	  entry	  or	   in	  other	  parts	  of	   the	   cell	   cycle	  phases	   [102,	  103].	  Apart	  from	  cell	  cycle	  stage,	  the	  timing	  of	  cilium	  biogenesis	  is	  also	  regulated	  by	  centriole	  age,	  with	  the	  older	  mother	  centrioles	  forming	  cilia	  sooner	  than	  the	  daughter	  centrioles	  [104].	   The	   molecular	   switches	   that	   govern	   ciliary	   assembly	   and	   disassembly	   remain	  poorly	  understood.	  Studies	  have	  revealed	  that	  centrosomal	  proteins	  CP110	  and	  Cep97	  are	  regulators	  of	  ciliogenesis.	  Cep97	  recruits	  CP110	  to	  the	  centriole,	  where	  CP110	  caps	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FIGURE	  1.8.	  Dual	  use	  of	  the	  centrioles	  during	  cell	  cycle	  and	  primary	  cilium	  formation:	  In	  most	  cells,	  cilium	  formation	  first	  occurs	  during	  G1	  following	  centrosomal	  docking	  to	  the	  membrane.	   IFT	   and	   accessory	   proteins	   build	   the	   ciliary	   axoneme,	  which	   extends	   directly	  from	  the	  mother	  centriole’s	  triplet	  microtubules.	  During	  this	  stage	  of	  the	  cell	  cycle,	  as	  well	  as	  in	  G0,	  the	  cilium	  functions	  as	  a	  cellular	  antenna,	  interpreting	  extracellular	  signals	  such	  as	  Hedgehog	  and	   PDGF.	   Upon	   entry	   into	  S	  phase,	   the	   cell’s	   centrioles	   and	   the	  DNA	   begin	   to	  replicate.	   The	   centrioles	   reach	   maturity	   during	   late	   G2,	   at	   which	   point	   the	   cilium	   is	  disassembled	  so	  that	  the	  engaged	  centrioles	  can	  be	  liberated	  for	  mitotic	  spindle	  formation.	  Once	   cell	   division	   is	   complete,	   the	   centrioles	   can	   proceed	   to	   ciliary	   re-­‐assembly	   in	   G1.	  (Figure	  taken	  from	  [241]).	  
	   20	  
1.1.7.	  The	  primary	  cilium	  and	  its	  significance	  	  Initially	  dismissed	  as	  a	  vestigial	  organelle,	  the	  primary	  cilium	  has	  now	  taken	  the	  center	  stage	   in	   view	   of	   the	   recent	   findings	   that	   defects	   in	   the	   formation	   or	   function	   of	   the	  primary	   cilium	   results	   in	   a	   wide	   variety	   of	   human	   disorders.	   More	   than	   a	   decade	   of	  research	  has	  revealed	  that	  primary	  cilia	  function	  as	  sensors	  of	  extracellular	  signals.	  They	  capture	  signals	  from	  their	  immediate	  surroundings	  and	  pass	  them	  on	  to	  the	  cell,	  which	  is	   informed	  of	  how	   it	   should	  develop	   itself.	  Thus,	   a	  primary	   cilium	  acts	   as	   an	  antenna	  that	   serves	   as	   a	   communication	   device	   between	   the	   cell	   and	   the	   extracellular	  environment.	  To	  facilitate	  this	  communication,	  a	  large	  diversity	  of	  receptors,	  channels	  or	  proteins	  can	  be	  present	  on	  the	  same	  cilium.	  More	  than	  a	  thousand	  proteins	  have	  been	  found	  to	  be	  either	  located	  in	  the	  cilium,	  or	  associated	  with	  the	  formation	  or	  function	  of	  the	  cilium.	  Mutations	  or	  defects	  in	  many	  of	  these	  proteins	  lead	  to	  major	  developmental	  irregularities	  in	  the	  body,	  thereby	  indicating	  that	  normal	  growth	  and	  development	  of	  an	  individual	  is	  dependent	  on	  the	  structural	  and	  functional	  integrity	  of	  the	  cilium.	  	  
1.1.8.	  The	  primary	  cilium	  as	  a	  sensory	  organelle	  	  The	  antenna-­‐like	  geometry	  and	  extracellular	  location	  of	  the	  primary	  cilium	  bestow	  it	  the	  unique	  ability	  to	  act	  as	  a	  sensory	  organelle.	  Being	  densely	  studded	  with	  receptors	  in	  its	  membrane,	   the	   primary	   cilium	   can	   sense	   and	   transmit	   both	   physical	   and	   biochemical	  stimuli	   from	   the	  exterior	   environment	   to	   the	   cell	   interior.	   Such	   stimuli	  may	   consist	   of	  physical	   factors	   like	   flow	   and	   pressure,	   or	   chemical	   substances	   like	   growth	   factors,	  ligands	  and	  morphogens.	  This	  results	  in	  activation	  of	  signaling	  pathways,	  which	  regulate	  cellular	   activities	   such	   as	   migration	   [106],	   homeostasis	   [9],	   division,	   apoptosis	   [107],	  intracellular	   calcium	   regulation	   [108]	   and	   cell	   polarity.	   Owing	   to	   its	   sensory	   role,	   the	  primary	  cilium	  has	  been	  designated	  with	  a	  variety	  of	  names	  such	  as	  'cellular	  GPS'	  [109],	  'cybernetic	   probe'	   [110]	   and	   'environmental	   rheostat	   [111].	   The	   presence	   of	   a	   large	  number	  of	   specialized	  proteins	  enables	   the	  cilium	  to	  perform	  diverse	  sensory	  roles	  as	  discussed	  below.	  	  
1.1.8.1.	   Fluid	   flow:	   Flow	   sensing	   ability	   is	   one	   of	   the	   most	   studied	   functions	   of	   the	  primary	   cilium.	   Cilia	   play	   an	   important	   role	   in	   both	   detection	   and	   generation	   of	   fluid	  flow.	   In	  the	  kidneys,	  bending	  of	  primary	  cilia	   is	  essential	   for	  the	  normal	   functioning	  of	  renal	   tubule	   cells	   [112,	   113].	   The	   urine	   passing	   along	   the	   kidney	   tubules	   physically	  bends	   the	  primary	  cilium	  resulting	   in	  an	   increase	   in	   intracellular	   calcium	  and	   thereby	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activating	  a	  downstream	  signal.	  By	  bending,	  the	  cilium	  senses	  and	  interprets	  fluid	  shear	  force	   as	   a	   developmental	   signal.	   This	   mechanosensing	   function	   of	   primary	   cilia	   is	  attributed	  to	  a	  mechanosensor	  complex	  consisting	  of	  proteins	  polycystin-­‐1	  and	  -­‐2	  that	  is	  localized	   in	   the	   cilium	   [114,	   115].	   Polycystin-­‐2	   has	   been	   shown	   to	   act	   as	   a	   calcium	  channel.	   Activation	   of	   Polycystin-­‐2	   is	   dependent	   on	   Polycystin-­‐1.	   Removal	   of	   cilia	   by	  genetic	   manipulation	   or	   chemical	   ablation	   resulted	   in	   cells	   that	   were	   mechano-­‐insensitive	  to	  fluid	  flow,	  supporting	  mechanosensory	  function	  of	  the	  cilium	  [112].	  Apart	  from	  kidneys,	  primary	  cilia	  are	  also	  known	  to	  detect	   fluid	   flow	  and	  serve	  as	  mechano-­‐sensors	  in	  other	  organs	  like	  liver,	  heart,	  pancreas	  and	  bone.	  	  
1,1.8.2.	   Left	   right	   axis	   specification:	   Primary	   cilia	   play	   a	   vital	   role	   in	   embryonic	  development	  by	  generating	  fluid	  movement	  in	  restricted	  embryonic	  spaces	  to	  establish	  left-­‐right	   asymmetry	   [116].	   A	   well-­‐studied	   example	   of	   this	   phenomenon	   is	   in	   the	  embryonic	   node.	   Two	   theories	   have	   been	   proposed	   to	   explain	   the	   role	   of	   cilia	   in	   the	  generation	   of	   sidedness	   (left	   vs	   right).	   First	   is	   the	   "morphogen	   hypothesis",	   which	  believes	   that	   the	   node	   has	   motile	   cilia	   that	   set	   up	   a	   leftward	   flow	   to	   preferentially	  transport	   the	   morphogens	   to	   the	   left	   side	   of	   the	   node.	   The	   leftward	   nodal	   flow	   is	  continually	   refined	  and	  reinforced	  by	  a	   circular	   clockwise	   rotational	  motion	  unique	   to	  nodal	  cilia	  [117,	  118].	  The	  second	  hypothesis	  called	  the	  "two-­‐cilia	  model"	  involves	  both	  motile	  and	  non-­‐motile	  cilia	  at	  the	  node	  [119].	  It	  suggests	  that	  motile	  cilia	  generate	  a	  fluid	  flow	  in	  the	  leftward	  direction,	  which	  is	  detected	  by	  the	  non-­‐motile	  sensory	  cilia	  present	  on	   the	  periphery	  of	   the	  node	   and	   transduced	   into	   an	   increase	   in	   intracellular	   calcium	  leading	   to	   left-­‐right	   asymmetry	   [120].	   It	   is	   still	   unclear	   how	  exactly	   this	   nodal	   flow	   is	  detected	   and	   transduced	   to	   generate	   left-­‐right	   asymmetry.	  However,	   recent	   studies	   in	  mouse	  embryo	  and	  fish	  medaka	  models	  argue	  in	  favor	  of	  the	  latter	  hypothesis	  and	  raise	  a	  tantalizing	  possibility	  that	  both	  motility	  and	  sensory	  functions	  of	  the	  nodal	  cilia	  might	  dwell	  in	  the	  same	  organelle	  [121].	  	  
1.1.8.3.	   Olfactory,	   photoreceptor	   and	   audio	   sensation:	  Primary	   cilia	   are	  necessary	  for	  sensing	  odors,	  light	  and	  sound.	  Cilia	  present	  on	  olfactory	  sensory	  neurons	  can	  detect	  and	  transduce	  odor	  through	  olfactory	  receptors	  which	  are	  specialized	  GPCRs	  present	  on	  the	  ciliary	  membrane	  [122].	  Activation	  of	  these	  receptors	  by	  binding	  of	  specific	  olfactory	  ligands	  initiates	  a	  signaling	  cascade	  through	  the	  production	  of	  second	  messenger	  cAMP	  within	  the	  cilium.	  cAMP	  mediates	  the	  opening	  of	  cyclic	  nucleotide-­‐gated	  channel	  located	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in	  the	  cilium,	  leading	  to	  the	  depolarization	  of	  olfactory	  neurons	  and	  thereby	  resulting	  in	  the	   sensation	   of	   smell	   [123,	   124].	   Olfactory	   neurons	   with	   dysfunctional	   cilia	   lack	  odorant	  sensation	  [125].	  Recently,	  it	  has	  been	  discovered	  that	  the	  sensitivity	  of	  olfactory	  cilia	   is	   dependent	   on	   their	   length	   and	   location	   in	   the	   nasal	   cavity.	   A	   gradient	   in	   cilia	  length	  exists	  in	  the	  nose	  where	  neuronal	  cells	  in	  front	  of	  the	  nose	  have	  longer	  cilia	  than	  those	   in	   the	   back.	   The	   longer	   olfactory	   cilia	   are	  more	   sensitive	   and	   are	   located	   in	   the	  nasal	  cavity	  where	  they	  can	  detect	  more	  odor-­‐specific	  molecules	  [126].	  	  Photoreception	   is	  mediated	  by	  the	  primary	  cilium	  in	  the	  rod	  and	  cone	  cells,	  which	  are	  the	  actual	  photoreceptor	   cells	  of	   retina.	  The	  primary	   cilia	  of	   these	  photoreceptor	   cells	  have	  a	  specialized	  tip	  called	  the	  outer	  segment,	  which	  contains	  the	  photoreceptors	  that	  receive	  light.	  Upon	  light	  stimulation,	  a	  signal	  is	  initiated	  by	  an	  increase	  in	  cGMP,	  hence	  resulting	  in	  a	  closure	  of	  cGMP	  channels	  [127].	  This	  is	  followed	  by	  transduction	  of	  visual	  signals	   to	   electrical	   signals	   via	   rhodopsin.	   The	   electrical	   signals	   are	   eventually	  transmitted	  via	  the	  optic	  nerve	  to	  the	  brain	  where	  they	  are	  interpreted	  as	  an	  image.	  	  Primary	   cilia	   have	   also	   been	   linked	   to	   hearing.	   In	   drosophila,	   the	   cilia	   of	   auditory	  sensory	   neurons	   contain	   two	   TRP	   channels	   that	   mediate	   the	   reception	   of	   sound	  vibrations	  at	  the	  antenna	  [128].	  TRP	  channels	  have	  also	  been	  reported	  to	  localize	  to	  cilia	  of	   sensory	   neurons	   in	   C.elegans,	   where	   they	   sense	   and	   respond	   to	   high	   osmolarity,	  thereby	  implicating	  cilia	  in	  osmo-­‐regulation	  [129].	  	  
1.1.8.4.	   Gravity	   sensation:	   Recently,	   new	   sensory	   functions	   have	   been	   attributed	   to	  primary	   cilia.	   Interestingly,	   it	   has	   been	   suggested	   that	   primary	   cilia	   function	   as	  transducers	  of	   gravitational	   force	   [130].	  Variability	  of	   gene	  expression	   levels	   in	   rohon	  beard	   neurons	   of	   zebrafish	   embryos	   is	   linked	   to	   cyclic	   changes	   in	   the	   earth's	  gravitational	  field	  due	  to	  the	  sun	  and	  moon.	  This	  variability	  is	  no	  longer	  observed	  when	  primary	  cilia	  are	  selectively	  ablated	  from	  the	  rohon	  beard	  neurons.	  Deciliated	  neuronal	  cells	   subjected	   to	   different	   gravitational	   forces	   resulted	   in	   homogeneous	   gene	  expression.	   The	   link	   between	   variability	   in	   gene	   expression	   and	   changes	   in	   earth's	  gravitational	  field	  is	  restored	  when	  neurons	  regrow	  their	  primary	  cilia.	  	  
1.1.8.5.	   Hunger	   and	   satiety	   sensation:	   Primary	   cilia	   in	   the	   central	   nervous	   system	  (CNS)	   maintain	   body	   mass	   homeostasis	   by	   regulating	   the	   feeding	   behaviour	   and	  appetite.	  The	  cilia	  of	  proopiomelanocortin (POMC)	  neurons	  present	  in	  appetite-­‐regulating	  part	   of	   the	   brain	   control	   hunger	   and	   satiation	   by	   regulating	   leptin-­‐mediated	   pathway	  
	   23	  
that	  represses	  the	  urge	  to	  eat.	  Ciliary	  loss	  or	  dysfunction	  in	  these	  neurons	  results	  in	  an	  increase	  in	  the	  feeding	  behaviour	  leading	  to	  obesity	  [131].	  
	  
1.1.8.6.	  Chemosensation:	  Chemical	  signal	  is	  another	  kind	  of	  external	  stimulus	  that	  can	  be	   sensed	   by	   the	   primary	   cilium.	   Localization	   of	   specialized	   receptors	   to	   the	   ciliary	  membrane	  renders	  a	  chemosensory	  role	  to	  this	  organelle.	  It	  acts	  as	  a	  site	  to	  concentrate	  the	  receptors.	  Stationing	  of	  important	  signaling	  receptors	  on	  the	  ciliary	  surface	  instead	  of	  general	  distribution	   in	   the	  plasma	  membrane	   increases	   the	   likelihood	  that	   they	  will	  encounter	   a	   chemical	   mediator	   or	   agonist.	   The	   interaction	   of	   a	   ligand	   or	   a	   chemical	  mediator	  with	   its	   specific	   receptor	   activates	   the	  appropriate	   signaling	   cascade	  housed	  within	  the	  cilium.	  The	  concentration	  of	  receptors	  on	  the	  surface	  along	  with	  the	  unique	  housing	  of	  these	  signaling	  cascades	  asserts	  the	  role	  of	  primary	  cilium	  as	  a	  chemosensor	  and	  a	  critical	  coordinator	  of	  cellular	  signaling	  and	  developmental	  processes.	  Examples	  of	  proteins	   and	   receptors	   that	   coordinate	   cilium-­‐based	   signal	   transduction	  pathways	   are	  Patched	  and	  Smoothened	  receptors	  of	  Hedgehog	  signaling	  [7],	  Inversin	  of	  Wnt	  signaling	  [132],	  PDGFRa	  [9],	  Somatostatin	  receptor	  3	  [133]	  etc.	  
	  
1.1.9.	  The	  primary	  cilium	  as	  a	  hub	  of	  cellular	  signaling	  	  Proper	   embryonic	   development	   and	  maintenance	   of	   tissues	   and	   organs	   relies	   on	   the	  concerted	   action	   of	   diverse	   signaling	   pathways	   that	   orchestrate	   intimate	   interactions	  between	   the	   cells	   and	   their	   environment.	   It	   is	   now	   a	   well-­‐established	   fact	   that	   the	  primary	   cilium	  plays	   a	   unique	   role	   in	   the	   coordination	   of	   a	   number	   of	   developmental	  signaling	   pathways	   in	   normal	   tissues	   [5].	   Signal	   transduction	   through	   primary	   cilium	  has	   two	   advantages.	   Firstly,	   as	   previously	   mentioned,	   it	   allows	   the	   concentration	   of	  signal	  transducers	  because	  of	  the	  presence	  of	  a	  diffusion	  barrier	  between	  the	  cilium	  and	  the	  cell	  body.	  This	  enables	   fine-­‐tuning	  of	  contact	  between	  the	  cell	  and	   its	  extracellular	  environment.	  Secondly,	  it	  allows	  modulation	  of	  signaling	  pathways	  by	  regulating	  ciliary	  localization	  of	  signal	  transducers.	  Depending	  on	  the	  type	  of	  signal	  or	  pathway	  involved,	  specific	   proteins	   either	   translocate	   to	   the	   cilium	   for	   their	   activation,	   or	   they	   can	   be	  trapped	   in	   the	   cilium	   to	   prevent	   their	   active	   function	   in	   the	   cytoplasm.	   Thus,	   by	  interacting	   with	   the	   extracellular	   environment	   and	   by	   regulating	   the	   entry	   or	   exit	   of	  signaling	  proteins,	   the	  primary	   cilium	  provides	   a	  nexus	   for	   signaling	  pathways	  during	  tissue	  growth	  and	  development.	  This	  section	  reviews	  the	  important	  signaling	  pathways	  as	  well	  as	  some	  less	  known	  ones	  that	  have	  been	  linked	  to	  the	  primary	  cilium.	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1.1.9.1.	  Hedgehog	  signaling:	  Of	  all	  the	  signal	  transduction	  pathways	  regulated	  by	  cilia,	  the	   mechanism	   of	   sonic	   hedgehog	   (Shh)	   signaling	   has	   been	   best	   characterized.	   In	  mammals,	  hedgehog	  signaling	  plays	  an	   important	   role	  during	  embryonic	  development	  by	   regulating	   a	   variety	   of	   processes	   that	   include	   cell	   fate	   specification,	   regulation	   of	  growth	  patterning,	  cell	  proliferation	  and	  cell	  survival	  [134].	  Few	  examples	  that	  illustrate	  the	   importance	   of	   hedgehog	   signaling	   in	   normal	   development	   are	   in	   establishment	   of	  left-­‐right	   symmetry	   [135],	   patterning	   of	   digits	   in	   the	   limbs	   and	   skeletogenesis	   [136],	  ovarian	   function	   and	   mammary	   gland	   development	   [137],	   cerebellar	   development	  [138],	   lung	   and	   heart	   and	   pancreas	   development	   [139-­‐141]	   and	   formation	   of	   neural	  tube	  [142].	  With	  the	  discovery	  that	  mutations	  in	  cilia	  affect	  Shh	  signaling,	  a	  number	  of	  experimental	  studies	  have	  been	  undertaken	  to	   firmly	  establish	  that	  presence	  of	  cilia	   is	  required	   for	   proper	   signaling	   to	   occur	   [6,	   143,	   144].	  Hedgehog	   is	   a	   family	   of	   secreted	  proteins,	   which	   include	   Sonic	   Hedgehog	   (Shh),	   Indian	   Hedgehog	   (Ihh)	   and	   Desert	  Hedgehog	   (Dhh).	   Binding	   of	   these	   proteins	   to	   the	   transmembrane	  protein	   Patch	   (Ptc)	  frees	  the	  seven-­‐transmembrane	  receptor	  Smoothened	  (Smo)	   from	  the	   inhibitory	  effect	  of	  Ptc,	  which	  migrates	  out	  of	  the	  cilium.	  The	  free	  Smo	  receptor	  localizes	  to	  the	  primary	  cilium	   [145,	   146].	   This	   allows	   Smo	   to	   activate	   Glioma-­‐associated	   (Gli)	   transcription	  factor	   to	  express	  Hedgehog	   (Hh)	   target	  genes	   in	   the	  nucleus	   that	   control	   responses	  at	  different	   times	   and	   in	   different	   cell	   types	   [147].	   Figure	   1.9	   shows	   how	   primary	   cilia	  regulate	  the	  Hh	  pathway	  under	  normal	  conditions.	  	  There	   are	   three	   Gli	   transcription	   factors.	   In	   the	   absence	   of	   Hh	   ligand,	   Gli1	   is	   not	  expressed,	  Gli2	  is	  inactive	  and	  Gli3	  is	  in	  a	  repressor	  form	  called	  Gli3R.	  In	  the	  presence	  of	  Hh	   ligand,	   the	   pathway	   is	   activated	   and	   Gli1	   is	   expressed	   whereas	   Gli2	   and	   Gli3	   are	  processed	  by	  the	  proteasome.	  Thus,	  depending	  on	  the	  absence	  or	  presence	  of	  Hh,	  Gli2	  and	   Gli3	   proteins	   undergo	   post-­‐translational	   processing	   into	   repressor	   or	   activator	  forms	  respectively.	  The	  extent	  of	  Hh	  response	  is	  determined	  by	  the	  overall	  balance	  of	  Gli	  transcription	  activators	  and	  repressors.	  The	  primary	  cilium	  may	  serve	  as	  a	  location	  for	  the	   assembly	   and	   concentration	   of	   protein	   complexes	   that	   are	   required	   for	   proper	  processing	   and	   activation	   of	   the	   Gli	   transcription	   factors.	   [148].	   Therefore	   the	   cilium	  regulates	  the	  Hedgehog	  pathway	  by	  increasing	  the	  local	  concentration	  of	  pathway	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FIGURE	  1.9.	  Regulation	  of	  the	  Hh	  pathway	  by	  primary	  cilia	  in	  normal	  cells.	  	  Kinesin	  2	  moves	   the	   IFT	  complex	  and	   its	   cargo	   (e.g.,	  Gli,	  Ptch,	   and	  Smo)	   toward	   the	  plus	  end	  of	  	  microtubules	  (ciliary	  tip).	  Dynein	  2	  moves	  the	  IFT	  complex	  and	  its	  cargo	  toward	  the	  minus	  end	  of	  microtubules	  (cell	  body).	  Hh	  regulation:	  In	  the	  absence	  of	  Hh	  (left),	  Gli	  protein	  is	  converted	  to	  its	  repressor	   form	  (GliR).	  Also	   in	  the	  absence	  of	  Hh,	  Ptch1	  is	   localized	  to	   the	   ciliary	  membrane	  and	  Smo	  is	  kept	  out	  of	  the	  cilium.	  In	  the	  presence	  of	  Hh	  (right),	  Gli	  protein	  levels	  increase	  in	  the	  cilium	  and	   Gli	   is	   processed	   into	   the	   activator	   form	   (GliA)	   for	   transport	   out	   of	   the	   cilium	   and	   into	   the	  nucleus,	  where	   it	  activates	  Hh	  target	  genes.	   In	  the	  presence	  of	  Hh,	  Ptch1	  moves	  out	  of	  the	  cilium	  and	  Smo	  moves	   into	  the	   cilium,	  where	   it	  promotes	   formation	  of	   the	  activator	   form	  of	  Gli	   (GliA).	  (Figure	  taken	  from	  [281]).	  
	   26	  
components	  thereby	  bringing	  them	  together	  to	  facilitate	  key	  interactions	  necessary	  for	  pathway	  regulation.	  It	  has	  been	  shown	  that	  Gli	  proteins	  and	  SuFu,	  a	  negative	  regulator	  	  of	   the	   pathway	   that	   binds	   to	   Gli	   proteins,	   all	   localize	   to	   the	   distal	   tip	   of	   the	   primary	  cilium,	   suggesting	   that	  Hedgehog	   signaling	  machinery	   is	   located	   in	   the	  primary	   cilium	  [148].	   Mutations	   leading	   to	   loss	   of	   cilia	   result	   in	   abnormal	   processing	   of	   both	   the	  repressor	  and	  activator	  forms,	  confirming	  the	  ciliary	  dependence	  of	  this	  pathway	  [149].	  As	  Hedgehog	  pathway	  is	  a	  key	  regulator	  of	  cellular	  growth	  and	  differentiation,	  abnormal	  activation	   of	   this	   pathway	   is	   a	   critical	   factor	   in	   the	   development	   of	   a	  wide	   variety	   of	  cancers.	   For	   this	   reason,	  manipulation	  of	  Hh	   signaling	  pathway	   is	   being	   explored	   as	   a	  therapeutic	   target	   to	   potentially	   delay	   or	   cure	   cancers.	   Preclinical	   studies	   and	   clinical	  trials	  are	  already	  underway	  to	  test	  the	  feasibility	  of	  this	  therapeutic	  approach	  in	  a	  range	  of	  malignancies	  [150,	  151].	  	  
1.1.9.2.	   Wnt	   signaling:	  Wnt	   signaling	   is	   a	   key	   pathway	   involved	   in	   homeostatic	   and	  developmental	  processes	  like	  gastrulation,	  organogenesis,	  sex	  determination,	  bone	  and	  cartilage	   formation,	   self-­‐renewal	   of	   tissues	   and	   hematopoeisis	   [152].	   The	   vertebrate	  Wnt	  signaling	  is	  classified	  into	  two	  types:	  canonical	  (β-­‐catenin-­‐dependent)	  pathway	  and	  the	   non-­‐canonical	   pathway	   [153].	   The	   canonical	  Wnt	   pathway	   has	   been	   implicated	   in	  cell	  differentiation,	  proliferation,	  adhesion	  and	  survival	  [154].	  Activation	  of	  this	  pathway	  occurs	  when	  the	  Wnt	  ligand	  binds	  to	  co-­‐receptors	  Frizzled	  (Fz)	  and	  LRP,	  which	  in	  turn,	  activate	  cytoplasmic	  Dishevelled	  (Dvl).	  Activated	  Dvl	  inhibits	  Glycogen	  synthase	  kinase	  3	  (GSK3)	  to	  prevent	  phosphorylation	  and	  destruction	  of	  β-­‐catenin	  [155].	  This	  results	  in	  the	  accumulation	  of	  β-­‐catenin	   in	   the	  cytoplasm	  before	   it	   is	   translocated	  to	   the	  nucleus	  where	   it	   activates	   T-­‐cell	   factor	   (TCF)/lymphocyte	   enhancer	   factor	   (LEF)	   leading	   to	  transcription	  of	  Wnt	  target	  genes	  such	  as	  c-­‐Myc,	  Tcf1	  and	  CyclinD1	  [156].	  In	  the	  absence	  of	  Wnt	   ligand,	  β-­‐catenin	   is	  phosphorylated	  and	  destroyed	  by	  proteasomal	  degradation	  mediated	   by	   a	   destruction	   complex	   that	   consists	   of	   β-­‐catenin,	   Casein	   Kinase	   I	   (CKI),	  Adenomatous	   Polyposis	   Coli	   (APC),	   Axin	   I	   and	   GSK3-­‐β	   [156].	   The	   non-­‐canonical	  Wnt	  pathway	   diversifies	   into	   several	   pathways	   of	  which	  Wnt-­‐calcium	   pathway	   and	   Planar	  Cell	  Polarity	  (PCP)	  pathway	  are	  relatively	  well	  studied	  [153].	  The	  Wnt-­‐calcium	  pathway	  has	   been	   linked	   to	   embryonic	   dorsal-­‐ventral	   patterning	   and	   in	   the	   regulation	   of	   cell	  migration	   and	   development	   [157].	   PCP	   pathway	   is	   associated	   with	   cell	   polarity,	  migration	  and	  orientation	  during	  embryogenesis	  and	  organization	  of	  stereo	  cilia	  in	  the	  inner	  ear	  [158,	  159].	  Non-­‐canonical	  Wnt	  signaling	  is	  activated	  when	  Wnt	  ligand	  binds	  to	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Fz	  receptor,	  which	  in	  turn	  activates	  the	  membrane-­‐bound	  Dvl,	   independent	  of	  LRP5/6.	  The	  activated	  Dvl	  regulates	  RhoA,	  Rock	  and	  Jnk	  kinases	  and	  intracellular	  calcium	  levels.	  Through	   these	   downstream	   effectors,	   the	   non-­‐canonical	   Wnt	   signaling	   coordinates	  Planar	   Cell	   Polarity	   (PCP)	   and	   calcium	   pathways.	   In	   the	   canonical	   pathway,	   both	  cytoplasmic	  and	  membrane-­‐bound	  Dvl	  can	  participate	  whereas	  only	  membrane-­‐bound	  Dvl	   can	   activate	   the	   non-­‐canonical	  Wnt	   pathway	   [160].	   Recent	   studies	   have	   revealed	  that	  binding	  of	  ciliary	  protein	  Inversin	  (Inv)	  to	  cytoplasmic	  Dvl	  prevented	  the	  activation	  of	   canonical	   Wnt	   signaling,	   suggesting	   that	   primary	   cilium	   may	   operate	   as	   a	   switch	  between	  canonical	  and	  non-­‐canonical	  signaling	  [8].	  	  
1.1.9.3.	   PDGFR	   signaling:	  PDGFR	   signaling	   is	   another	  pathway	  acting	   at	   the	  primary	  cilium.	   It	   is	   important	   for	   embryogenesis	   [161],	   stimulation	   of	   fibroblast	   migration	  during	   wound	   healing	   [162],	   proliferation	   and	   apoptosis	   [163].	   Aberrant	   PDGFR	  signaling	   is	   a	   causal	   factor	   in	   a	   broad	   range	   of	   diseases	   like	   cancer,	   fibrosis,	   vascular	  disorders	   and	   developmental	   malfunctions	   [164].	   PDGFs	   and	   their	   receptors	   are	  synthesized	   in	   a	   wide	   variety	   of	   ciliated	   cells	   like	   epithelial	   cells,	   fibroblasts,	   smooth	  muscle	  cells	  and	  glial	  cells	  [165].	  The	  PDGF	  pathway	  comprises	  of	  four	  ligands	  (PDGF	  A,	  B,	  C	  and	  D)	  and	  two	  receptors	  (PDGFR-­‐α	  and	  -­‐β).	  The	  receptor	  PDGFR-­‐α	  localizes	  to	  the	  primary	  cilium	  during	  growth	  arrest	   in	  mouse	  embryonic	   fibroblasts	  (MEFs)	  and	  NIH-­‐3T3	  cells	  [9].	  The	  importance	  of	  primary	  cilia	  for	  PDGFR-­‐α	  signaling	  was	  accentuated	  by	  demonstrating	   that	   this	   pathway	   was	   compromised	   in	   ORPK	   mouse	   model	   in	   which	  ciliogenesis	   is	   disrupted	   [9].	   For	   the	   pathway	   to	   be	   stimulated,	   ligand	  PDGFA	   forms	   a	  homodimer	  (PDGFAA)	  and	  binds	  to	  two	  PDGFR-­‐α	  receptors	  simultaneously,	  resulting	  in	  the	  activation	  of	  Akt	  and	  MEK	  1/2	  pathways	  in	  and	  at	  the	  base	  of	  the	  cilium	  [9].	  Further	  studies	  show	  chemotaxis	  of	   fibroblasts	   towards	  PDGFA	  ligand,	  with	  their	  primary	  cilia	  oriented	  towards	  the	  direction	  of	  cell	  movement	  during	  wound	  healing	  response.	  ORPK	  MEFs	   with	   no	   cilia	   fail	   to	   respond	   to	   PDGFA	   ligand	   and	   do	   not	   exhibit	   chemotaxis,	  emphasizing	  a	  significant	  role	  of	  primary	  cilia	   in	  regulation	  of	  cell	  migration	  [106].	  By	  induction	   of	   cell	   proliferation	   and	   maintenance	   of	   cells	   in	   an	   undifferentiated	   state	  through	  PDGFR-­‐α	  signaling,	  the	  hESC	  primary	  cilium	  controls	  pluripotency	  of	  embryonic	  stem	   cells	   [166].	   In	   view	   of	   its	   connection	   to	   proliferation	   and	   apoptosis,	   PDGFR-­‐α	  signaling	  also	  provides	  a	  link	  between	  cilia	  and	  carcinogenesis.	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1.1.9.4.	   FGF	   signaling:	   The	   primary	   cilium	   is	   also	   a	   host	   to	   several	   receptors	   of	  fibroblast	  growth	  factor	  (FGF)	  [167].	  FGF	  signaling	  is	  required	  for	  normal	  development	  as	   it	   regulates	  proliferation,	   differentiation	   and	  migration	   in	   a	  wide	   array	   of	   cells	   and	  tissues	  of	  both	  vertebrates	  and	  invertebrates.	  This	  pathway	  has	  been	  associated	  with	  the	  correct	  endowment	  of	  left-­‐right	  asymmetry	  in	  mice	  and	  zebrafish	  embryos	  through	  the	  creation	  of	  morphogen	  gradients	  in	  the	  embryonic	  node	  [168].	  Knockdown	  of	  fibroblast	  growth	  factor	  receptor	  FGFR2	  and	  ligands	  FGF8	  and	  FGF24	  in	  zebrafish	  tissues	  resulted	  in	  shortening	  of	  cilia,	  implicating	  FGF	  signaling	  in	  the	  regulation	  of	  cilium	  length	  [168].	  It	  has	   been	   further	   shown	   that	   FGF	   signaling	   controls	   ciliary	   length	   by	   regulating	   the	  expression	  of	  genes	  like	  ift88,	  foxj1,	  rfx2,	  fibp1	  etc.	  that	  are	  responsible	  for	  ciliogenesis	  [168].	   Also,	   dysregulation	   of	   FGF	   pathway	   or	  mutations	   in	   FGFRs	   can	   lead	   to	   skeletal	  defects	   called	   craniosynostosis,	   suggesting	   a	   critical	   role	   for	   FGF	   signaling	   in	   the	  regulation	   of	   craniofacial	   development	   [169].	   Moreover,	   expression	   profiling	   of	   renal	  cystic	  tissues	  has	  shown	  that	  FGF	  signaling	  is	  upregulated	  in	  polycystic	  kidney	  disease	  patients.	  Further	  studies	  are	  needed	  to	  address	  whether	  FGF	  signaling	  has	  a	  general	  role	  in	   cilia	   formation	   or	   its	   activity	   is	   limited	   to	   a	   subset	   of	   specialized	   cilia.	   Besides,	   the	  mechanism	   by	   which	   it	   regulates	   the	   formation	   or	   maintenance	   of	   cilia	   is	   yet	   to	   be	  elucidated.	  	  
1.1.9.5.	  Notch	   signaling:	  The	  notch	  signaling	  pathway	   is	  known	  to	  be	   involved	   in	   the	  development	   of	   many	   organs,	   stem	   cell	   maintenance	   and	   proliferation	   [170].	   The	  pathway	  is	  initiated	  by	  binding	  of	  notch	  ligands	  to	  the	  notch	  receptor,	  which	  undergoes	  two	   proteolytic	   cleavage	   events	   that	   promote	   the	   downstream	   activation	   and	  transcription	  of	  notch	  target	  genes	  [171].	  Mutations	  in	  the	  receptor	  or	  ligands	  of	  notch	  signaling	   results	   in	   aberrations	   in	   tissues	   and	   organs	   like	   limbs,	   kidneys,	   heart,	  craniofacial	  region	  etc.	  [172].	  Recent	  studies	  establish	  that	  notch	  signaling	  is	  involved	  in	  various	   cilium-­‐associated	   processes.	   Notch	   signaling,	   which	   regulates	   epidermal	  differentiation	   during	   skin	   development,	   occurs	   only	   in	   the	   presence	   of	   cilia	   [173].	  Notch3	  localizes	  to	  the	  ciliary	  axoneme	  in	  epidermal	  cells	  of	  mouse	  embryos.	  Presenilin-­‐2,	  the	  catalytic	  protein	  that	  cleaves	  notch	  receptor	  for	  pathway	  activation,	  is	  found	  to	  be	  concentrated	   at	   the	   basal	   body.	   Removal	   of	   cilia	   by	   knockdown	   of	   intraflagellar	  transport	   proteins	   (IFTs)	   and	   conditional	   knockout	   of	   genes	   critical	   for	   ciliogenesis,	  Ift88	   and	  Kif3a	   during	   embryogenesis	   in	  mice	   resulted	   in	   notch	   signaling	   defects	   and	  hyperproliferation	  [173].	  Furthermore,	  over	  activation	  of	  notch	  signaling	  results	  in	  cilia	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elongation,	  which	  implicates	  a	  role	  for	  this	  pathway	  in	  control	  of	  cilium	  length	  [174].	  It	  has	  also	  been	  shown	  that	  notch	  signaling	  is	  involved	  in	  senescence	  [175].	  Expression	  of	  Notch3	   is	   increased	   in	   senescent	   cells.	   Moreover,	   it	   has	   been	   observed	   that	   Notch3	  expression	  is	  decreased	  in	  tumor	  cells	  and	  that	  restoration	  of	  this	  expression	  resulted	  in	  inhibition	  of	  cell	  proliferation	  and	  activation	  of	  senescence	  [176].	  Collectively,	  these	  data	  provide	  a	  link	  between	  cilia	  and	  notch	  signaling.	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1.2.	  CILIA-­‐RELATED	  DISORDERS:	  CILIOPATHIES	  Ciliopathies	  are	  a	  heterogeneous	  group	  of	  usually	   rare	  diseases	   resulting	   from	  genetic	  defects	  that	  compromise	  cilia	  formation	  or	  function	  [181].	  These	  diseases	  manifest	  as	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
FIGURE	  1.10.	  Cilia	  defects	  and	  ciliopathies:	  Defects	  in	  cilia	  result	  in	  a	  spectrum	  of	  disorders	  collectively	   called	  as	   ciliopathies.	  Cilia	   can	  be	   defective	  due	   to	   several	   reasons.	   (1)	  Centrioles	  are	  normal,	  but	  they	  fail	  to	  migrate,	  or	  are	  not	  properly	  anchored,	  to	  the	  cortex.	  (2)	  Centrioles	  may	  be	  structurally	  defective	  and	  so	  unable	  to	  initiate	  proper	  cilia	  formation.	  (3)	  Cilia	  assembly	  may	  be	  defective.	  (4)	  Proteins	  normally	  present	  in	  the	  specialized	  membrane	  surrounding	  the	  cilium	  may	  be	  defective.	   (5)	  Cilia	  may	  be	  positioned	   in	   the	  wrong	  orientation.	  The	  numerous	  syndromes	   in	   humans	   resulting	   from	   either	   or	   more	   of	   these	   defects	   is	   represented	  diagrammatically.	  (Figure	  taken	  from	  [5]	  &	  [180]).	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either	   single	   organ	   or	  multisystemic	   clinical	   symptoms	   that	   include	   a	   constellation	   of	  features	   like	   retinal	   degeneration,	   cystic	   kidneys,	   mental	   retardation,	   polydactyly,	  skeletal	  abnormalities,	  hydrocephalus,	  hearing	  loss,	  obesity	  etc.	  [182,	  183]	  (figure	  1.10).	  Given	   the	   fact	   that	   primary	   cilia	   are	   present	   on	   almost	   all	   mammalian	   tissues,	  ciliopathies	   often	   display	   overlapping	   clinical	   symptoms.	   These	   symptoms	   become	  prominent	  either	  at	  birth	  or	  later	  in	  childhood,	  depending	  on	  the	  severity	  of	  underlying	  mutation	  or	  on	  the	  number	  of	  mutations	  in	  the	  ciliary	  gene.	  Presently,	  the	  spectrum	  of	  ciliopathy	   encompasses	   more	   than	   50	   disorders	   that	   include	   developmental	   and	  syndromic	  diseases.	  In	  addition,	  numerous	  diseases	  are	  being	  redefined	  to	  include	  cilia	  as	  a	  pathogenesis	  factor.	  In	  principle,	  following	  criteria	  should	  be	  fulfilled	  to	  consider	  a	  disease	  as	  ciliopathy	  [184]	  	  	  (1)	  the	  disease	  is	  caused	  by	  mutations	  in	  genes	  that	  encode	  proteins,	  that	  localize	  to	  the	  cilium	  and	  have	  a	  cilium-­‐specific	  function;	  	  (2)	   abnormalities	   in	   the	   structural	   and	   functional	   aspects	   of	   the	   cilium	   have	   been	  demonstrated	  in	  patient-­‐derived	  tissue	  or	  an	  animal	  model	  of	  the	  disease;	  and	  	  (3)	  the	  disease	  is	  characterized	  by	  abnormalities	  of	  the	  types	  associated	  with	  a	  known	  ciliopathy.	  	  If	  a	  disease	  satisfies	  either	  one	  or	  two,	  but	  not	  all	  the	  three	  criteria,	   it	   is	  classified	  as	  a	  suspected	  but	  not	  proven	  ciliopathy.	  The	  rapidly	  expanding	  list	  of	  suspected	  ciliopathies	  highlights	  the	  importance	  of	  understanding	  the	  role	  of	  cilia	  in	  human	  health	  and	  disease.	  The	  predominant	  organs	  that	  are	  affected	  by	  ciliary	  dysfunction	  include	  the	  kidney,	  eye,	  brain	  and	  liver.	  Ciliopathies	  can	  arise	  from	  defects	  in	  either	  motile	  or	  sensory	  functions	  of	   cilia.	   A	   number	   of	   well-­‐known	   and	   some	   lesser-­‐known	   ciliopathies	   are	   discussed	  below.	  	  
1.2.1.	   Primary	   Ciliary	   Dyskinesia:	   The	   first	   ciliopathy	   to	   be	   identified	  was	   primary	  ciliary	   dyskinesia	   (PCD),	   also	   known	   as	   immotile	   cilia	   syndrome,	   which	   is	   caused	   by	  defects	   in	   motile	   cilia	   [185,	   186].	   Patients	   with	   PCD	   are	   characterized	   by	   chronic	  bronchitis	  and	  sinusitis	  due	  to	  the	  failure	  of	  cilia	  to	  clear	  mucus	  and	  inhaled	  bacteria	  out	  of	  the	  respiratory	  tract.	  This	  defect	  in	  mucociliary	  clearance	  leads	  to	  recurrent	  infections	  by	  pathogenic	  bacteria	  like	  Haemophilus	  influenzae,	  Staphylococcus	  aureus,	  Streptococcus	  
pneumoniae	   resulting	   in	   recurrent	  pneumonia,	  bronchiectasis	  and	   irreversible	  dilation	  
	   32	  
of	   bronchi,	   which	   severely	   impairs	   respiratory	   function.	   Male	   infertility	   and	   reduced	  fertility	   in	  women	  are	   commonly	  observed	  as	   this	  disorder	  also	  affects	   the	  motility	  of	  sperm	   flagella	   and	   cilia	   of	   fallopian	   tubes.	   Moreover,	   the	   patients	   develop	  hydrocephalus,	   which	   is	   enlargement	   of	   the	   head	   due	   to	   abnormal	   accumulation	   of	  cerebrospinal	   fluid	   resulting	   from	  defective	  motility	   of	   ependymal	   cilia	   present	   in	   the	  brain	   [187].	   Almost	   half	   of	   the	   PCD	   patients	   display	   situs	   inversus,	   also	   known	   as	  Kartagener's	  syndrome	  [188].	  It	  is	  a	  developmental	  defect	  in	  which	  the	  positions	  of	  the	  heart	   and	   other	   internal	   organs	   are	   reversed	   forming	   a	   mirror	   image	   of	   the	   normal	  positioning.	   This	   happens	   due	   to	   the	   impaired	  motility	   of	   nodal	   cilia	   that	   initiate	   the	  normal	  left-­‐right	  asymmetry	  in	  early	  embryo	  [189].	  Currently,	  more	  than	  28	  PCD	  genes	  have	  been	  identified	  [190].	  Almost	  50%	  of	  the	  PCD	  patients	  have	  defects	   in	  genes	  that	  encode	   proteins	   of	   the	   outer	   dynein	   arm	   that	   is	   necessary	   for	   ciliary	  motility.	   Hence,	  these	  genes	  make	  an	  attractive	  target	  for	  genetic	  screening	  of	  PCD.	  In	  general,	  mutations	  that	  affect	  motile	  cilia	  lead	  to	  a	  set	  of	  symptoms	  that	  are	  different	  as	  compared	  to	  those	  affecting	  sensory	  cilia	  (primary	  cilia).	  	  
1.2.2.	   Polycystic	   Kidney	   Disease:	   In	   humans,	   polycystic	   kidney	   disease	   (PKD)	   is	   the	  most	   common	   life-­‐threatening	   ciliopathy.	   It	   manifests	   in	   two	   major	   forms	   namely	  autosomal	   dominant	   and	   autosomal	   recessive.	   The	  most	   prevalent	   form	  of	   PKD	   is	   the	  autosomal	   dominant	   polycystic	   kidney	   disease	   (ADPKD),	   which	   usually	   affects	   adults	  and	   has	   an	   incidence	   of	   1:1000.	   The	   disorder	   is	   characterized	   by	   grossly	   enlarged	  kidneys,	  predisposition	  to	  renal	  stones	  and	  development	  of	  renal	  cysts	  leading	  to	  kidney	  failure.	   The	   end-­‐stage	   patients	   may	   require	   therapy	   by	   dialysis	   or	   kidney	  transplantation.	   Apart	   from	   kidneys,	   cysts	   are	   also	   formed	   in	   the	   liver,	   pancreas	   and	  intestine	   of	   ADPKD	   patients	   along	   with	   cardiovascular	   defects,	   hypertension	   and	  recurrent	   urinary	   tract	   infections.	   Autosomal	   recessive	   polycystic	   kidney	   disease	  (ARPKD)	  is	  more	  common	  in	  neonates	  and	  children.	   It	  has	  an	  occurrence	  of	  up	  to	  1	   in	  6000	   live	   births	   and	   has	   a	   high	   mortality	   rate	   in	   affected	   newborns.	   Characteristic	  features	   include	   renal	   cystic	   degeneration,	   dilation	   of	   collecting	   ducts	   of	   kidneys	   and	  liver	  fibrosis.	  The	  causative	  genes	  of	  ADPKD	  are	  PKD1	  and	  PKD2	  that	  encode	  polycystin-­‐1	  (PC-­‐1)	  and	  polycystin-­‐2	  (PC-­‐2)	  respectively	  [191].	  Mutation	  in	  either	  of	  the	  two	  genes	  can	  lead	  to	  ADPKD	  although	  mutation	  in	  PKD1	  is	  found	  in	  more	  than	  85%	  of	  all	  cases.	  ARPKD	   is	   caused	   by	   mutation	   in	   a	   single	   gene	   PKHD1	   that	   encodes	   the	   protein	  fibrocystin.	  Interestingly,	  PC-­‐1,	  PC-­‐2	  and	  fibrocystin	  have	  been	  shown	  to	  localize	  to	  the	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primary	   cilium	   [36,	   192].	   PC-­‐1	   and	   PC-­‐2	   interact	   with	   each	   other	   to	   form	   a	   calcium	  permeable	  channel	  on	  the	  ciliary	  surface	  that	   is	  required	  to	  mediate	  a	   flow-­‐dependent	  calcium	   response	   [114].	   Owing	   to	   the	   presence	   of	   these	   calcium	   channels	   on	   their	  surface,	  primary	  cilia	  act	  as	  flow	  sensors	  in	  the	  lumen	  of	  renal	  tubules.	  Deflection	  of	  cilia	  in	   response	   to	   renal	   fluid	   flow	   triggers	   the	   entry	   of	   calcium	   into	   the	   cells,	   which	   is	  necessary	   for	   the	   activation	   of	   signaling	   pathways	   that	   control	   kidney	   epithelial	   cell	  differentiation	  and	  proliferation	  [193].	  Therefore,	  mutations	  in	  these	  proteins	  or	  failure	  in	  the	  assembly	  of	  cilium	  as	  a	  whole	  results	  in	  the	  disruption	  of	  ciliary	  signaling	  leading	  to	  PKD.	  	  
1.2.3.	   Bardet-­‐Biedl	   Syndrome:	   Bardet-­‐Biedl	   syndrome	   (BBS)	   is	   a	   multisystemic	  disorder	   with	   primary	   features	   that	   include	   obesity,	   renal	   anomalies,	   hypogonadism,	  mental	   retardation,	   developmental	   delay,	   polydactyly	   and	   retinal	   degeneration	   [194].	  Almost	   all	   patients	  with	   BBS	   are	   obese,	  which	  may	   be	   linked	   to	   dysfunctional	   cilia	   of	  neurons	  present	   in	   the	   satiety	   center	   of	   hypothalamus	   [195].	   BBS	   is	   a	   ciliopathy	  with	  highly	   variable	   clinical	   features.	   Secondary	   features	   include	   anosmia,	   diabetes,	   ataxia,	  asthma,	  cardiovascular	  anomalies	  and	  occasionally	  situs	  inversus.	  The	  leading	  cause	  of	  mortality	  in	  BBS	  patients	  is	  kidney	  failure	  due	  to	  cystic	  tubular	  disease	  and	  anatomical	  malformations.	   BBS	   is	   characterized	   by	   genetic	   heterogeneity	   as	   it	   is	   caused	   by	  mutations	  in	  one	  of	  the	  18	  genes	  (BBS1	  to	  BBS18)	  that	  are	  highly	  conserved	  in	  ciliated	  organisms.	  Symptoms	  can	  differ	  depending	  on	  which	  of	  the	  causative	  genes	  is	  mutated.	  However,	  genotype-­‐phenotype	  correlations	  have	  not	  been	  consistently	  established	  yet.	  For	   example,	   human	   BBS	   patients	   often	   exhibit	   polydactyly	   but	   it	   has	   not	   yet	   been	  reported	  in	  mutant	  mice.	  All	  the	  BBS	  genes	  encode	  primary	  cilia	  proteins	  that	  localize	  to	  the	  centrosome,	  basal	  body	  or	  ciliary	  axoneme	  and	  are	   involved	  in	  the	  maintenance	  of	  axonemal	  microtubules	  and	   in	   the	  coordination	  of	  cell	   cycle.	  Eight	  of	   the	  BBS	  proteins	  combine	  to	  form	  an	  octameric	  complex	  called	  BBSome,	  which	  has	  been	  implicated	  in	  IFT	  assembly	   and	   in	   the	   localization	   of	   certain	   receptors	   to	   the	   primary	   cilia	   in	   neurons	  [196,	  197].	  The	  localization	  of	  BBSome	  to	  the	  centriole	  at	  the	  base	  of	  cilium	  depends	  on	  the	   interaction	   of	   BBSome	   with	   proteins	   expressed	   at	   centriolar	   satellites	   [198].	   The	  interaction	  of	  the	  BBS4	  component	  of	  BBSome	  with	  centriolar	  satellite	  protein	  CEP290	  is	   necessary	   for	   the	   recruitment	   of	   BBSome	   to	   the	   cilium.	  Mutations	   in	   CEP290	   have	  been	  shown	  to	  disrupt	  BBSome	  formation	  and	   its	   localization	  to	  the	  cilium	  [198,	  199].	  Recent	   studies	   have	   identified	   that	   the	   interaction	   between	   BBSome	   and	   CEP290	   is	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mediated	  by	  another	  centriolar	  satellite	  protein	  SSX2IP,	  which	  is	  needed	  to	  target	  BBS2,	  BBS4,	   BBS8,	   CEP290,	   SSTR3,	   RAB8A	   to	   the	   cilium	   [200].	   Other	   studies	   show	   that	  Nephrocystin-­‐5	  (NPHP5)	  protein	  and	  CEP290	  interact	  with	  each	  other	  in	  the	  transition	  zone	   and	   both	   can	   bind	   BBSome	   proteins	   to	   alter	   their	   localization.	   However,	   their	  interaction	  with	  the	  BBSome	  appears	  to	  have	  different	  effects	  on	  BBSome	  stability	  [201].	  It	  has	  also	  been	  shown	  that	  BBSome	  binds	  with	  ARL6	  to	   form	  a	  coat	  on	  the	  surface	  of	  vesicular	  membrane	   lipids	   in	   the	   cell	   [85].	   A	   recent	   study	   has	   revealed	   that	   this	   coat	  allows	   the	  sorting	  of	  membrane	  proteins	   into	   the	  cilium	  through	  recognition	  of	  ciliary	  targeting	  sequences	  by	  the	  BBSome	  [202].	  	  
1.2.4.	   Orofaciodigital	   Syndrome:	   Orofaciodigital	   Syndrome	   type	   1	   (OFDS1)	   is	   an	   X-­‐linked	   dominant	   disorder	   caused	   by	   mutations	   in	   the	   gene	   OFD1,	   which	   encodes	   a	  centrosomal	  protein	  that	  localizes	  to	  the	  basal	  body	  and	  is	  essential	  for	  the	  organization	  of	  the	  centrosome	  and	  regulation	  of	  the	  cilium	  [203].	  It	  is	  a	  male	  lethal	  disorder	  in	  which	  affected	  males	   die	   in	   utero.	   The	  disease	   is	   characterized	  by	  malformations	   of	   the	   oral	  cavity,	   facial	  dysmorphologies,	  digit	  abnormalities,	   cystic	  kidneys	  and	  abnormalities	  of	  the	  central	  nervous	  system	  (CNS)	  with	  accompanying	  mental	  retardation	  [204].	  OFDS1	  shares	  phenotypic	  similarities	  with	  other	  forms	  of	  this	  syndrome	  (OFD	  type	  II	  to	  XIV).	  In	  recent	  years,	  11	  different	  causative	  genes	  of	  OFDS	  have	  been	  identified,	  most	  of	  which	  have	  been	  proven	  to	  be	  involved	  in	  primary	  cilia	  or	  basal	  body	  function	  [205].	  The	  genes	  TMEM231	   (OFDIII),	   TMEM216	   and	   TMEM107	   (OFDIV)	   share	   an	   overlap	  with	   Joubert	  and	  Meckel	  Gruber	  Syndromes.	  C2CD3,	  the	  causative	  gene	  of	  the	  recently	  identified	  OFD	  type	   XIV	   has	   been	   shown	   to	   be	   responsible	   for	   centriole	   elongation,	   suggesting	   that	  regulation	   of	   centriole	   length	   is	   likely	   to	   gain	   focus	   as	   an	   emerging	   mechanism	   in	  ciliopathies	   [206].	   Another	   recent	   study	   shows	   that	  KIAA0753/OFIP	   protein,	  which	   is	  conserved	   in	   ciliated	   species,	   was	   found	   to	   be	   mutated	   in	   a	   patient	   with	   OFDVI	  syndrome	  [207].	  The	  authors	  further	  showed	  that	  the	  mutated	  KIAA0753/OFIP	  loses	  its	  capacity	  to	  interact	  with	  FOR20	  and	  OFD1	  causing	  defective	  recruitment	  of	  components	  to	  centrosomes	  and	  satellites,	  which	  might	  be	  the	  molecular	  basis	  of	  the	  defect	  causing	  OFDVI	  syndrome.	  	  
1.2.5.	   Joubert	   Syndrome:	   Joubert	   syndrome	   (JBTS)	   is	   a	   group	   of	   disorders	  characterized	   by	   mental	   retardation	   and	   ataxia	   due	   to	   hypoplasia	   of	   the	   cerebellar	  vermis,	   hypotonia,	   severe	   psychomotor	   delay,	   episodes	   of	   rapid	   breathing,	   and	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oculomotor	   apraxia.	   The	   other	   common	   features	   include	   cystic	   kidney	   disease,	  nephronophthisis,	   hepatic	   fibrosis,	   polydactyly,	   retinal	   degeneration,	   endocrine	  abnormalities	  and	  craniofacial	  dysmorphologies.	  JBTS	  is	  diagnosed	  by	  the	  appearance	  of	  characteristic	   "molar	   tooth	   sign"	   on	   magnetic	   resonance	   imaging,	   a	   consequence	   of	  underdevelopment	   of	   cerebellar	   vermis	   and	   abnormal	   formation	   of	   midbrain	   and	  hindbrain	  [208].	  The	  syndrome	  is	  associated	  with	  multiple	  causative	  genes	  resulting	  in	  genetic	  heterogeneity	   that	  brings	  variability	  and	  overlap	  of	   features	   in	   JBTS	  and	  other	  ciliopathies.	  Based	  on	  the	  underlying	  gene	  responsible	  for	  the	  disease,	  JBTS	  is	  classified	  into	   21	   types	   (JBTS	   type	   1	   to	   20	   and	   one	   unassigned	   yet).	   Causative	   genes	   that	   are	  mutated	   include,	   INPP5E	   (JBTS1),	   TMEM216	   (JBTS2),	   AHI1	   (JBTS3),	   NPHP1	   (JBTS4),	  CEP290	   (JBTS5),	   TMEM67	   (JBTS6),	   RPGRIP1L	   (JBTS7),	   ARL13B	   (JBTS8),	   CC2D2A	  (JBTS9),	  OFD1	  (JBTS10),	  TTC21B	  (JBTS11),	  KIF7	  (JBTS12),	  TCTN1	  (JBTS13),	  TMEM237	  (JBTS14),	   CEP41	   (JBTS15),	   TMEM138	   (JBTS16),	   C5Orf42	   (JBTS17),	   TCTN3	   (JBTS18),	  ZNF423	   (JBTS19),	   TMEM231	   (JBTS	   20),	   TCTN2	   (JBTS-­‐unassigned),	  most	   of	  which	   are	  known	  to	  localize	  to	  the	  primary	  cilium	  or	  basal	  body.	  Emerging	  studies	  show	  that	  many	  more	   genes	   involved	   in	   JBTS	   are	   being	   identified	   at	   a	   fast	   pace.	   Different	   groups	   of	  researchers	  have	  identified	  mutations	  in	  genes	  CEP104,	  CEP120,	  CSPP1,	  KIAA0556	  and	  KIAA0586	   that	   lead	   to	   Joubert	   syndrome	   [209-­‐213].	   The	   transition	   zone	   protein	  TMEM107	   has	   recently	   been	   reported	   to	   cause	   Joubert	   Syndrome	   by	   recruiting	   other	  ciliopathy	  proteins	  to	   the	  transition	  zone	  [214].	  Almost	  50%	  of	   the	   JBTS	  patients	  have	  mutations	   in	   CEP290,	   which	   may	   be	   attributed	   to	   the	   large	   number	   of	   proteins	   that	  CEP290	  interacts	  with	  [215].	  Involvement	  of	  ARL13B	  points	  towards	  a	  possible	  role	  for	  primary	   cilia-­‐mediated	   hedgehog	   signaling	   in	   the	   pathogenesis	   of	   JBTS	   [216].	   The	  disease	  shares	  a	  genetic	  overlap	  of	  at	   least	  13	  causative	  genes	  with	  another	  ciliopathy	  Meckel	  syndrome	  (MKS).	  	  
1.2.6.	  Meckel	  Syndrome:	  Meckel	  Syndrome	  is	  a	  lethal	  autosomal	  recessive	  multi-­‐organ	  ciliopathy	  characterized	  by	  perinatal	   lethality,	   fibrotic	  changes	   in	   the	   liver,	  renal	  cysts,	  occipital	   encephalocele,	   cardiac	   abnormalities,	   central	   nervous	   system	   defects,	  polydactyly	   and	   cleft	   palate.	   Patients	   with	   Meckel	   Syndrome	   (MKS)	   invariably	   die	   of	  renal	  or	  respiratory	   failure.	  So	   far,	  MKS	  has	  been	  classified	   into	  13	  types	  based	  on	  the	  following	   causative	   gene	   for	   each	   type:	   MKS1	   (MKS1),	   TMEM216	   (MKS2),	   TMEM67	  (MKS3),	   CEP290	   (MKS4),	  RPGRIP1L	   (MKS5),	   CC2D2A	   (MKS6),	  NPHP3	   (MKS7),	   TCTN2	  (MKS8),	   B9D1	   (MKS9),	   B9D2	   (MKS10),	   TMEM231	   (MKS11),	   KIF14	   (MKS12)	   and	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TMEM107	   (MKS13).	   All	   of	   these	   genes	   are	   associated	   with	   ciliary	   functions.	   MKS	  proteins	   are	   involved	   in	   functions	   like	   establishment	   of	   barrier	   at	   the	   base	   of	   cilium	  during	   early	   ciliogenesis,	   basal	   body	  docking,	  maintenance	   of	   normal	   Shh	   signaling	   in	  neural	   tube	   and	   the	   developing	   limb	   [26,	   37,	   42].	   Most	   of	   the	   morphological	   defects	  associated	  with	  MKS	  type1	  have	  been	  attributed	  to	  aberrant	  Hedgehog	  signaling	  [217].	  MKS3,	   also	   known	   as	   Meckelin,	   is	   structurally	   similar	   to	   Frizzled	   receptor	   and	   could	  possibly	  play	  a	  direct	  role	  in	  non-­‐canonical	  Wnt	  signal	  transduction	  although	  it	  is	  yet	  to	  be	  proven	  [218].	  	  
1.2.7.	   Monosomy	   1p36:	  Monosomy	  1p36	   is	   a	   terminal	   deletion	   syndrome	   caused	  by	  deletion	  of	   the	  distal	   tip	  of	   the	  short	  arm	  (p)	  of	   chromosome	  1,	  which	   is	   rich	   in	  many	  genes	  that	  include	  Rer1p.	  Recent	  evidence	  shows	  that	  Rer1p,	  an	  ER-­‐Golgi	  cargo	  receptor	  protein	  is	  involved	  in	  the	  regulation	  of	  ciliary	  length	  and	  function.	  Loss	  of	  Rer1p	  results	  in	  shortened	  cilia	  and	  defective	  sensory	  function	  of	  cilia,	  leading	  to	  a	  number	  of	  clinical	  characteristics	  similar	  to	  those	  associated	  with	  monosomy	  1p36	  [90].	  Hence,	  monosomy	  1p36	   appears	   to	   be	   another	   addition	   to	   the	   ever-­‐growing	   list	   of	   ciliopathies.	   The	  frequency	  of	  occurrence	  of	  this	  syndrome	  is	  estimated	  to	  be	  1	  in	  every	  5000	  births.	  The	  syndrome	   is	   characterized	   by	   distinctive	   facial	   dysmorphic	   features,	   intellectual	  disability,	   developmental	   delay,	   hypotonia,	   seizures,	   hearing	   impairment	   and	   heart	  defects.	   The	   severity	   of	   the	   syndrome	   varies	   between	   the	   patients.	   Although	   some	  patients	   reach	   adulthood,	   data	   on	   projected	   lifespan	   is	   lacking	   as	   it	   is	   a	   recently	  discovered	  syndrome.	  	  
1.2.8.	   Birt-­‐Hogg-­‐Dube	   Syndrome:	   Birt-­‐Hogg-­‐Dube	   (BHD)	   Syndrome	   is	   an	   autosomal	  dominant	  disorder	  caused	  by	  inactivating	  mutations	  in	  the	  FLCN	  gene	  that	  encodes	  for	  a	  tumor	   suppressor	   protein	   called	   folliculin	   [219].	   Lung	   and	   kidney	   cysts,	   benign	   skin	  tumors	  and	  predisposition	  to	  kidney	  cancer	  characterize	  this	  condition.	  It	  is	  thought	  that	  FLCN	  might	  act	  as	  a	  tumor	  suppressor	  in	  the	  kidney	  as	  a	  majority	  of	  renal	  tumors	  show	  a	   somatic	   loss	   of	   the	   wild-­‐type	   allele	   [220].	   Recent	   studies	   have	   revealed	   that	   FLCN	  interacts	   with	   binding	   proteins	   FNIP1	   and	   FNIP2,	   which	   cooperate	   with	   FLCN	   to	  suppress	  kidney	  tumors	  [221].	  The	  authors	  show	  that	  double	  inactivation	  of	  Fnip1	  and	  Fnip2	  leads	  to	  enlargement	  of	  polycystic	  kidneys	  or	  the	  development	  of	  kidney	  cancer,	  which	  mimics	   the	  Flcn-­‐deficient	  kidney	  phenotypes.	   FLCN	  has	   also	  been	   implicated	   in	  the	  nucleocytoplasmic	  shuttling	  of	  TDP-­‐43,	  a	  protein	  whose	  nuclear	  loss	  in	  combination	  
	   37	  
with	  cytosolic	  accumulation	  initiates	  the	  early	  stages	  of	  neurodegeneration	  [222].	  Since	  BHD	  exhibits	  characteristics	  of	  ciliopathies,	  it	  has	  been	  speculated	  that	  FLCN	  might	  have	  a	  ciliary	  role.	  Studies	  have	  proved	  that	  FLCN	  localizes	  to	  cilia,	  centrosomes	  and	  mitotic	  spindle	   [219].	   Alterations	   in	   the	   levels	   of	   FLCN	   result	   in	   changes	   in	   the	   onset	   of	  ciliogenesis	   rather	   than	  abrogation	  of	  cilia.	  The	  observed	  symptoms	  of	  BHD	  are	  partly	  attributed	  to	  the	  deregulation	  of	  canonical	  Wnt	  signaling	  due	  to	  abnormal	  ciliogenesis.	  BHD	  provides	  an	  interesting	  link	  between	  ciliopathies	  and	  cancer,	  providing	  strength	  to	  the	  argument	  that	  certain	  cancers	  might	  be	  a	  part	  of	  the	  ciliopathy	  spectrum.	  
	  
1.3.	  THE	  PRIMARY	  CILIUM	  AND	  CANCER	  It	  has	  been	  recently	  contemplated	  that	  defects	  in	  the	  biogenesis	  of	  primary	  cilium	  might	  be	  a	  crucial	  step	  in	  the	  development	  of	  cancer.	  This	  hypothesis	  stems	  from	  the	  fact	  that	  cilia	   not	   only	   have	   the	   ability	   to	   influence	   cellular	   signaling	   pathways	   but	   also	   to	  physically	   alter	   the	   progression	   of	   cell	   cycle.	   Plenty	   of	   evidence	   exists	   to	   show	   a	  compelling	  link	  between	  primary	  cilia	  dynamics	  and	  the	  development	  of	  cancer.	  Several	  reports	  document	  the	  loss	  of	  primary	  cilia	  in	  cancer	  cell	  populations	  of	  different	  types	  of	  tissues.	   Because	   the	   primary	   cilium	   regulates	   signaling	   pathways,	   the	   loss	   of	   this	  organelle	   may	   contribute	   to	   aberrant	   signaling	   leading	   to	   cancer	   progression.	   The	  different	  aspects	  of	  the	  primary	  cilium	  in	  development	  of	  cancer	  are	  discussed	  below	  in	  more	  detail.	  	  
1.3.1.	  Role	  of	  the	  primary	  cilium	  in	  cancer	  predisposition	  syndromes	  	  Emerging	  studies	  on	   the	  role	  of	   cilia	   in	   familial	  hereditary	  syndromes	  have	  revealed	  a	  predisposition	   of	   these	   syndromes	   to	   cancer	   development.	   Interestingly,	   several	  well-­‐established	  tumor	  suppressor	  proteins	  have	  been	  identified	  in	  these	  syndromes,	  which	  are	   involved	   in	   the	   biogenesis	   of	   cilia	   in	   addition	   to	   their	   attributed	   functions.	   This	  association	  between	  tumor	  suppressor	  proteins	  and	  cilia	  suggests	  that	  ciliary	  loss	  could	  be	   an	   early	   event	   in	   tumorigenesis.	   For	   example,	   the	   familial	   cancer	   syndrome	   von	  Hippel-­‐Lindau	   disease	   (VHL)	   is	   caused	   by	   mutations	   in	   the	   VHL	   tumor	   suppressor,	  which	  is	  required	  for	  the	  formation	  of	  primary	  cilium	  in	  conjunction	  with	  GSK-­‐3β.	  This	  syndrome	  is	  characterized	  by	  renal	  and	  pancreatic	  cysts,	  clear	  cell	  renal	  cell	  carcinoma	  (ccRCC),	   retinal	   angiomas,	   tumor	   in	   the	   adrenal	   gland,	   cysts	   and	   hemangiomas	   in	   the	  central	  nervous	  system	  [223].	  Similarly,	  mutation	  in	  APC	  tumor	  suppressor	  gene	  causes	  familial	   adenomatous	   polyposis	   (FAP),	   a	   spectrum	  of	   diseases	   that	   includes	  Gardner's	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syndrome	  which	   shows	  manifestations	   like	   desmoid	   tumors,	   osteomas	   and	   skin	   cysts	  [224].	   APC	   protein	   binds	   to	   kinesin-­‐2	   and	   stabilizes	   microtubules	   [225].	   Another	  example	  is	  Gorlin	  syndrome,	  which	  is	  caused	  by	  mutations	  in	  the	  hedgehog	  components	  like	  Ptch1	  or	  SuFu	   that	  are	  associated	  with	  cilia	   [226].	  Characteristics	  of	   this	  disorder	  include	  predisposition	   for	   basal	   cell	   carcinoma	   (BCC)	   and	  medulloblastoma.	  Tuberous	  Sclerosis	  Complex	  (TSC)	  is	  an	  inherited	  genetic	  syndrome	  associated	  with	  the	  formation	  of	  benign	  tumors	  in	  the	  brain,	  kidneys,	  lungs,	  eyes,	  heart	  and	  skin	  [227].	  Normally,	  TSC-­‐associated	   tumors	   are	   not	   malignant	   but	   those	   that	   are	   malignant	   usually	   affect	   the	  kidneys.	  The	  disease	  is	  caused	  by	  mutations	  in	  either	  TSC1	  or	  TSC2	  genes	  that	  code	  for	  tumor	   suppressors	   harmarin	   and	   tuberin	   respectively	   [228].	   Loss	   of	   TSC1	   or	   TSC2	  enhances	   cilia	   length	   in	   fibroblasts	   and	   renal	   tubules	   [229].	   A	   recent	   study	   has	  demonstrated	  that	  interplay	  between	  PKD	  and	  TSC	  genes	  leads	  to	  renal	  cyst	  formation	  in	  a	  TSC	  mouse	  model	   through	  negative	  regulation	  of	  polycystin-­‐1	  (PC-­‐1)	  by	  mTORC1,	  which	  also	  impairs	  the	  trafficking	  of	  PC-­‐1/2	  complex	  to	  the	  cilium	  [230].	  Therefore,	  the	  predisposition	  of	  TSC	  to	  renal	  cancers	  is	  possibly	  linked	  to	  PKD.	  These	  results	  also	  open	  up	  a	  new	  perspective	  for	  the	  use	  of	  mTOR	  inhibitors	  like	  rapamycin	  for	  the	  treatment	  of	  PKD	   and	   TSC.	   Whole-­‐exome	   sequencing	   studies	   have	   revealed	   that	   predisposition	   to	  nasopharyngeal	   carcinoma	   might	   be	   linked	   to	   a	   cilia-­‐related	   gene	   MST1R,	   which	   is	  important	   for	   ciliary	  motility	   in	   the	   epithelial	   cells	   of	   normal	   nasopharyngeal	  mucosa	  [231].	  	  To	   explain	   the	   role	   of	   cilia	   in	   the	   development	   of	   cancer	   in	   familial	   syndromes,	   it	   is	  generally	  agreed	  that	  a	  mutation	  occurs	  or	   is	   inherited	  which	  directly	  affects	  cilia	  or	  a	  pathway	   associated	   with	   ciliary	   function.	   The	   loss	   of	   normal	   ciliary	   function	   leads	   to	  increase	  in	  proliferation,	  which	  may	  result	  in	  immediate	  tumor	  formation	  depending	  on	  the	  function	  of	  mutated	  gene	  involved	  or	  on	  the	  sensitivity	  of	  the	  cell	  to	  ciliary	  signaling.	  In	  other	  cases,	  increased	  proliferation	  results	  in	  pre-­‐cancerous	  benign	  growths	  that	  are	  unstable	   and	   predispose	   the	   cells	   to	   further	   mutations	   that	   ultimately	   lead	   to	   tumor	  formation.	  	  
1.3.2.	  Is	  cancer	  a	  ciliopathy?	  	  The	  development	  of	  cancer	  does	  not	  depend	  on	  one	  single	  event,	  but	  rather	  is	  a	  multi-­‐step	  process	  that	  requires	  the	  cell	  to	  acquire	  several	  capabilities	  that	  allow	  survival	  and	  growth.	  The	  cancer	  cell	  achieves	  these	  required	  capabilities	  by	  promoting	  chromosomal	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instability,	  which	  leads	  to	  the	  accumulation	  of	  multiple	  germline	  and	  somatic	  mutations	  over	  a	  course	  of	  several	  years	  [232].	  Thus,	  mutations	  leading	  to	  the	  loss	  of	  cilium	  alone	  cannot	  be	   a	   sufficient	   requirement	   to	  drive	  or	  prohibit	   tumorigenesis.	  Although	  many	  ciliopathies	   involve	   cell	   cycle	   defects,	   not	   all	   ciliopathies	   predispose	   to	   cancer.	  Therefore,	   it	   would	   be	   incorrect	   to	   proclaim	   that	   cancer	   is	   a	   ciliopathy	   although	   it	  overlaps	  with	  many	  disorders	  of	  the	  ciliopathy	  spectrum.	  	  	  
1.3.3.	  Clinical	  correlation	  between	  primary	  cilia	  and	  cancer	  A	  correlation	  between	  the	   loss	  of	  primary	  cilium	  and	  cellular	   transformation	  has	  been	  observed	  for	  more	  than	  a	  decade	  [233].	  Based	  on	  clinical	  evidence,	  it	  is	  widely	  accepted	  that	  loss	  of	  primary	  cilia	  is	  a	  common	  feature	  of	  cancers.	  A	  number	  of	  reports	  show	  that	  many	  types	  of	  cancers	  tend	  to	  lose	  the	  cilium.	  This	  supports	  the	  line	  of	  scientific	  thinking	  that	  cilia	  might	  act	  as	  tumor	  suppressors.	  However,	  recent	  reports	  provide	  evidence	  that	  some	   types	  of	   cancers	   appear	   to	  be	  dependent	  of	   the	  presence	  of	   cilium,	   suggesting	  a	  tumor-­‐promoting	   role	   of	   cilia.	   Since	   primary	   cilia	   are	   present	   in	   most	   tissues	   of	   the	  human	   body,	   ciliary	   frequencies	   have	   been	   evaluated	   in	   several	   tissues	   and	   their	  corresponding	  tumor	  types.	  	  	  
1.3.3.1.	  Tumors	  dependent	  on	  ciliary	  loss	  
(i)	   Breast	   cancer:	  Microscopic	  analysis	  of	  breast	  cancer	   tissues	  and	  cell	   lines	  derived	  from	  breast	  cancer	  revealed	  decreased	  ciliary	  frequencies	  as	  compared	  to	  normal	  breast	  tissue	   epithelia	   and	   fibroblasts	   [234].	   Cell	   lines	   derived	   from	   aggressive	   cancer	   tissue	  showed	   severely	   reduced	   cilia	   frequencies	   even	   upon	   prolonged	   serum	   starvation.	  However,	  this	  was	  shown	  to	  be	  independent	  of	  increased	  proliferation	  as	  determined	  by	  Ki67	  staining	   [234,	  235].	  Several	  cilia-­‐associated	  genes	   like	  Gli1,	  RPGRIP1	  and	  DNAH9	  are	  known	   to	  be	  mutated	   in	  breast	   cancers	   [236].	  Moreover,	   the	  gene	  NPHP9	  (NEK8),	  which	  is	  a	  known	  modulator	  of	  ciliary	  length,	  is	  upregulated	  in	  breast	  cancers	  [237].	  	  
(ii)	   Kidney	   cancer:	   In	   these	   cancers,	   ciliary	   dysfunction	   usually	   leads	   to	   the	  development	   of	   renal	   cysts,	   which	   is	   a	   hallmark	   characteristic	   of	   many	   classic	  ciliopathies.	   The	   formation	   of	   renal	   cysts	   is	   caused	   in	   part	   by	   the	   deregulation	   of	  canonical	   Wnt	   signaling	   and	   planar	   cell	   polarity	   (PCP)	   pathways	   [238].	   Mounting	  evidence	   suggests	   that	   such	   cystic	   lesions	   increase	   the	   risk	   of	   renal	   cancer	   [239].	  Interestingly,	  Von	  Hippel	  Lindau	  (VHL)	  patients	  display	  complex	  renal	  cysts	  that	  can	  be	  considered	   as	   premalignant	   tumors.	   VHL,	   a	   tumor	   suppressor	   gene	   has	   been	   well	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characterized	  for	  its	  role	  in	  the	  maintenance	  of	  cilia.	  Analysis	  of	  a	  cohort	  of	  kidney	  tissue	  samples	   from	   renal	   cell	   carcinoma	   patients	   revealed	   a	  marked	   decrease	   in	   the	   ciliary	  frequency	   in	   tumor	   tissue	   as	   compared	   to	   adjacent	   normal	   parenchyma	   tissue	   [238].	  This	   observation	   suggests	   that	   primary	   cilia	   are	   predominantly	   lost	   in	   renal	  tumorigenesis	   and	   this	   ciliary	   loss	   might	   possibly	   participate	   in	   malignant	   tumor	  development.	  	  	  
(iii)	   Pancreatic	   cancer:	   Loss	   of	   cilia	   has	   been	   reported	   in	   human	   pancreatic	   ductal	  adenocarcinoma	   (PDAC)	   [240].	   Reduced	   ciliary	   frequencies	   were	   observed	   in	   both	  pancreatic	   cancer	   cells	   and	   pancreatic	   intraepithelial	   neoplasia	   (PanIN)	   lesions	   in	  human	   patients.	   Loss	   of	   cilia	   was	   observed	   to	   occur	   in	   the	   early	   stages	   of	   tumor	  development	   [241].	   Primary	   cilia	   were	   absent	   even	   when	   the	   cells	   were	   not	   actively	  proliferating.	   PDACs	   are	   also	   characterized	   by	   activated	   kras	   signaling	   [242].	  Ciliogenesis	   was	   restored	   in	   a	   mouse	   pancreatic	   cancer	   cell	   line	   upon	   inhibition	   of	  oncogenic	  kras	  pathway,	  thereby	  indicating	  a	  role	  of	  kras	  in	  cilia	  repression	  [240].	  	  	  
(iv)	  Colorectal	  cancer:	  The	  role	  of	  primary	  cilia	  is	  beginning	  to	  emerge	  with	  reports	  of	  mutations	  in	  several	  cilia-­‐associated	  genes	  in	  this	  type	  of	  cancer.	  Aurora	  A,	  a	  kinase	  that	  promotes	   ciliary	   disassembly	   is	   commonly	   mutated	   in	   colorectal	   cancers	   [243].	  Intriguingly,	  the	  gene	  PKHD1,	  which	  is	  often	  mutated	  in	  polycystic	  kidney	  disease	  (PKD)	  has	  also	  been	  found	  to	  be	  mutated	  in	  colorectal	  cancers	  [244].	  Furthermore,	  mutations	  in	  Gli3,	  a	  member	  of	  the	  Hedgehog	  pathway,	  have	  also	  been	  observed	  in	  these	  cancers	  [245].	  Recent	  studies	  have	  shown	  that	  reduction	  in	  the	  number	  of	  primary	  cilia	  in	  colon	  tissue	  is	  strongly	  associated	  with	  an	  increase	  in	  the	  proliferation	  of	  colon	  epithelial	  cells	  [246].	  Put	   together,	   these	  pieces	  of	  evidence	  converge	   to	  a	   role	  of	  primary	  cilia	   in	   the	  pathogenesis	  of	  colorectal	  cancers.	  	  	  
(v)	   Ovarian	   cancer:	   Aberrant	   Hedgehog	   and	   PDGF	   signaling	   has	   been	   reported	   in	  ovarian	  cancer	  cells	  originating	  from	  the	  ovarian	  surface	  epithelium	  [247].	  Perturbation	  of	  these	  two	  critical	  signaling	  pathways	  is	  associated	  with	  defects	  in	  the	  primary	  cilia	  of	  these	  cells.	  Suppression	  of	  ciliogenesis	  was	  observed	  even	  under	  proliferation-­‐limiting	  conditions	  created	  by	  growth	  arrest	  of	  cells	  [247].	  Ovarian	  cancer	  cells	  also	  show	  higher	  levels	  of	  Aurora	  A	  as	  compared	  to	  corresponding	  normal	  cells.	  Given	  that	  these	  cancers	  have	  low	  cilia	  frequencies,	  it	  can	  be	  deduced	  that	  higher	  levels	  of	  Aurora	  A	  are	  involved	  in	   the	   suppression	   of	   ciliogenesis.	   Co-­‐evolutionary	   analysis	   of	   ovarian	   serous	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cystoadenoma	  has	  revealed	  an	  overrepresentation	  of	  mutated	  cilia	  genes	   in	  this	   tissue	  [248].	  Based	  on	   this	  observation,	   the	  authors	  postulate	   that	  deregulation	  of	   the	  ciliary	  network	  of	  proteins	  will	  result	  in	  proliferation	  and	  cancer	  development	  [248].	  	  	  
(vi)	  Melanoma:	  In	  melanomas,	  the	  presence	  of	  cilia	  was	  evaluated	  at	  different	  stages	  of	  development.	  Whereas	  primary	  cilia	  were	  present	  on	  normal	  melanocytes,	  very	  few	  cilia	  were	  present	   in	   early	  melanomas	   in	   situ	   [249].	   Cilia	   are	   completely	   lost	   as	   the	   tumor	  progresses	  to	  invasive	  and	  metastatic	  phases.	  This	  study	  demonstrates	  that	  primary	  cilia	  are	  progressively	  depleted	  in	  cutaneous	  melanoma	  and	  establishes	  the	   loss	  of	  primary	  cilia	  as	  an	  early	  phase	  of	  melanoma	  development	  [249].	  A	  similar	  trend	  was	  observed	  in	  dysplastic	  melanocytic	  nevi	  where	  the	  loss	  of	  cilia	  correlates	  with	  increasing	  degree	  of	  dysplasia	  [250].	  Recent	  studies	  show	  that	  the	  loss	  of	  cilia	  in	  melanomas	  is	  independent	  of	  increased	  proliferation	  and	  cell	  cycle	  progression	  [251].	  	  	  
(vii)	   Prostate	   cancer:	   Primary	   cilia	   are	   lost	   through	   prostate	   cancer	   progression.	   A	  decrease	   in	   the	   percentage	   of	   ciliated	   cells	   was	   observed	   in	   both	   preinvasive	   and	  invasive	  prostate	  cancer	  tissue	  as	  compared	  to	  normal	  tissue	  [252].	  The	  few	  visible	  cilia	  on	  the	  cancer	  tissue	  appeared	  shorter	  and	  dysfunctional,	  as	  assessed	  by	  measurement	  of	  cilia	   length,	  an	  indirect	  measure	  of	  functionality.	  Hh	  and	  canonical	  Wnt	  pathways	  have	  been	  reported	   to	  be	  upregulated	   in	  prostate	  cancers	   [252,	  253].	  Loss	  of	   cilia	  has	  been	  attributed	  to	  the	  increased	  activation	  of	  these	  pathways,	  which	  result	  in	  the	  progression	  of	  prostate	  cancer.	  	  	  
1.3.3.2.	  Cilium-­‐dependent	  tumors	  	  Some	   studies	   have	   provided	   evidence	   that	   cilia	   are	   present	   in	   certain	   cancer-­‐types	  giving	   rise	   to	   the	   notion	   that	   they	  may	   play	   a	   role	   in	   the	   promotion	   of	   such	   cancers.	  Primary	  cilia	  have	  been	  detected	  in	  glioblastoma	  tumor	  biopsies	  and	  primary	  cell	   lines	  in	   a	   subpopulation	   of	   cells	   that	   were	   more	   proliferative,	   invasive	   and	   resistant	   to	  therapeutics	  [254].	  Basal	  cell	  carcinomas	  (BCC)	  and	  medulloblastomas	  have	  been	  shown	  to	  be	  heavily	  dependent	  on	  cilia	  for	  their	  growth	  [255,	  256].	  It	  has	  been	  demonstrated	  that	   KIF3A-­‐mediated	   knockdown	   of	   cilia	   inhibits	   the	   growth	   of	  medulloblastoma	   and	  basal	  cell	  carcinoma	  cells	  [257].	  Primary	  cilia	  were	  also	  reported	  to	  be	  present	  in	  around	  25%	   of	   pancreatic	   ductal	   adenocarcinoma	   tumor	   samples	   and	   the	   presence	   of	   cilia	  correlated	  with	  poor	  prognosis	  [258].	  There	  appears	  to	  be	  a	  range	  in	  the	  percentage	  of	  tumor	  samples	  with	  cilia	  and	  a	  range	  in	  the	  percentage	  of	  cells	  with	  cilia	  in	  an	  individual	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tumor.	   These	   ranges	   should	   be	   further	   explored	   to	   correlate	   specific	   levels	   of	   cilia	  frequency	   with	   specific	   cancer	   subtypes	   and	   response	   to	   treatment.	   Future	   studies	  should	   focus	   on	   the	   separation	   of	   cancer	   cell	   populations	   with	   and	   without	   cilia	   to	  compare	  the	  differences	  between	  them.	  
	  
1.3.4.	  The	  primary	  cilium	  as	  a	  tumor	  promoter	  	  Recent	  studies	  have	  shown	  that	  via	  regulation	  of	  Hh	  pathway,	  cilia	  can	  either	  promote	  or	  prevent	  tumorigenesis.	  The	  outcome	  is	  dependent	  on	  the	  nature	  of	  the	  initiating	  event	  i.e.	  where	  in	  the	  Hh	  pathway	  the	  oncogenic	  mutations	  occur	  [256,	  257]	  (figure	  1.11).	  If	  activating	  mutations	  occur	  downstream	  of	  the	  Hh	  pathway	  (affecting	  Gli2),	  presence	  of	  primary	  cilia	  is	  not	  required	  for	  Hh	  activation	  and	  tumor	  development.	  On	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  the	   contrary,	   when	   mutations	   occur	   at	   the	   receptor	   level	   (Smoothened	   or	   Patched),	  primary	   cilia	   are	   needed	   for	   Hh	   signaling	   and	   consequent	   tumorigenesis.	   Epithelial	  cancers	  like	  ovarian,	  colon	  and	  pancreatic	  cancers	  harbor	  mutations	  downstream	  of	  Hh	  
FIGURE	  1.11.	  Dual	  role	  of	  primary	  cilia	  in	  Hedgehog	  (Hh)-­‐induced	  tumor	  development:	  (a)	  In	  the	  absence	  of	  ligand,	  the	  PTCH	  receptor	  is	  localized	  to	  the	  cilia,	  whereas	  the	  SMO	  co-­‐receptor	  is	  excluded	  from	  the	  cilia.	  The	  GLI3	  repressor	  (GLI3R)	  	  prevents	  activation	  of	  target	  genes.	  (b)	  In	  the	   presence	   of	   primary	   cilia,	   the	   mutant	   oncogenic	   Hedgehog	   co-­‐receptor	   SMO	   constitutively	  localizes	   to	   this	   organelle,	   inhibits	   formation	   of	   GLI3R	   and	   activates	   the	   downstream	   GLI	  transcription	   factors	   (for	   example,	   GLI2).	   GLI2	   stimulates	   target	   gene	   activation,	   promoting	  increased	  cell	  proliferation	  and	  tumor	  development.	  (c)	  Activation	  of	  GLI2	  can	  also	  preferentially	  stimulate	   tumor	   development	   in	   the	   absence	   of	   cilia.	   The	   authors	   propose	   that	   GLI3R	   is	  downregulated	  in	  these	  cells,	  but	  the	  mechanism	  is	  still	  unclear.	  (Figure	  taken	  from	  [253]).	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pathway	   resulting	   in	   indirect	   activation	   of	   Gli2.	   Loss	   of	   cilia	   in	   such	   cancer	   types	  accelerates	   the	   growth	   of	   tumors	   indicating	   that	   primary	   cilia	   function	   as	   tumor	  suppressors	  in	  Gli2-­‐expressing	  cells	  [256,	  259].	  In	  contrast,	  subtypes	  of	  cancers	  that	  are	  heavily	   dependent	   on	   hedgehog	   signaling,	   like	   basal	   cell	   carcinoma,	  medulloblastoma	  and	  glioblastoma	  are	   induced	  by	  an	  activated	   form	  of	  smo	  and	  are	   thus	  dependent	  on	  the	   presence	   of	   cilia	   for	   their	   proliferation	   and	   survival	   [256,	   257,	   260].	   Removal	   of	  primary	  cilium	  strongly	  inhibits	  the	  growth	  of	  these	  tumors.	  Notably,	  the	  role	  of	  primary	  cilia	  may	  extend	  beyond	  Hh-­‐driven	   tumorigenesis,	  which	   is	   evidenced	  by	   the	   fact	   that	  primary	   cilia	   are	   also	   present	   on	   human	   medulloblastomas	   that	   are	   driven	   by	   Wnt	  activation	  [256,	  261,	  262].	  Remarkably,	  some	  human	  medulloblastomas	  display	  primary	  cilia	   whereas	   others	   do	   not.	   In	   fact,	   primary	   cilia	   are	   exclusively	   present	   in	  medulloblastomas	   that	   arise	   due	   to	   activations	   in	   Hh	   or	   Wnt	   signaling	   but	   not	   in	  medulloblastomas	  that	  belong	  to	  other	  distinct	  molecular	  subgroups.	  
	  
1.3.5.	  The	  primary	  cilium	  as	  a	  potential	  tumor	  suppressor	  Given	  the	  ability	  of	  primary	  cilia	  to	  influence	  cell	  cycle	  and	  to	  regulate	  cilia-­‐related	  signal	  transduction,	   any	   defect,	   dysfunction	   or	   loss	   of	   cilia	   has	   been	   considered	   to	   be	   an	  indispensable	  step	  for	  cancer	  development	  [263].	  It	  has	  been	  proposed	  that	  the	  loss	  of	  cilia	  in	  cancer	  cells	  reduces	  or	  alters	  the	  responsiveness	  of	  cells	  to	  extracellular	  cues	  that	  regulate	   cellular	   growth	   and	   differentiation	   [111].	   Cancer	   cells	   lacking	   cilia	   are	   thus	  insensitive	  to	  environmental	  repressive	  signals.	  Many	  recent	  studies	  have	  shown	  that	  a	  large	   number	   of	   receptors	   for	   critical	   signaling	   pathways	   and	   adhesion	  molecules	   are	  clustered	  on	  the	  surface	  of	  the	  cilium,	  which	  necessitates	  the	  presence	  of	  an	  intact	  cilium	  for	  normal	  function.	  These	  include	  components	  of	  several	  pathways	  like	  Sonic	  Hedgehog	  (Shh),	   platelet	   derived	   growth	   factor	   receptor	   a	   (PDGFRα),	   planar	   cell	   polarity	   (PCP),	  von	  Hippel-­‐Lindau	   and	  Glycogen	   Synthase	  Kinase	   3β	   (VHL/GSK3B)	   pathways	   [9,	   146,	  264].	   Therefore,	   primary	   cilia	   are	   necessary	   from	   both	   structural	   and	   signaling	  perspective	  for	  the	  normal	  growth	  and	  development	  of	  a	  cell.	  	  	  Although	  defective	  cilia	  have	  always	  been	  associated	  with	  cancer,	  a	  direct	  role	  of	  cilia	  in	  tumorigenesis	   is	   yet	   to	   be	   established.	   The	   first	   molecular	   link	   between	   ciliary	  disassembly	   and	   cell	   cycle	   progression	   was	   provided	   by	   Snell	   and	   co-­‐workers	   who	  demonstrated	   that	   the	   disassembly	   of	   cilia	   in	   chlamydomonas	   was	   mediated	   by	   the	  protein	   CALK,	   an	   Aurora	   kinase	   that	   promotes	   cell	   cycle	   [265].	   Later,	   the	   group	   of	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Golemis	  replicated	  this	  finding	  in	  mammalian	  cells.	  They	  found	  that	  shortening	  of	  cilia	  in	  mammalian	   cells	   is	   also	  mediated	   through	  Aurora	   kinase-­‐dependent	   pathway	   [17].	   In	  the	   presence	   of	   serum,	   HEF1	   activates	   Aurora	   A,	   which	   phosphorylates	   HDAC6	   to	  promote	  disassembly	  of	  cilia	  followed	  by	  cell	  cycle	  re-­‐entry	  [17,	  266].	  Moreover,	  loss	  of	  genes	   that	   encode	   proteins	   required	   for	   ciliary	   assembly	   leads	   to	   cancer-­‐promoting	  conditions	   like	   defects	   in	   planar	   cell	   polarity,	   constitutive	   activation	   of	   Wnt,	   TGF-­‐β,	  MAPK	   signaling,	   deregulation	   of	   Hh	   signaling,	   EGFR	   and	   c-­‐Myc	   accumulation,	   cystic	  disease,	  epithelial	  hyperplasia	  and	  metaplasia	  [60,	  267-­‐271].	  Increased	  lipogenesis	   is	  a	  feature	  observed	   in	  many	  cancers	  [272].	  The	   lipogenic	  transcription	  factor	  SREBP1c	   is	  often	  aberrantly	  activated	   in	  many	  cancers.	  Our	  group	  has	  recently	  shown	  that	   loss	  of	  cilia	  is	  mediated	  by	  the	  lipogenic	  transcription	  factor	  SREBP1c	  (see	  also	  1.1.5.5.)	  [101].	  Based	  on	  these	  observations,	  it	  would	  be	  reasonable	  to	  expect	  that	  dysfunction	  or	  loss	  of	  the	  cilium	  may	  trigger	  the	  development	  of	  tumors	  and	  malignancies.	  However,	  it	  cannot	  be	  ruled	  out	  that	  cilium	  resorption	  may	  occur	  as	  a	  physiologic	  consequence	  of	  cell	  cycle	  progression	   and	   the	   loss	   of	   cilium	   might	   merely	   represent	   the	   enhanced	   rate	   of	   cell	  division.	  Although	  transformed	  cells	  usually	  lack	  cilia,	  no	  clear	  picture	  has	  emerged	  yet	  to	   ascertain	   whether	   this	   lack	   is	   a	   cause	   or	   consequence	   of	   transformation.	   It	   still	  remains	  a	  long-­‐standing	  unresolved	  question.	  	  Ciliogenesis	   and	   cell	   division	   are	   considered	   as	   events	   that	   are	   mutually	   exclusive.	  Because	   the	   centrioles	  must	   be	   released	   from	   the	   basal	   body	   to	   function	   as	   a	  mitotic	  spindle,	   a	   causal	   relationship	   exists	   between	   cilia	   and	   cell	   cycle	   [33,	   103].	   Based	   on	  studies	  on	  trichoplein	  [76]	  and	  Nek2-­‐Kif24	  [273],	  a	  model	  was	  proposed	  which	  requires	  a	  continuous	  suppression	  of	  primary	  cilia	  formation	  in	  proliferating	  cells	  for	  proper	  cell	  cycle	   progression	   to	   occur	   [274].	   Thus,	   from	   a	   structural	   perspective,	   the	   physical	  presence	  of	  cilium	  on	  a	  cell	  can	  act	  as	  a	  brake	  to	  prevent	  cell	  cycle	  re-­‐entry	  [275].	  This	  concept	   in	   which	   the	   cilium	   functions	   as	   a	   physical	   check	   point	   to	   hamper	   the	  progression	  of	   cell	   cycle	   is	   substantially	   supported	  by	   evidence	   from	   studies	   on	  Nde1	  and	  Tctex-­‐1	   [69,	  81].	  Knockdown	  of	  Nde1,	   a	   centrosomal	  protein,	   results	   in	  elongated	  cilia	   in	   mammalian	   cells.	   Interestingly,	   cells	   with	   longer	   cilia	   due	   to	   Nde1	   depletion	  exhibited	  a	  delay	  in	  cell	  cycle	  re-­‐entry	  after	  serum	  addition.	  Co-­‐depletion	  of	  Nde1	  with	  either	  Ift88	  or	  Ift20,	  two	  essential	  genes	  for	  ciliogenesis,	  reversed	  the	  effect	  confirming	  that	   the	  delayed	   re-­‐entry	  was	  because	   of	   the	   cilium	   [81].	   These	   findings	  were	   further	  substantiated	   by	   reports	   that	   depletion	   of	   Tctex-­‐1,	   a	   dynein	   light	   chain,	   resulted	   in	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delayed	  cilia	  disassembly	  along	  with	  a	  delay	  in	  cell	  cycle	  re-­‐entry	  in	  ciliated	  cells,	  but	  not	  in	  non-­‐ciliated	  cells	  [69].	  Recent	  advances	  in	  the	  understanding	  of	  link	  between	  cilia	  and	  cell	   cycle	   have	   revealed	   several	   mechanisms	   that	   connect	   cell	   cycle	   to	   positive	   and	  negative	  regulators	  of	  ciliogenesis,	  most	  of	  which	  are	  associated	  with	  the	  regulation	  of	  ciliary	   length	   as	   described	   in	   section	   1.1.5.3	   and	   figure	   1.6.	   	   Thus,	   cilia	   appear	   to	  influence	   the	   crucial	   decision	   to	   divide	   or	   differentiate.	   These	   results	   point	   towards	   a	  suppressive	   role	   of	   cilia	   in	   cell	   cycle	   progression	   and	   suggest	   that	   presence	   of	   cilia	  provides	  a	  brake	  mechanism	  to	  restrict	  cell	  cycle	  progression	  in	  cancer	  cells.	  Also,	  from	  a	   therapeutic	   point	   of	   view,	   these	   results	   indicate	   that	   restoration	   of	   primary	   cilia	   in	  cancer	  cells	  could	  suppress	  the	  proliferation	  and	  growth	  of	  tumors.	  	  	  With	   a	   perspective	   on	   tumorigenesis,	   a	   growing	   body	   of	   evidence	   suggests	   that	   the	  regulation	  of	  a	  normal	  cell	  cycle	  depends	  on	  the	  continuous	  tipping	  of	  balance	  to	  recruit	  the	  centrosome	  for	  either	  cell	  division	  or	  ciliogenesis.	  The	  primary	  cilium	  helps	  to	  keep	  cancer	  at	  bay	  by	  maintaining	  a	  balance	  in	  favor	  of	  normal	  cell	  growth.	  Any	  disturbance	  in	   this	   delicate	   balance	   may	   serve	   as	   a	   pro	   cancer	   stimulus	   and	   accelerate	   the	  progression	  of	  cell	  cycle.	  Misregulation	  of	  several	  cilia-­‐associated	  proteins	  or	  shortening	  of	  ciliary	   length	  have	  been	  recognized	  as	   factors	   that	  can	  alter	   this	  balance	   in	   favor	  of	  tumorigenesis.	   Many	   proteins	   that	   are	   closely	   associated	   with	   ciliogenesis	   and	   cilia	  function	  have	  been	   implicated	   in	   cell	   cycle	   control.	  Malfunction	   of	   these	   cilia	   proteins	  result	   in	   cell	   cycle	   defects	   like	   alterations	   in	   cell	   cycle	   timing,	   fidelity	   of	   centrosome	  duplication,	  chromosome	  segregation	  and	  cytokinesis.	  Depletion	  of	  IFT88	  in	  non-­‐ciliated	  cells	   induces	   cell	   cycle	   progression	   whereas	   overexpression	   blocks	   G1/S	   transition	  [276].	  Knockdown	  of	  IFT27	  in	  Chlamydomonas	  delays	  cell	  cycle	  progression	  and	  affects	  cytokinesis	   [277].	   It	   has	   also	   been	   shown	   that	   IFT27	   and	   IFT46	   are	   dynamically	  regulated	  during	  the	  cell	  cycle	  in	  Chlamydomonas,	  implying	  that	  transcriptional	  control	  of	   these	   IFT	   proteins	   is	   restricted	   within	   the	   cell	   cycle	   [278].	   Ciliary	   protein	   BBS4	   is	  required	   for	   the	   anchoring	   of	  microtubules	   to	   centrosome	   and	   has	   been	   shown	   to	   be	  essential	   for	   cell	   cycle	  progression	   [279].	  Knockdown	  of	  BBS4	   in	   cultured	   cells	   blocks	  the	  progression	  of	  cell	  division	  and	  induces	  apoptosis.	  Overall,	  these	  observations	  of	  cell	  cycle	   defects	   have	   led	   to	   the	   hypothesis	   that	   abnormally	   functioning	   cilia	   proteins	  disturb	  the	  balance	  between	  centrosome	  and	  basal	  body	  transition,	  leading	  to	  cell	  cycle	  checkpoint	  activation	  [111].	  The	  disengagement	  of	  centrosomes	  from	  ciliation	  results	  in	  the	  activation	  of	  key	  regulators	  of	  G1/S	  transition,	  Cdk2	  and	  cyclin	  E,	  which	  may	  tip	  the	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balance	   towards	   tumorigenesis	   [111].	   The	   above	   observations	   also	   provide	   evidence	  that	  many	  proteins	  initially	  linked	  to	  the	  cilium	  have	  functions	  that	  are	  not	  limited	  to	  the	  cilium	  alone,	  but	  are	  essential	  for	  cell	  cycle	  and	  other	  important	  cellular	  processes.	  	  
1.4.	  THE	  PRIMARY	  CILIUM	  AS	  A	  THERAPEUTIC	  TARGET	  	  In	   spite	  of	   substantial	   progress	   in	   the	   identification	  of	   ciliopathy	  genes,	   no	  direct	   cilia	  therapies	   are	   available	   to	   the	   patients	   yet.	   Recent	   effort	   to	   treat	   a	   ciliopathy	   by	   gene	  therapy	  has	  yielded	  encouraging	  results.	  The	  utility	  of	  this	  approach	  was	  demonstrated	  in	   ORPK	  mice	   that	   were	   anosmic	   as	   a	   result	   of	   ciliary	   loss	   in	   their	   olfactory	   sensory	  neurons	   (OSN)	   due	   to	  mutations	   in	   IFT88	   gene	   [280].	   Rescue	   of	   ciliary	   structure	   and	  olfactory	   function	   was	   successfully	   achieved	   by	   adenoviral-­‐mediated	   expression	   of	  IFT88	  gene	   in	   fully	  differentiated	  OSNs	  of	   these	  mice.	  Thus,	  re-­‐establishment	  of	  ciliary	  structure	   and	   function	   by	   gene	   therapy	   offers	   a	   viable	   therapeutic	   option	   for	   the	  treatment	  of	  ciliopathies.	  Pharmacological	  development	  of	  orphan	  drugs	  to	  specifically	  treat	   rare	   diseases	   like	   ciliopathies	   is	   economically	   unfeasible.	   Hence	   identification	   of	  cilia	  modulators	   from	   approved	   drugs	   already	   existing	   in	   the	  market	   could	   provide	   a	  quicker	  and	  economical	  solution	  for	  the	  treatment	  of	  ciliopathies.	  We	  have	  exploited	  this	  concept	  in	  our	  lab	  to	  identify	  a	  number	  of	  cilia	  modulating	  drugs,	  which	  is	  discussed	  in	  detail	   in	   the	   later	   part	   of	   this	   thesis.	   Presently,	   cilia	   proteome	   consists	   of	   up	   to	   500	  proteins,	  and	  this	  number	  is	  rising	  with	  the	  discovery	  of	  new	  ciliopathies	  and	  associated	  proteins	   [281,	   282].	   Since	   the	   biological	   functions	   of	   most	   of	   these	   proteins	   are	  unknown,	  the	  future	  approach	  should	  be	  aimed	  at	  performing	  genome	  or	  ciliome-­‐wide	  screens	  to	  identify	  novel	  interactions	  of	  these	  proteins.	  Knowledge	  of	  these	  interactions	  will	   aid	   in	   the	   elucidation	   of	   new	   molecular	   mechanisms,	   which	   can	   be	   exploited	   to	  develop	  therapeutic	  strategies	  for	  ciliopathies	  in	  which,	  so	  far,	  only	  organ	  replacement	  therapy	   is	   the	  possible	   treatment	  option.	  Recently,	  bioengineering	  strategies	  are	  being	  employed	  to	  treat	  degenerative	  diseases	  by	  manipulating	  the	  length	  of	  primary	  cilia	   in	  stem	   cells	   [283].	   Growing	   adult	   stem	   cells	   on	   nanotechnology	   implants	   with	   micro-­‐grooved	  surfaces	  results	  in	  the	  disruption	  of	  biochemical	  pathway	  that	  regulates	  ciliary	  length.	  The	  manipulation	  of	   ciliary	   length	   leads	   to	  changes	   in	  stem	  cell	  differentiation,	  which	  can	  be	  controlled	  to	  alter	  the	  specialization	  of	  stem	  cells.	  Thus	  primary	  cilia	  can	  be	  used	   to	  control	  which	  specialized	  role	  stem	  cells	  go	  on	   to	  perform.	  This	   strategy	   is	  being	  considered	  to	  treat	  a	  number	  of	  degenerative	  conditions	  like	  Parkinson's	  disease,	  Alzheimer's	  disease	  and	  arthritis.	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Several	  of	   the	  numerous	  proteins	  that	  are	  associated	  with	  ciliary	  structure	  or	   function	  might	   serve	   as	   new	   targets	   for	   knockdown	   and	   pharmacological	   inhibition	   studies	   to	  identify	  druggable	  targets.	  Since	  several	  transcription	  factors	  like	  RFX	  factors	  and	  FOXJ1	  that	  regulate	  the	  transcriptional	  program	  in	  cilia	  formation	  have	  been	  implicated	  in	  the	  development	  of	  cancer	  [65],	  investigation	  of	  the	  signaling,	  structural	  and	  transcriptional	  aspects	   of	   the	   primary	   cilium	   has	   the	   potential	   to	   contribute	   valuable	   tools	   for	  improving	  the	  diagnosis	  and	  prognosis	  of	  cancers.	  	  A	  number	  of	  cilia-­‐regulated	  signaling	  pathways	   implicated	   in	   oncogenesis	   (e.g.	   Hh	   pathway)	   are	   being	   considered	   as	   new	  cancer	   drug	   targets	   It	   must	   be	   noted	   that	   the	   efficacy	   of	   therapeutics	   targeting	   Hh	  signaling	  will	  rely	  on	  whether	  the	  activation	  of	  Hh	  pathway	  is	  dependent	  (upstream)	  or	  independent	   (downstream)	   of	   cilia.	   Thus,	   it	   can	   be	   challenging	   to	   manipulate	   an	  organelle	   that	   exerts	   both	   positive	   and	   negative	   effects	   on	   the	   pathway	   activity	   and	  tumorigenesis	  [284].	  As	  a	  future	  direction,	  clinical	  relevance	  of	  the	  relationship	  between	  the	   presence	   of	   cilia	   and	   their	   responsiveness	   to	   Hh	   pathway	   inhibitors	   needs	   to	   be	  evaluated	  so	  that	  it	  can	  be	  used	  as	  a	  tool	  by	  clinicians	  to	  choose	  Hh-­‐targeted	  drugs	  for	  treating	   individual	  cancers.	  From	  the	  perspective	  of	  diagnosis,	  presence	  of	  cilia	  can	  be	  exploited	  as	  a	  useful	  biomarker	  for	  the	  identification	  of	  Hh-­‐dependent	  cancers	  that	  are	  responsive	   to	   Smo	   inhibitors.	   Since	   some	   types	   of	   human	   brain	   cancers	   possess	   cilia	  while	   others	   do	   not,	   cilia	   could	   also	   be	   the	   basis	   in	   diagnosing	   the	   cancer	   type.	  Additionally,	  primary	  cilium	  could	  serve	  as	  a	  useful	  diagnostic	  to	  direct	  the	  treatment	  by	  functioning	   as	   an	   indicator	   of	   the	   specific	   mutation	   responsible	   for	   a	   cancer	   and	   by	  identifying	  the	  aggressiveness	  of	  a	  tumor.	  	  Such	  strategies	  demonstrate	  the	  potential	  of	  primary	  cilium	  as	  a	  new	  avenue	  of	  treatment	  for	  cancers.	  Future	  studies	  should	  focus	  on	  understanding	  the	  relationship	  between	  cilium,	  cell	  cycle	  and	  ciliary	  signaling	   in	  order	  to	  facilitate	  the	  development	  of	  strategies	  that	  can	  regulate	  cancer	  and	  cell-­‐division	  rates	  rather	  than	  targeting	  the	  cells	  themselves.	  	  	  
1.5.	  HYPOTHESIS	  As	   detailed	   above,	   evidence	   is	   accumulating	   that	   the	   primary	   cilium	   functions	   as	   a	  unique	  cellular	  antenna	  that	  senses	  a	  number	  of	  external	  parameters	  and	  converts	  these	  to	   intracellular	   signals	   that	   regulate	   normal	   tissue	   development	   and	   homeostasis.	  Defects	   in	  the	  formation	  or	  functioning	  of	  the	  cilium	  contribute	  to	  various	  pathologies,	  ranging	  from	  classical	  ciliopathologies	  to	  cancer.	  	  In	  cancer	  the	  primary	  cilium	  seems	  to	  play	   a	   dual	   role	   in	   most	   cancer	   types	   like	   melanoma,	   breast,	   kidney,	   pancreatic,	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1.6.	  AIMS	  AND	  OBJECTIVES	  In	  view	  of	  the	  central	  role	  of	  the	  primary	  cilium	  in	  cellular	  physiology	  and	  its	  emerging	  role	  in	  various	  diseases	  including	  cancer,	  the	  prime	  goal	  of	  this	  research	  project	  was	  to	  explore	   the	   feasibility	   of	   using	   small	   molecules	   to	   normalize	   the	   cilium	   in	   disease	  conditions,	   with	   cancer	   as	   the	   main	   paradigm.	   	   As	   currently	   only	   few	   chemical	  compounds	  affecting	  the	  cilium	  are	  known,	  the	  main	  aims	  of	  this	  project	  were:	  	  I.	   To	  identify	  novel	  small	  molecule	  modulators	  of	  the	  primary	  cilium.	  	  II.	   	   	  To	  explore	   the	   feasibility	  of	   these	   chemical	  modulators	   to	  normalize	   the	   cilium	   in	  cancer	  models	  (and	  a	  ciliopathy	  model).	  III.	   To	   examine	   the	   mechanisms	   by	   which	   some	   of	   these	   compounds	   normalize	  ciliogenesis	  	   To	  this	  end	  a	  small	  molecule	  screening	  platform	  was	  developed	  based	  on	  an	  IN	  Cell	  high	  content	   analysis	   screen	   involving	   immunostaining	   and	   quantification	   of	   ciliation	   in	  otherwise	  poorly	  ciliated	  pancreatic	  cancer	  cells.	  The	  feasibility	  of	  the	  identified	  hits	  to	  restore	   ciliogenesis	   in	   pancreatic	   cancer	   cells	   and	   to	   attenuate	   their	   proliferation	  was	  examined	  	  (Chapter	  2).	  	  	  For	  a	  selection	  of	   the	  compounds	   identified	   in	  Chapter	  2,	   the	  role	  of	  secreted	  ATP	  and	  the	   purinergic	   receptor	   signaling	   pathway	   in	   cilium	   normalization	   was	   explored	  (Chapter	  3).	  	  In	   Chapter	   4,	   the	   same	   screening	   platform	   was	   used	   to	   identify	   compounds	   from	   a	  kinase	  inhibitor	  library	  as	  cilium	  modulators.	  	   Finally,	   an	   independent	   screening	   platform	   was	   set	   up	   based	   on	   SREBP1c-­‐mediated	  cilium	  suppression	  in	  MDCK	  kidney	  cells.	  This	  platform	  was	  used	  to	  screen	  a	  library	  of	  new	   compounds.	   	   The	   identified	   compounds	   were	   tested	   in	   cancer	   models	   and	   in	   a	  ciliopathy	  model,	  and	  the	  involvement	  of	  vesicle	  trafficking	  in	  the	  normalization	  of	  the	  cilium	  was	  examined	  (Chapter	  5).	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2.1.	  Abstract	  The	   development	   of	   cancer	   is	   often	   accompanied	   by	   a	   loss	   of	   the	   primary	   cilium,	   a	  microtubule-­‐based	  cellular	  protrusion	  that	  functions	  as	  a	  cellular	  antenna	  and	  that	  puts	  a	  break	  on	  cell	  proliferation.	  Hence,	  restoration	  of	  the	  primary	  cilium	  in	  cancer	  cells	  may	  represent	  a	  novel	  promising	  approach	  to	  attenuate	  tumor	  growth.	  Using	  a	  high	  content	  analysis-­‐based	   approach	  we	   screened	   a	   library	   of	   clinically	   evaluated	   compounds	   and	  marketed	   drugs	   for	   their	   ability	   to	   restore	   primary	   cilium	   expression	   in	   pancreatic	  ductal	  cancer	  cells.	  A	  diverse	  set	  of	  118	  compounds	  stimulating	  cilium	  expression	  was	  identified.	   These	   included	   glucocorticoids,	   fibrates	   and	   other	   nuclear	   receptor	  modulators,	   neurotransmitter	   regulators,	   ion	   channel	   modulators,	   tyrosine	   kinase	  inhibitors,	   DNA	   gyrase/topoisomerase	   inhibitors,	   antibacterial	   compounds,	   protein	  inhibitors,	   microtubule	   modulators,	   and	   COX	   inhibitors.	   Certain	   compounds	   also	  dramatically	  affected	  the	  length	  of	  the	  cilium.	  For	  a	  selection	  of	  compounds	  (Clofibrate,	  Gefitinib,	   Sirolimus,	   Imexon	   and	   Dexamethasone)	   their	   ability	   to	   restore	   ciliogenesis	  was	  confirmed	  in	  a	  panel	  of	  human	  cancer	  cell	  line	  models	  representing	  different	  cancer	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types	  (pancreas,	  lung,	  kidney,	  breast).	  Most	  compounds	  attenuated	  cell	  proliferation,	  at	  least	  in	  part	  through	  induction	  of	  the	  primary	  cilium,	  as	  demonstrated	  by	  cilium	  removal	  using	  chloral	  hydrate.	  These	  findings	  reveal	  that	  several	  commonly	  used	  drugs	  restore	  ciliogenesis	   in	   cancer	   cells,	   and	   warrant	   further	   investigation	   of	   their	   antineoplastic	  properties.	  	  
2.2.	  Introduction	  The	   primary	   cilium	   is	   a	   single,	   microtubule-­‐based	   structure	   that	   protrudes	   from	   the	  surface	   of	   most	   mammalian	   cells	   [1].	   It	   functions	   as	   a	   cellular	   antenna	   that	   captures	  signals	  from	  the	  environment	  and	  serves	  as	  a	  hub	  of	  key	  developmental	  and	  homeostatic	  signaling	   pathways	   including	  Wnt,	   planar	   cell	   polarity,	   and	   Hedgehog	   signaling	   [2-­‐4].	  Defects	   that	   compromise	   ciliary	   function	   contribute	   to	   specific	   disorders	   including	  Polycystic	   Kidney	   Disease	   (PKD),	   Birt-­‐Hogg-­‐Dubé	   (BHD)	   syndrome,	   Bardet-­‐Biedl	  Syndrome	   (BBS)	   and	   others.	   Interestingly,	   several	   of	   these	   syndromes	   predispose	  affected	   carriers	   to	   the	  onset	  of	   cancer	   [5-­‐7].	  Moreover,	   an	  ever-­‐increasing	  number	  of	  papers	   report	   on	   a	   decrease,	   loss,	   or	   distortion	   of	   the	   primary	   cilium	   in	   a	   variety	   of	  cancer	   types	   [8-­‐11].	   These	   include	   pancreatic	   cancer,	   breast	   cancer,	   melanoma,	   and	  prostate	   cancer.	   It	   is	   commonly	   assumed	   that	   the	   cilium	   puts	   a	   break	   on	   cell	  proliferation	   as	   it	   uses	   the	   same	   structural	   components	   required	   for	   chromosome	  segregation	  [12-­‐14].	  Loss	  of	  the	  cilium	  in	  cancer	  cells	  may,	  therefore,	  release	  this	  break	  and,	   moreover,	   may	   contribute	   to	   distorted	   cellular	   signaling,	   which	   is	   a	   hallmark	   of	  cancer.	  Hence,	   restoration	  of	   the	  primary	  cilium	   in	  cancer	  cells	  may	  represent	  a	  novel	  promising	  approach	  to	  attenuate	  cell	  proliferation	  and	  may	  provide	  novel	  opportunities	  for	   therapeutic	   antineoplastic	   intervention.	   However,	   so	   far	   few	   chemical	   compounds	  are	  known	  that	  normalize	  ciliogenesis	  in	  cancer	  cells.	  Here,	  we	  have	   established	   a	  high	   content	   analysis-­‐based	   screening	  method	   to	   identify	  small	   molecules	   that	   have	   the	   ability	   to	   restore	   the	   primary	   cilium	   in	   cancer	   cells.	  Further	   application	   of	   this	   method	   to	   screen	   a	   repurposing	   library	   composed	   of	  clinically	  evaluated	  compounds	  and	  marketed	  drugs	  revealed	  that	  many	  commonly	  used	  drugs	  restore	  the	  primary	  cilium	  in	  cancer	  cells	  and	  attenuate	  cell	  proliferation.	  These	  findings	  provide	  new	  insight	  into	  the	  spectrum	  of	  action	  of	  some	  commonly	  used	  drugs	  and	  may	  promote	  the	  expedited	  application	  of	  cilia-­‐based	  therapies	  via	  repurposing	  of	  existing	  drugs	  in	  the	  field	  of	  oncology	  and	  beyond.	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2.3.	  Results	  
2.3.1.	   High	   content	   analysis-­‐based	   screening	   for	   cilium-­‐inducing	   compounds	   in	  
pancreatic	  ductal	  cancer	  cells	  To	  screen	  a	  compound	  library	  for	  potential	  modulators	  of	  ciliogenesis,	  we	  developed	  an	  immunofluorescence	   microscopy-­‐based	   phenotypic	   screening	   strategy	   in	   a	   96-­‐well	  format	   using	   an	   IN	   Cell	   2000	   High	   Content	   Analyzer	   (Figure	   2.1).	   Pancreatic	   ductal	  cancer	  cells	  were	  chosen	  as	  the	  prime	  biological	  model	  in	  view	  of	  their	  well-­‐documented	  loss	   of	   the	   primary	   cilium	   [10].	   From	   a	   preliminary	   screening	   of	   a	   panel	   of	   human	  pancreatic	   cancer	   cell	   lines,	   CFPAC-­‐1	   cells	  were	   selected	   for	   the	   compound	   screening	  based	  on	   their	   ability	   to	   grow	  as	   flat	  monolayers,	  which	   is	   a	  prerequisite	   for	   accurate	  automated	   image	  acquisition,	   and	   for	   their	   inherent	   low	  rate	  of	   ciliogenesis,	   even	  at	   a	  high	  confluence	  (Figure	  2.2).	  After	  incubation	  with	  1600	  different	  compounds	  from	  the	  Pharmakon	  1600	  library	  (all	  drugs	  added	  at	  10	  micromolar	  in	  DMSO),	  the	  percentage	  of	  ciliated	   cells	   was	   assessed	   in	   single	   wells	   by	   fluorescence	   microscopy-­‐based	  visualization	   of	   the	   primary	   cilium	   using	   antibodies	   targeting	   cilium-­‐associated	  acetylated	   tubulin.	   Nuclei	   were	   stained	   with	   Hoechst-­‐33258.	   Images	   were	   analyzed	  using	  IN	  Cell	  Developer	  software	  according	  to	  the	  workflow	  illustrated	  in	  Figure	  2.2.	  A	  cell	   was	   considered	   ciliated	   when	   the	   primary	   cilium	   signal	   (fluorescent	   dot)	   was	  enclosed	  within	  the	  nuclear	  border	  of	  the	  segmented	  nuclei.	  If	  more	  than	  one	  cilium-­‐like	  dot	  was	  detected	  within	   the	  nuclear	  border,	   the	  bigger	  dot	  was	  selected	  as	   the	  match.	  The	  number	  of	  ciliated	  cells	  was	  then	  determined	  by	  counting	  the	  total	  number	  of	  nuclei	  and	   linked	   cilia	   in	   20	   fields	   in	   a	   single	   well.	   Compounds	   were	   considered	   ciliogenic	  based	  on	  their	  ability	  to	   increase	  the	  percentage	  of	  ciliated	  cells	  by	  at	   least	  3	  standard	  deviations	  compared	  to	  vehicle	  control.	  Using	  this	  approach,	  156	  ciliogenic	  compounds	  were	  identified	  in	  the	  initial	  screen.	  To	  eliminate	  false	  positives,	  the	  initial	  hits	  were	  re-­‐evaluated	  in	  triplicate	   in	  a	  secondary	  screen	  using	  the	  same	  screening	  strategy.	   In	  this	  screen	  118	  cilium-­‐enhancing	  compounds	  were	  confirmed.	  110	  of	  these	  compounds	  were	  found	   to	   increase	   ciliogenesis	   by	   at	   least	   a	   factor	   2	   (Figure	   2.3A).	   Besides	   cilium-­‐enhancing	   compounds,	   we	   identified	   22	   compounds	   that	   decreased	   ciliogenesis	   by	   at	  least	   2-­‐folds.	   The	   stimulatory	   compounds	   were	   categorized	   into	   9	   different	   classes	  based	   on	   their	   potential	   molecular	   targets	   (Table	   2.1).	   More	   than	   one	   third	   of	   the	  positive	   compounds	   (49/118)	   were	   classified	   as	   glucocorticoids,	   fibrates	   or	   other	  nuclear	   receptor	   modulators	   (Figure	   2.3B).	   14/118	   compounds	   were	   categorized	   as	  neurotransmitter	  modulators.	  Other	  classes	   included	   ion	  channel	  modulators,	   tyrosine	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Figure	   2.1.	   Schematic	   representation	  of	   the	   screening	  strategy	  of	   the	  Pharmakon	  Library	  using	  the	  human	  CFPAC-­‐1	  pancreatic	  cancer	  cell	  line	  model.	  	  































Figure	   2.2.	   Imaging	   of	  ciliated	  cells	  using	  the	  IN	  Cell	  Analyzer	   2000	   Imaging	  system.	   (A)	   Depiction	   of	   the	  image	  processing	  procedure,	  including	   the	   use	   of	   a	  watershed	   clump	   breaking	  algorithm	  to	  delineate	  nuclei.	  (B)	  Example	  of	  processed	  IN	  Cell	   Analyzer	   images	   of	  poorly	   ciliated	   control	  CFPAC-­‐1	   cells	   (left	   panel)	  and	   well-­‐ciliated	   Gefitinib-­‐treated	   CFPAC-­‐1	   cells	   (right	  panel).	  Nuclei	  are	  delineated	  by	   yellow	   lines.	   Cilia	   are	  indicated	   by	   small	   green	  circles.	  	  	  
Figure	  2.3.	  Summary	  of	  the	  outcome	  of	  the	  high	  content	  screen.	  (A)	  Ciliogenic	  capacity	  of	  1600	  compounds	  of	  the	  Pharmakon	  1600	  library	  in	  CFPAC-­‐1	  cells	  using	  IN	  Cell	  Analyzer	  high	  content	  analysis.	   Compounds	   are	   ranked	   according	   to	   their	   potency	   to	   increase	   the	   percentage	   of	  ciliated	  cells	  relative	  to	  vehicle-­‐treated	  cells	  (red	  dotted	  line).	  (B)	  Target	  diversity	  of	  confirmed	  hits	  is	  shown	  as	  a	  percentage	  of	  abundances	  of	  compounds	  in	  each	  class.	  	  





RATIO ACTION TARGET 
1. STEROID RECEPTOR MODULATORS       
Glucocorticoid receptor modulators             
HYDROCORTISONE	  BUTYRATE	   6.33	   Glucocorticoid,	  anti-­‐inflammatory	   GR	  
AMCINONIDE	   6.30	   Glucocorticoid,	  anti-­‐inflammatory	   GR	  
DESONIDE	   6.25	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
CLOBETASOL	  PROPIONATE	   6.11	   Glucocorticoid,	  anti-­‐inflammatory	   GR	  
PREDNISOLONE	  HEMISUCCINATE	   6.10	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
BETAMETHASONE	  17,21-­‐DIPROPIONATE	   6.00	   Glucocorticoid,	  anti-­‐inflammatory	   GR	  
ALCLOMETAZONE	  DIPROPIONATE	   5.89	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
DESOXYMETASONE	   5.64	   Anti-­‐inflammatory	   GR	  
BETAMETHASONE	  ACETATE	   5.26	   Anti-­‐inflammatory	   GR	  
PREDNICARBATE	   5.19	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
TRIAMCINOLONE	  DIACETATE	   5.16	   Anti-­‐inflammatory	   GR	  
DEXAMETHASONE	   5.09	   Glucocorticoid	   GR	  
PREDNISOLONE	  SODIUM	  PHOSPHATE	   5.09	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
METHYLPREDNISOLONE	  SODIUM	  
SUCCINATE	  
4.93	   Glucocorticoid,	  anti-­‐inflammatory	   GR	  
TRIAMCINOLONE	  ACETONIDE	   4.88	   Anti-­‐inflammatory	   GR	  
BECLOMETHASONE	  DIPROPIONATE	   4.83	   Anti-­‐asthmatic,	  topical	  antiinflammatory	   GR	  
TRIAMCINOLONE	   4.82	   Glucocorticoid	   GR	  
HYDROCORTISONE	  HEMISUCCINATE	   4.82	   Glucocorticoid	   GR	  
FLUOROMETHOLONE	   4.71	   Glucocorticoid,	  Anti-­‐inflammatory	   GR	  
ISOFLUPREDNONE	  ACETATE	   4.68	   Anti-­‐inflammatory	   GR	  
DEXAMETHASONE	  SODIUM	  PHOSPHATE	   4.66	   Glucocorticoid,	  Anti-­‐inflammatory	   GR	  
FLUOCINOLONE	  ACETONIDE	   4.65	   Glucocorticoid,	  Anti-­‐inflammatory	   GR	  
HYDROCORTISONE	  PHOSPHATE	  TRIETHYLAMINE	   4.64	   Glucocorticoid	   GR	  
DEFLAZACORT	   4.62	   Anti-­‐inflammatory	  	   GR	  
BUDESONIDE	   4.61	   Anti-­‐inflammatory	  	   GR	  
DEXAMETHASONE	  ACETATE	   4.60	   Glucocorticoid,	  Anti-­‐inflammatory	   GR	  
FLUMETHAZONE	  PIVALATE	   4.59	   Glucocorticoid,	  Anti-­‐inflammatory	   GR	  
PREDNISOLONE	  ACETATE	   4.28	   Glucocorticoid	   GR	  
FLUDROCORTISONE	  ACETATE	   4.20	   Mineralocorticoid	   GR/MR	  
PREDNISOLONE	   4.27	   Glucocorticoid	   GR	  
HYDROCORTISONE	  ACETATE	   4.18	   Glucocorticoid,	  antiinflammatory	   GR	  
FLUTICASONE	  PROPIONATE	   4.12	   Anti-­‐inflammatory	   GR	  
FLUNISOLIDE	   3.87	   Anti-­‐inflammatory	  	   GR	  
FLUMETHASONE	   3.82	   Anti-­‐inflammatory	   GR	  
FLUOCINONIDE	   3.78	   Anti-­‐inflammatory,	  Glucocorticoid	   GR/MR	  
DIFLORASONE	  DIACETATE	   3.74	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
BETAMETHASONE	  SODIUM	  PHOSPHATE	   3.62	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
BETAMETHASONE	  VALERATE	   3.56	   Glucocorticoid	   GR	  
MEDRYSONE	   3.54	   Glucocorticoid	   GR	  
HYDROCORTISONE	  VALERATE	   3.52	   Anti-­‐inflammatory,	  glucocorticoid	   GR	  
FLURANDRENOLIDE	   3.45	   Anti-­‐inflammatory	  	   GR	  
BETAMETHASONE	   3.40	   Glucocorticoid,	  anti-­‐inflammatory	   GR	  
METHYLPREDNISOLONE	   3.34	   Glucocorticoid	   GR	  
Estrogen receptor modulators 
	  	   	  	   	  	  
ESTRADIOL	  BENZOATE	   3.96	   Estrogen	   ER	  
Progesteron receptor modulators 	  	   	  	   	  	  
MEDROXYPROGESTERONE	  ACETATE	   3.42	   Contraceptive	   PR	  agonist	  
Thyroid receptor modulators 
	  	   	  	   	  	  
IOPANIC	  ACID	   3.29	   Radio-­‐opaque	  agent	   5'deiodinase	  73-­‐74	  
conversion	  	  
LIOTHYRONINE	   1.35	   Thyroid	  hormone	  blocker,	  antidepressant	   THR	  
Table	  2.1.	  List	  of	  ciliogenic	  drugs	  identified	  from	  the	  Pharmakon	  1600	  library	  screen.	   	  Compounds	  are	   classified	   according	   to	   their	   potential	   targets	   and	   arranged	   in	   descending	   order	   of	   ciliogenic	  potential	  in	  CFPAC-­‐1	  cells	  as	  assessed	  by	  IN	  Cell	  analysis	  (expressed	  as	  ratio	  of	  %	  of	  ciliated	  cells	  in	  treated	   cultures	   versus	   vehicle	   control)	   within	   each	   group.	   GR,	   glucocorticoid	   receptor;	   MR,	  mineralocorticoid	   receptor;	   ER,	   estrogen	   receptor;	   PR,	   progesterone	   receptor;	   THR,	   thyroid	  hormone	   receptor;	  MAO,	  mono	   amine	   oxidase;	   DR,	   dopamine	   receptor;	   NCR,	   nicotinic	   cholinergic	  receptor;	  MOR,	  mu-­‐opioid	   receptor;	   A1AR,	   alpha	   1	   adrenergic	   receptor;	   A2AR,	   alpha	   2	   adrenergic	  receptor;	   B1AR,	   beta	   1	   adrenergic	   receptor;	   COX,	   cyclooxygenase;	   TKR,	   tyrosine	   kinase	   receptor;	  ACE,	  angiotensin-­‐converting	  enzyme.	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PPAR receptor modulators 
	  	   	  	   	  	  
CLOFIBRATE	   6.06	   Antihyperlipidemic	   (PPAR)	  alpha	  agonist	  	  
PIOGLITAZONE	  HYDROCHLORIDE	   2.15	   Antidiabetic	   (PPAR)	  gamma	  agonist	  	  
2. NEUROTRANSMITTER 
MODULATORS 
	  	   	  	   	  	  
Serotonin transporter inhibitors 
PAROXETINE	  HYDROCHLORIDE	   6.69	   Antidepressant	   Serotonin	  transporter	  	  
MILNACIPRAN	  HYDROCHLORIDE	   3.80	   Inhibitor	  of	  norepinephrine	  and	  seritonin	  
uptake,	  treatment	  of	  fibromyalgia	  
Serotonin	  transporter	  	  
Serotonin breakdown inhibitors 	  	  
	  	   	  	  
PARGYLINE	  HYDROCHLORIDE	   4.55	   Antihypertensive	   MAO	  
Serotonin receptor inhibitors 	  	   	  	   	  	  
TEGASEROD	  MALEATE	   5.90	   5HT4	  receptor	  agonist,	  peristaltic	  stimulant	   5HT	  receptor	  
ALMOTRIPTAN	   3.96	   5HT	  1B/2D	  receptor	  agonist	   5HT	  receptor	  
RIZATRIPTAN	  BENZOATE	   1.45	   5HT-­‐1B/1D	  agonist,	  antimigraine	   5HT	  receptor	  
Dopamine receptor modulators 	  	   	  	  
	  	  
PERGOLIDE	  MESYLATE	   3.59	   Dopamine	  receptor	  agonist	   DR	  
Nicotinic cholinergic receptor modulators 	  	   	  	  
	  	  
GALLAMINE	  TRIETHIODIDE	   2.27	   Muscle	  relaxant	  (skeletal)	   NCR	  antagonist	  
Mu-opiod receptor modulators 	  	   	  	  
	  	  
LOPERAMIDE	  HYDROCHLORIDE	   3.85	   Ca	  channel	  blocker	   MOR	  agonist	  
Alpha1-adrenergic receptor modulators 	  	   	  	  
	  	  
OXYMETAZOLINE	  HYDROCHLORIDE	   3.55	   Adrenergic	  agonist,	  nasal	  decongestant	   A1AR	  agonist	  
ADRENOLONE	  HYDROCHLORIDE	   2.42	   Adrenergic	  (opthalmic)	   A1AR	  agonist	  
Alpha2-adrenergic receptor modulators 
	  	   	  	   	  	  
XYLAZINE	   3.76	   Analgesic	   A2AR	  
Beta1-adrenergic receptor modulators 	  	   	  	  
	  	  
DOBUTAMINE	  HYDROCHLORIDE	   4.83	   Cardiotonic	   B1AR	  agonist	  
ACEBUTOLOL	  HYDROCHLORIDE	   3.90	   Antihypertensive,	  antianginal,	  antiarrhythmic	   B1AR	  antagonist	  
3. ION CHANNEL MODULATORS 	  	   	  	   	  	  
CAPSAICIN	   4.52	   Analgesic	  (topical)	   TRPV1	  channel	  
ESOMEPRAZOLE	  POTASSIUM	   4.47	   Gastric	  acid	  secretion	  inhibitor	   H+/K+	  exchange,	  alpha	  
polypeptide	  	  
BUPIVACAINE	  HYDROCHLORIDE	   4.29	   Anesthetic	  (local)	   SCN10A	  blocker	  
SURAMIN	  HEXASODIUM	   2.85	   Antiprotozoal,	  trypanocidal,	  antiviral	   ATP-­‐activated	  ion	  channel	  
blocker	  
OXCARBAZEPINE	   1.38	   Antipsychotic	  /	  Na	  channel	  inhibition	   SCN1A	  blocker	  
4. COX INHIBITORS 	  	   	  	  
	  	  
KETOROLAC	  TROMETHAMINE	   3.92	   Anti-­‐inflammatory	  /	  cyclooxygenase	   COX	  
INDOPROFEN	   1.88	   Analgesic,	  anti-­‐inflammatory	  /	  cyclooxygenase	   COX	  
5. TYROSINE KINASE INHIBITORS 	  	   	  	   	  	  
GEFITINIB	   4.89	   Antineoplastic	  /	  EGFR	  inhibitor	   TKR	  
LEFLUNOMIDE	   4.24	   Antineoplastic,	  PDGF	  receptor	  blocker	   TKR	  
TANDUTINIB	   2.81	   Tyrosine	  kinase	  inhibitor	   TKR	  
6. ANTIBACTERIAL PEPTIDOGLYCAN 
SYNTHESIS INHIBITORS 
 
	  	   	  	   	  	  
CEFPROZIL	   4.48	   Antibacterial	   Peptidoglycan	  synthesis	  	  
CEFOXITIN	  SODIUM	   4.11	   Antibacterial	   Peptidoglycan	  synthesis	  	  
CEFAMANDOLE	  SODIUM	   3.76	   Antibacterial	   Peptidoglycan	  synthesis	  	  
HETACILLIN	  POTASSIUM	   1.90	   Antibacterial	   Peptidoglycan	  synthesis	  	  
CEFTIBUTEN	   1.42	   Antibacterial	   Peptidoglycan	  synthesis	  	  
7. DNA GYRASE/TOPOISOMERASE 
INHIBITORS 
	  	   	  	   	  	  
CIPROFLOXACIN	   6.45	   Antibacterial,	  fungicide	   DNA	  gyrase	  topoisomerase	  
GEMIFLOXACIN	  MESYLATE	   4.49	   Antibacterial	   DNA	  gyrase	  topoisomerase	  
LOMEFLOXACIN	  HYDROCHLORIDE	   3.94	   Antibacterial	   DNA	  gyrase	  topoisomerase	  
8. PROTEIN SYNTHESIS INHIBITORS 	  	   	  	  
	  	  
SIROLIMUS	   6.06	   Immunosuppressant,	  antineoplastic;	  rapamycin	   mTOR	  /	  protein	  synthesis	  
OXYTETRACYCLINE	   4.02	   Antibacterial	   Protein	  synthesis	  	  
MECLOCYCLINE	  SULFOSALICYLATE	   3.57	   Antibacterial	   Protein	  synthesis	  	  
GENTAMICIN	  SULFATE	   2.45	   Antibacterial	   Protein	  synthesis	  	  
9. MICROTUBULE MODULATORS 	  	   	  	  
	  	  
DOCETAXEL	   2.51	   Antineoplastic	   Microtubule	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OTHERS (unclassified so far) 	  	   	  	   	  	  
IMEXON	   5.39	   Antineoplastic	   	  	  
SEMUSTINE	   5.31	   Antineoplastic	   	  	  
DENATONIUM	  BENZOATE	   4.92	   Denaturing	  agent,	  bitter	  principle	   	  	  
TRANILAST	   4.82	   Antiallergic,	  mast	  cell	  degranulation	  inhibitor,	  
angiogenesis	  blocker	  
	  	  
DICHLORISONE	  ACETATE	   4.42	   Antipruretic	   	  	  
OSELTAMIVIR	  PHOSPHATE	   4.38	   Antiviral	   Neuraminidase	  	  
DIBENZOTHIOPHENE	   4.36	   Keratolytic	   	  	  
PENTAGASTRIN	   4.29	   Gastric	  secretion	  indicator	   	  	  
RETINYL	  PALMITATE	   4.05	   Provitamin,	  antixerophthalamic	   	  	  
SULCONAZOLE	  NITRATE	   4.03	   Antifungal	   Sterol	  14alpha-­‐
demethylase	  	  
DOCUSATE	  SODIUM	   4.02	   Stool	  softener	   Anionic	  surfactant	  
BIFONAZOLE	   3.93	   Antifungal,	  calmodulin	  antagonist	   Sterol	  14alpha-­‐
demethylase	  	  
TRANDOLAPRIL	   3.89	   Antihypertensive,	  ACE	  inhibitor	   ACE	  
PROCARBAZINE	  HYDROCHLORIDE	   3.60	   Antineoplastic	   	  	  
MANNITOL	   3.59	   Diuretic,	  sweetener,	  diagnostic	  aid	   	  	  
ARGININE	  HYDROCHLORIDE	   3.32	   Ammonia	  detoxicant,	  diagnostic	  aid	   	  	  
TOLNAFTATE	   3.31	   Antifungal	   Squalene	  epoxidase	  	  
PENTETIC	  ACID	   3.18	   Chelating	  agent,	  diagnostic	  aid	   	  	  
AVOBENZONE	   3.04	   Sunscreen	   	  	  
IODOQUINOL	   2.99	   Antiamebic	   	  	  
PRILOCAINE	  HYDROCHLORIDE	   2.93	   Anesthetic	  (local)	   	  	  
AMPYZINE	  SULFATE	   2.88	   CNS	  stimulant	   	  	  
BENZOXIQUINE	   2.71	   Anti-­‐infective	   	  	  
PRASUGREL	   2.69	   Platelet	  aggregation	  inhibitor	   	  	  
TRIENTINE	  HYDROCHLORIDE	   2.60	   Chelating	  agent	   	  	  
PARAROSANILINE	  PAMOATE	   2.56	   Antihelminthic,	  antischistosomal	   	  	  
NADIDE	   2.24	   Alcohol	  and	  narcotic	  antagonist	   	  	  
ANEBROMPHENIRAMINE	  MALEATE	   2.14	   H1	  antihistamine	   	  	  
ISOTRETINON	   2.12	   Anti-­‐acne,	  antineoplastic	   	  	  
ANETHOLE	   2.02	   Expectorant,	  gastric	  stimulant,	  insecticide	   	  	  
CLOFZAMINE	   1.92	   Antibacterial,	  antilepretic,	  antituberculosis	   Guanine,	  PLA2,	  
inhibits	  Smase	  
LITHIUM	  CITRATE	   1.38	   Antidepressant	   	  	  
	  
	  
2.3.2.	  Confirmation	  of	  ciliogenic	  ability	  of	  representative	  compounds	  by	  confocal	  
microscopy.	  	  From	  the	  118	  cilium-­‐enhancing	  compounds	  identified	  in	  the	  IN	  Cell	  Analyzer	  screen,	  we	  selected	  20	  representative	  compounds	   from	  the	  different	  classes	   for	  reconfirmation	  of	  their	   cilium	   modulating	   effect	   by	   a	   more	   robust	   confocal	   fluorescence	   microscopy	  approach,	   which	   also	   allowed	   assessment	   of	   changes	   in	   cilium	   length	   (Figure	   2.4).	  Clofibrate,	   Gefitinib,	   Sirolimus,	   Imexon,	   Ciprofloxacin,	   and	   Dexamethasone	   were	   the	  most	   potent	   inducers	   of	   cilia	   in	   terms	   of	   percentage	   of	   ciliated	   cells,	   showing	   a	  statistically	  significant	  increase	  of	  4-­‐fold	  or	  more,	  relative	  to	  control	  vehicle-­‐treated	  cells	  (Figure	   2.4A).	   In	   terms	   of	   cilium	   length,	   Imexon,	   Clofibrate,	   and	   Xylazine	   induced	   a	  significant	  increase	  of	  4-­‐fold	  or	  more,	  relative	  to	  control	  conditions	  (Figure	  2.4B).	  Some	  compounds	  like	  Clofibrate	  and	  Imexon	  were	  potent	  inducers	  of	  both	  cilium	  percentage	  and	  cilium	  length	  whereas	  other	  compounds	  primarily	  enhanced	  cilium	  percentage	  (e.g.	  Gefitinib).	   Figure	   2.5A	   shows	   representative	   confocal	   microscopy	   pictures	   of	   primary	  ciliation	   of	   cells	   treated	  with	   the	  most	   potent	   compounds	   as	   revealed	   by	   staining	   for	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Figure	  2.4.	  Quantitative	  analysis	  of	  the	  effect	  of	  representative	  compounds	  on	  the	  percentage	  of	  ciliation	  (A)	  and	  on	  average	  cilium	  length	  (B)	  in	  CFPAC-­‐1	  cells	  as	  assessed	  by	  confocal	   fluorescence	  microscopy	  analysis.	   Quantification	  was	   performed	  by	   counting	   100	   -­‐	   300	   cells	   from	   at	   least	   three	   regions	   of	   the	  well.	  Data	  are	  presented	  as	  mean	  ±SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	  compared	  to	  control.	  	  





























2.3.3.	  Identified	  ciliogenic	  drugs	  induce	  cilia	  in	  multiple	  cancer	  cell	  models	  To	  corroborate	  the	  ability	  of	  these	  compounds	  to	  induce	  cilia	  in	  cancer	  cells,	  we	  tested	  a	  selection	   of	   the	   most	   potent	   compounds	   (Clofibrate,	   Gefitinib,	   Sirolimus,	   Imexon	   and	  Dexamethasone)	  in	  a	  panel	  of	  human	  cell	  lines	  representing	  different	  cancer	  types:	  A549	  (lung	   cancer),	   UMRC2	   (kidney	   cancer),	   SUM159	   (breast	   cancer)	   and	   L3.6	   (pancreatic	  cancer)	   cell	   lines.	   As	   shown	   in	   Figure	   2.6,	   all	   compounds	   significantly	   increased	   the	  
Figure	   2.5.	  Confocal	  fluorescence	  microscopy	  images	  of	  primary	  cilia	   in	  CFPAC-­‐1	  cells	   treated	  with	  selected	   compounds.	  Cilia	  were	   stained	  with	  an	   antibody	   against	   acetylated	   tubulin	   (green)	   (A)	   or	  with	  an	  antibody	  against	  IFT88	  (red)	  (B).	  Nuclei	  were	  visualized	  by	  staining	  with	  DAPI	  (Blue).	  Images	  were	   captured	   using	   Bio-­‐Rad	   Radiance	   confocal	   microscope	   through	   a	   40X	   objective	   lens	   at	   2.3X	  zoom.	  The	  scale	  bar	  represents	  20	  µm.	  Images	  were	  processed	  manually	  to	  optimally	  visualize	  cilia.	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Figure	  2.6.	  Effect	  of	  a	  selection	  of	  compounds	  on	  ciliogenesis	  in	  different	  cancer	  cell	  line	  models	  as	  assessed	   by	   confocal	   fluorescence	   microscopy	   analysis.	   	   (A)	   Quantification	   of	   the	   percentage	   of	  ciliated	  cells.	  Data	  are	  presented	  as	  mean	  (n	  =	  100-­‐300)	  ±SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	   compared	   to	   control.	   (B)	  Representative	   images	   showing	   the	   effect	   of	   selected	   compounds	  on	  ciliation	  in	  different	  cancer	  cell	  line	  models.	  All	  Images	  were	  captured	  using	  Nikon	  C2	  Eclipse	  Ti-­‐E	  confocal	  microscope	  at	  1.0X	  zoom	  using	  a	  60x	  objective	  lens.	  	  	  



























Figure	  2.7.	  Anti-­‐proliferative	  effect	  of	  ciliogenic	  compounds	  and	  involvement	  of	  the	  primary	  cilium.	  (A)	  Changes	   in	   cell	   cycle	   profile	   as	   determined	   by	   FACS	   analysis	   of	   CFPAC-­‐1	   cells	   upon	   treatment	  with	   a	  selection	   of	   ciliogenic	   compounds.	   Data	   are	   presented	   as	   mean	   ±SEM,	   *p	   ≤	   0.05,	   **p	   ≤	   0.005,	   ***p	   ≤	  0.0005	   as	   compared	   to	   control.	   (B)	   Effect	   of	   selected	   compounds	   on	   spheroid	   formation	   of	   L3.6	  pancreatic	   cancer	   cells.	   Data	   are	   presented	   as	   mean	   of	   at	   least	   6	   spheroids	   ±SEM,	   *p	   <	   0.0001	   as	  compared	  to	  control.	   	  The	  bottom	  panel	  shows	  representative	  images	  of	  spheroids	  treated	  with	  vehicle	  control	   and	   with	   selected	   drugs.	   (C)	   Effect	   of	   compounds	   on	   cell	   proliferation	   of	   CFPAC-­‐1	   cells	   as	  measured	   by	   BrdU	   incorporation	   and	   impact	   of	   deciliation	   by	   treatment	   with	   chloral	   hydrate	   (CH).	  Proliferation	   of	   cells	   was	   measured	   by	   BrdU	   incorporation	   24	   hours	   after	   deciliation.	   Differences	   in	  proliferation	  were	  expressed	  as	  percentage	  of	  BrdU	  incorporation	  as	  compared	  to	  untreated	  control	  (red	  bar).	  Data	  are	  presented	  as	  mean	  ±SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005.Confocal	  microscope	  images	  show	  the	  effect	  of	  4	  mM	  chloral	  hydrate	  on	  sirolimus-­‐treated	  CFPAC-­‐1	  cells.	  Primary	  cilia	  are	  stained	  for	  acetylated	  tubulin	  (green)	  and	  nuclei	  are	  stained	  with	  DAPI	  (blue).	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2.3.4.	   Ciliogenic	   drugs	   attenuate	   cell	   proliferation	   at	   least	   in	   part	   through	  
induction	  of	  the	  primary	  cilium	  As	   the	   presence	   of	   the	   primary	   cilium	   is	   dependent	   on	   the	   cell	   cycle	   and	   is	   most	  prominent	  in	  the	  G0/G1	  phase,	  we	  examined	  the	  effect	  of	  the	  selected	  drugs	  on	  the	  cell	  cycle	  using	  FACS	  analysis.	  Although	  under	  the	  culture	  condition	  that	  we	  used,	  cultures	  were	  not	  highly	  proliferative	  even	  in	  control	  conditions,	  most	  compounds	  resulted	  in	  a	  further	   increase	   in	   the	   percentage	   of	   cells	   in	   the	   G0/G1	   phase,	   indicative	   of	   a	   further	  induction	  of	  growth	  arrest	   (Figure	  2.7A).	   In	   line	  with	   these	   findings,	  most	   compounds	  attenuated	   cell	   proliferation	   as	   assessed	   by	   a	   spheroid	   formation	   assay	   of	   L3.6	   cells	  (Figure	  2.7B)	  and	  BrdU	  incorporation	  in	  CFPAC-­‐1	  cells	  (Figure	  7C).	  To	  explore	  to	  what	  extent	   primary	   cilium	   occurs	   secondarily	   to	   the	   growth	   arrest	   or	   in	   fact	   actively	  contributes	   to	   the	  observed	   attenuation	  of	   cell	   proliferation,	  we	   assessed	   the	   effect	   of	  these	   compounds	   on	   cell	   proliferation	   in	   the	   presence	   of	   the	   deciliation	   agent	   chloral	  hydrate,	  which	  completely	  removed	  the	  cilium	  (Figure	  2.7C).	  Interestingly,	  in	  most	  cases	  deciliation	   largely	   restored	   cell	   proliferation	   of	   compound-­‐treated	   cells	   (Figure	   2.7C),	  indicating	  that	  the	  antiproliferative	  effect	  of	  these	  compounds	  is	  at	  least	  in	  part	  caused	  by	  their	  ability	  to	  induce	  the	  primary	  cilium.	  	  	  
2.4.	  Discussion	  Building	   on	   the	   emerging	   concept	   that	   loss	   of	   the	   primary	   cilium	   is	   linked	   to	   the	  development	   of	   several	   tumor	   types	   and	   that	   re-­‐establishing	   the	   expression	   of	   this	  organelle	   may	   attenuate	   tumor	   growth,	   we	   have	   developed	   a	   semi-­‐high-­‐throughput	  approach	   to	   identify	   stimulators	   of	   ciliogenesis	   in	   cancer	   cells.	   Screening	   of	   the	  Pharmakon	  1600	   library	   resulted	   in	   the	   identification	  of	  118	  compounds	   that	   showed	  the	   ability	   to	   restore	   cilium	   expression	   in	   cancer	   cell	   line	  models.	   Among	   these	  were	  many	   glucocorticoids	   (43/118	   hits	   or	   43/47	   glucocorticoids	   in	   the	   entire	   library).	   A	  diverse	   set	   of	   other	   drugs	  was	   identified	   including	  many	   neurotransmitter	   regulators	  and	   ion	   channel	   modulators.	   Some	   of	   the	   compounds	   from	   our	   screen	   such	   as	  dexamethasone,	  hydrocortisone,	   estradiol,	  pargyline	  and	   lithium	  have	  previously	  been	  described	  as	  enhancers	  of	   the	  percentage	  of	   ciliated	   cells	   and/or	  of	   cilium	   length	   [15-­‐19].	   Others,	   like	   beclomethasone,	   fluticasone,	   flunisolide,	   mannitol	   and	   arginine	   are	  known	   to	   affect	   ciliary	  beat	   frequency	   (CBF),	  which	   in	  many	   cases	  varies	  with	  dosage	  and	   length	   of	   treatment	   [20-­‐23].	   It	   has	   been	   suggested	   that	   beta-­‐adrenergic	   receptor	  modulators	  may	  have	  a	  therapeutic	  role	  in	  the	  treatment	  of	  Primary	  Cilia	  Dyskinesia	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(PCD)	  [24,	  25].	  Pioglitazone	  has	  been	  shown	  to	  have	  beneficial	  effects	  in	  the	  treatment	  of	   Polycystic	   Kidney	   Disease	   (PKD)	   [26].	   Cilio-­‐modulatory	   activities	   have	   also	   been	  attributed	  to	  several	  other	  compounds	  from	  our	  screen	  like	  triamcinolone,	  budesonide,	  paroxetine,	   oxymetazoline	   and	   docetaxel	   [23,	   27-­‐30].	   Imexon,	   a	   potent	   enhancer	   of	  cilium	   length	   as	   shown	   in	   our	   results,	   is	   a	   known	   inducer	   of	   apoptosis	   and	   cell	   cycle	  arrest	   in	  pancreatic	   cancer	   cells	   [31].	  For	   this	   reason	   it	  has	  been	  used	   in	   combination	  drug	   trials	   along	   with	   gemcitabine	   for	   the	   treatment	   of	   patients	   with	   advanced	  pancreatic	   cancer.	   The	   anti-­‐diarrheal	   drug	   loperamide,	   a	   good	   inducer	   of	   cilia	   in	   our	  models,	   has	  been	   reported	   as	   a	   potential	   anti-­‐tumor	   agent	  due	   to	   its	   ability	   to	   induce	  apoptosis	  [32].	  	  With	   respect	   to	   the	   mechanisms	   underlying	   the	   cilium	   modulating	   effects	   of	   these	  compounds,	  many	  of	  them	  (steroid	  receptor	  modulators,	  neurotransmitter	  modulators,	  ion	   channel	   modulators)	   are	   known	   to	   affect	   levels	   of	   cAMP,	   calcium	   or	   other	   ions,	  which	   are	   established	   regulators	   of	   cilium	   expression	   and/or	   cilium	   length	   [33-­‐35]	  (Figure	   2.8).	   Microtubule	   modulators	   may	   affect	   the	   microtubule	   assembly	   and	  extension	   in	   the	   cilium	   or	   may	   disturb	   the	   transport	   towards	   the	   cilium	   [36-­‐38].	  Tyrosine	   kinase	   inhibitors	   may	   enhance	   ciliogenesis	   by	   inhibiting	   ligand-­‐dependent	  activation	  of	  cell-­‐cycle	  entry	  or	  by	  regulating	  the	  coordination	  of	  signaling	  events	  linked	  to	  cilium-­‐centrosome	  axis,	  that	  control	  cell	  cycle,	  differentiation	  and	  migration	  [39,	  40].	  Ciliogenic	  effects	  of	  sirolimus	  (rapamycin)	  might	  be	  mediated	  through	  mTOR	  signaling	  which	   is	   known	   to	  modulate	   ciliary	   size	   and	   function	   through	   translational	   regulation	  [41].	  Others	  (cephalosporins,	  DNA	  gyrase/topoisomerase	  inhibitors)	  are	  known	  to	  affect	  Aurora	  kinases	  [42-­‐44],	  which	  are	  also	  well-­‐established	  regulators	  of	  the	  primary	  cilium	  [45-­‐47].	   Several	   compounds	   may	   affect	   the	   cilium	   through	   extracellular	   ATP.	   Several	  studies	  show	  a	  relationship	  between	   intracellular	  calcium	   levels	  and	  extracellular	  ATP	  via	  the	  purinergic	  receptor	  [48-­‐51].	  Also	  glucocorticoids	  promote	  ATP	  release	  from	  the	  cell	   [52].	   Many	   of	   these	   compounds	   also	   affect	   cell	   proliferation	   as	   known	   from	   the	  literature	  [31,	  53-­‐63]	  or	  as	  revealed	  in	  our	  spheroid	  and	  BrdU	  assays.	  This	  effect	  was	  not	  always	  proportional	   to	   the	   induction	  of	   ciliogenesis,	  which	   is	   not	   surprising	   given	   the	  various	  mechanisms	  of	  action	  of	  these	  compounds.	  The	  further	  characterization	  of	  these	  mechanisms	  may	  be	  challenging	  in	  part	  because	  of	  the	  incomplete	  understanding	  of	  the	  mechanisms	  of	  action	  of	  some	  of	  these	  drugs	  and	  the	  processes	  involved	  in	  ciliogenesis.	  Many	  of	  the	  compounds	  we	  identified	  cause	  cell	  cycle	  arrest	  in	  the	  G0/G1	  phase,	  which	  is	  known	  to	  promote	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  ciliogenesis	  [13],	  suggesting	  that	  the	  ciliogenic	  effect	  of	  some	  of	  these	  compounds	  may	  be	  indirect	  and	  may	  be	  downstream	  of	  cell	  cycle	  arrest.	  	  Nevertheless,	  our	  findings	  that	  deciliation	  of	  compound-­‐treated	  cells	  restores	  cell	  proliferation	  strongly	  suggest	  that	  the	  compound-­‐induced	   ciliogenesis	   plays	   an	   active	   role	   in	   the	   antiproliferative	   effects	   of	  these	  compounds.	  	  	  Our	  findings	  that	  many	  common	  drugs	  have	  the	  ability	  to	  restore	  the	  primary	  cilium	  in	  cancer	  cell	  line	  models	  may	  provide	  interesting	  new	  insights	  in	  the	  spectrum	  of	  actions	  of	  these	  compounds	  and	  may	  warrant	  further	  investigation	  into	  application	  of	  some	  of	  these	  compounds	  in	  future	  antineoplastic	  approaches.	  They	  also	  promote	  the	  concept	  of	  harnessing	  the	  therapeutic	  potential	  of	  existing	  drugs	  for	  a	  novel	  use,	  generally	  referred	  
Figure	  2.8.	  Schematic	  overview	  of	  identified	  ciliogenic	  compounds	  based	  on	  their	  potential	  targets	  or	  putative	  mechanism	  of	  action.	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to	   as	   drug	   repurposing	   [64-­‐67].	   Development	   of	   a	   new	   drug	   is	   a	   complex,	   time-­‐consuming	   and	   costly	   process,	   mainly	   due	   to	   pharmacological	   hurdles	   like	  bioavailability,	   solubility,	   stability,	   toxicity	   etc.,	   which	   form	   bottlenecks	   in	   the	  therapeutic	  development	  process.	  This	  can	  be	  overcome	  by	  drug	  repurposing,	  a	  strategy	  that	   reduces	   the	   time	   frame,	   decreases	   the	   costs	   and	   improves	   the	   success	   rate	   by	  redirecting	  existing	  drugs	  for	  a	  new	  indication.	  Most	  of	  the	  drugs	  from	  the	  Pharmakon	  1600	   Library	   have	   already	   been	   tested	   for	   safety	   in	   humans	   and	   data	   is	   available	   on	  their	   pharmacology,	   formulation	   and	   toxicity,	   paving	   the	   way	   for	   an	   accelerated	  development	  of	  cilia-­‐based	  therapeutics.	  The	  success	  of	  our	  screening	  approach	  also	  sets	  the	  stage	  to	  screen	  other	  libraries	  of	  new	  compounds	  and	  to	  establish	  these	  as	  potential	  novel	   antineoplastic	   agents	  and/or	  agents	  exploitable	   in	  other	   cilium-­‐related	  diseases,	  including	  classical	  ciliopathies.	  	  	  
2.5.	  Materials	  and	  methods	  
2.5.1.	  Cell	  lines	  All	  cell	  lines	  were	  obtained	  from	  ATCC.	  	  A549	  (lung	  cancer),	  UMRC2	  (kidney	  cancer)	  and	  SUM159	   (breast	   cancer)	   were	   maintained	   in	   DMEM	   medium	   (Life	   Technologies)	  supplemented	   with	   10%	   FBS	   (Life	   Technologies).	   CFPAC-­‐1	   (pancreatic	   cancer)	   cells	  were	  cultured	  in	  RPMI-­‐1640	  medium	  (Life	  Technologies)	  supplemented	  with	  10%	  FBS.	  L3.6	   (pancreatic	   cancer)	   cells	  were	   grown	   in	   RPMI-­‐1640	  medium	   supplemented	  with	  10%	  FBS	  and	  2mM	  L-­‐Glutamine	   (Life	  Technologies).	  All	   cell	   lines	  were	   incubated	   in	  a	  humidified	  incubator	  at	  a	  temperature	  of	  37°C	  and	  5%	  levels	  of	  CO2.	  	  
2.5.2.	  Compound	  Library	  screening	  CFPAC-­‐1	   cells	   were	   seeded	   in	   96-­‐well	   microplates	   at	   a	   density	   of	   10,000	   cells/well	  containing	   200	   μl	   culture	  medium	   supplemented	  with	   10%	  FBS	   and	   incubated	   for	   48	  hours	  in	  a	  humidified	  incubator	  (37°C	  and	  5%	  CO2),	  after	  which	  medium	  was	  refreshed	  with	  200	  μl	  of	  RPMI-­‐1640	  medium	  containing	  2%	  FBS.	  	  The	  Pharmakon	  1600	  chemical	  library	   consisting	   of	   1600	   clinically	   evaluated	   compounds	   and	   marketed	   drugs	   was	  procured	   from	   MicroSource	   Discovery	   Systems	   Inc.	   (U.S.A).	   The	   compounds	   were	  dissolved	   as	   10	  mM	   stock	   solutions	   in	  DMSO	   and	   added	   to	   culture	  medium	   to	   a	   final	  concentration	  of	  10	  μM.	  Media	  and	  compounds	  were	  refreshed	  on	  the	  fourth	  day	  after	  the	   initial	   addition	   of	   the	   compounds.	   After	   8	   days	   of	   compound	   incubation,	   the	   cells	  were	  chemically	  fixed	  and	  stained	  with	  anti-­‐acetylated	  tubulin	  antibody	  (Sigma,	  Cat	  No.	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T6793-­‐.5ML),	  which	  stains	  the	  ciliary	  axoneme.	  A	  fluorescent	  secondary	  antibody	  (Life	  Technologies,	  AlexaFluor	  488,	  Cat	  No.	  A21145)	  was	  used	  against	  the	  primary	  antibody.	  The	  nuclei	  were	  counterstained	  with	  Hoechst-­‐33258	  (Cat	  No:	  382061,	  Calbiochem).	  20	  randomized	  fields	  per	  well	  were	  imaged	  at	  a	  single	  plane	  of	  focus	  at	  20X	  magnification	  in	  DPBS	  (Sigma)	  to	  reduce	  auto-­‐fluorescence	  from	  the	  medium	  and	  to	  minimize	  signal-­‐to-­‐noise	   ratio.	   Images	   acquired	   by	   the	   IN	   Cell	   Analyzer	   2000	   (GE	   Healthcare)	   were	  analyzed	  using	  IN	  Cell	  Developer	  software	  (GE	  Healthcare).	  	  
2.5.3.	  Confocal	  microscopy	  CFPAC-­‐1	   cells	   were	   seeded	   on	   glass	   coverslips	   in	   12-­‐well	   plates	   containing	   1	   ml	   of	  culture	  medium	  per	  well.	   	   At	   30%	   confluency,	   cell	  media	  was	   replaced	   by	   low	   serum	  medium	  containing	  2%	  FBS.	  After	  8	  days	  of	  compound	  treatment,	  cells	  were	  fixed	  with	  4%	   Formaldehyde	   (Merck),	   permeabilized	   with	   0.1%	   Triton	   X100	   (Merck)	   in	   DPBS,	  blocked	  with	  1%	  BSA	  (Applichem)	  in	  DPBS,	  and	  incubated	  with	  1:1000	  dilution	  of	  anti-­‐acetylated	  tubulin	  antibody	  or	  1:500	  dilution	  of	  anti-­‐IFT88	  antibody	  (Cat.	  No.	  13967-­‐1-­‐AP,	   Proteintech)	   for	   1h,	   followed	   by	   incubation	   with	   1:1000	   dilution	   of	   fluorescent	  secondary	  antibody	  for	  1h.	  Nuclei	  were	  counterstained	  with	  DAPI	  (Vector	  Laboratories,	  Vectashield	   (Cat.	   No.	   H-­‐1500).	   Images	   of	   primary	   cilia	  were	   captured	   by	   acquiring	   Z-­‐stacks	  using	  either	  a	  Bio-­‐Rad	  Radiance	  or	  Nikon	  C2	  Eclipse	  Ti-­‐E	  confocal	  laser	  scanning	  microscope	   by	   40X	   or	   60X	   oil	   immersion	   lenses.	   	   All	   drugs	   selected	   for	   confocal	  reconfirmation	  experiments	  were	  purchased	  from	  Sigma,	  except	  for	  Almotriptan	  Malate	  and	   Sirolimus	   which	   were	   obtained	   from	   Selleckchem.	   Gefitinib	   was	   from	   Invivogen,	  Cefprozil	  Monohydrate	   from	  Abcam	  and	   Imexon	   from	  MicroSource	  Discovery	  Systems	  Inc.	  	  	  
2.5.4.	  Confirmation	  of	  ciliogenesis	  in	  other	  cancer	  cell	  lines	  A549,	   UMRC2,	   SUM159	   and	   L3.6	   cells	   were	   treated	   as	   indicated	   and	   images	   were	  acquired	   as	   previous.	   Image	   stacks	   captured	   by	   confocal	   microscope	   were	   processed	  and	  analyzed	  for	  cilia	  percentage	  and	  cilium	  length	  using	  ImageJ	  software.	  	  
2.5.5.	  Chemical	  deciliation	  CFPAC-­‐1	  cells	  treated	  with	  ciliogenic	  compounds	  were	  exposed	  to	  4	  mM	  chloral	  hydrate	  (Cat.	  No.	  C8383-­‐100G,	  Sigma)	  for	  24h	  to	  remove	  cilia	  [68].	  Following	  deciliation,	  chloral	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hydrate	  was	  washed	  out	  and	  the	  cells	  were	  allowed	  to	  grow	  in	  fresh	  culture	  medium	  for	  24h	  before	  BrdU	  addition	  and	  measurement	  of	  proliferation.	  	  
2.5.6.	  Proliferation	  assays	  Spheroid	  assay	  -­‐	  Tumor	  spheroids	  were	  formed	  on	  agarose-­‐coated	  (1%)	  96-­‐well	  plates	  by	   seeding	   L3.6	   pancreatic	   cancer	   cells	   in	   200	   μl	   of	   culture	  medium.	   The	   plates	  were	  kept	  undisturbed	   in	  a	  humidified	   incubator	  at	  37°C	  and	  5%	  CO2	  for	  4	  days	  to	   facilitate	  spheroid	  formation.	  Treatment	  with	  compounds	  was	  started	  when	  the	  cells	  aggregated	  to	  form	  spheroids.	  Compounds	  and	  50%	  of	  the	  medium	  were	  refreshed	  every	  4th	  day.	  Images	  were	  captured	  at	   the	  beginning	  of	   treatment	  with	  5X	  objective	  mounted	  on	  an	  inverted	  light	  microscope.	  Imaging	  was	  done	  every	  4	  days	  for	  20	  days	  from	  the	  start	  of	  treatment.	   The	   images	   were	   analyzed	   by	   ImageJ	   software	   (rsb.info.nih.gov/ij)	   to	  calculate	  the	  differences	  in	  the	  volume	  of	  spheroids	  at	  different	  time	  points.	  BrdU	  incorporation	  assay	  -­‐	  BrdU	  incorporation	  assay	  was	  performed	  using	  5-­‐Bromo-­‐2-­‐deoxy-­‐uridine	  Labeling	  and	  Detection	  Kit	   III	   (Cat.	  No.	  11444611001,	  Roche)	  according	  to	  manufacturer's	  instructions.	  	  
2.5.7.	  Cell	  Cycle	  Analysis	  CFPAC-­‐1	   cells	   were	   plated	   at	   a	   density	   of	   300,000	   cells/well	   of	   a	   6-­‐well	   plate	   and	  allowed	  to	  grow	  for	   two	  days.	  This	  was	   followed	  by	  compound	  treatment	   for	  48h	  and	  harvesting	   of	   cells	   by	   trypsinization.	   Cells	   were	   fixed	   with	   4%	   formaldehyde	   and	  permeabilized	  in	  0.1%	  Triton	  X100	  solution.	  The	  permeabilized	  cells	  were	  washed	  with	  PBS	   and	   stained	  with	   Vybrant	   DyeCycle	   Green	   Stain	   (Cat.	   No.	   V35004,	   ThermoFisher	  Scientific).	  Cell	  cycle	  data	  was	  acquired	  by	  measuring	  at	  least	  10,000	  events	  per	  sample	  with	   BD	   FACSCanto	   Flow	   Cytometer	   (Becton	   Dickinson).	   Data	   was	   analyzed	   using	  FlowJo	   software	   (Becton	   Dickinson)	   and	   the	   cell	   cycle	   distribution	   was	   calculated	   by	  ImageJ	  software.	  	  	  
2.5.8.	  Statistical	  Analysis	  GraphPad	  Prism	  version	  6	  for	  Mac	  OS	  X	  (GraphPad	  Software,	  San	  Diego,	  California,	  USA)	  was	   used	   for	   statistical	   analysis.	   All	   data	   are	   expressed	   as	   mean	   ±SEM.	   Differences	  between	  two	  groups	  were	  assessed	  using	  the	  t-­‐test.	  To	  determine	  differences	  between	  more	   than	   two	   groups,	   two-­‐way	   ANOVA	   was	   used	   followed	   by	   Dunnett's	   multiple	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comparisons	  test.	  Differences	  with	  p	  values	  of	  <	  0.05	  were	  considered	  to	  be	  statistically	  significant.	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3.1.	  Abstract	  Malignant	  transformation	  of	  cells	  is	  often	  accompanied	  by	  the	  loss	  of	  the	  primary	  cilium,	  a	   protruding	   microtubule-­‐based	   sensory	   organelle,	   suggesting	   that	   it	   plays	   an	   “onco-­‐suppressive”	   role.	   Therefore,	   restoration	   of	   the	   primary	   cilium	   is	   being	   explored	   as	   a	  new	  therapeutic	  approach	  to	  attenuate	  tumor	  growth.	  Recently,	  several	  commonly	  used	  chemotherapeutic	  drugs	  have	  been	  identified	  to	  induce	  the	  primary	  cilium	  in	  pancreatic	  cancer	   cells.	   The	   mechanisms	   by	   which	   these	   drugs	   re-­‐express	   the	   cilium	   remain,	  however,	  enigmatic.	  Here,	  evaluation	  of	  a	  panel	  of	  diverse	  ciliogenic	  drugs	  on	  pancreatic	  cancer	   cell	   models	   revealed	   a	   significant	   positive	   relationship	   between	   drug-­‐induced	  extracellular	  ATP,	  released	  through	  pannexin	  channels,	  and	  the	  extent	  of	  primary	  cilium	  induction.	  Moreover,	  cilium	  induction	  by	  these	  drugs	  was	  hampered	  in	  the	  presence	  of	  the	  ATP	  degrading	  enzyme,	  apyrase,	  and	  in	  the	  presence	  of	  the	  pan-­‐purinergic	  receptor	  inhibitor,	  suramin.	  Our	  findings	  reveal	  that	  ciliogenic	  drug-­‐induced	  re-­‐expression	  of	  the	  primary	  cilium	  in	  pancreatic	  cancer	  cells	  is,	  at	  least	  in	  certain	  contexts,	  dependent	  on	  a	  hitherto	   unrecognized	   autocrine/paracrine	   loop	   involving	   the	   extracellular	   ATP-­‐purinergic	  receptor	  signaling	  pathway	   that	  can	  be	  exploited	   in	  a	   therapeutic	  approach	  targeting	  at	  restoring	  the	  primary	  cilium.	  	  
3.2.	  Introduction	  	  Primary	  cilia	  are	  microtubule-­‐based,	  antenna-­‐like	  structures	  present	  on	  the	  surface	  of	  a	  wide	  variety	  of	  mammalian	  cells	  [1].	  They	  serve	  as	  platforms	  for	  key	  signaling	  pathways	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that	   are	   critical	   for	   development	   and	   tissue	   homeostasis	   by	   specifically	   expressing	  crucial	   entities	   like	   ion	   channels,	   transporter	   proteins	   and	   receptors	   [2-­‐4].	   Hence,	  defects	   that	   compromise	   ciliary	   structure	   and/or	   function	   can	   have	   profound	  consequences	   for	   a	   cell	   [4].	   Cilia	   dysfunction	   is	   considered	   to	   be	   a	   common	   event	   in	  many	  cancer	  types,	  including	  melanoma,	  breast	  cancer	  and	  pancreatic	  cancer	  [4];	  and	  is	  associated	  with	  poor	  prognosis	  in	  patients	  [4-­‐8].	  Recently,	  a	  high-­‐throughput	  screening	  based	   on	   the	   pancreatic	   CFPAC-­‐1	   cancer	   cell	   line	   delineated	   chemotherapeutic	  compounds	  with	  the	  ability	  to	  induce	  primary	  cilia	  in	  cancer	  cells,	  and	  paved	  the	  way	  to	  explore	   cilium	   induction	   as	   a	   hitherto	   unexploited	   concept	   in	   the	   context	   of	   cancer	  chemotherapy	  [9].	  	  	  Armed	   with	   such	   novel	   ciliogenic	   drugs,	   we	   aimed	   to	   explore	   the	   mechanisms	  underlying	  cilium-­‐induction	   in	  pancreatic	  cancer	  cells.	  Recent	  discoveries	  demonstrate	  that	  several	  anticancer	  modalities,	  including	  chemotherapeutic	  drugs,	  cause	  secretion	  of	  ATP	  from	  cancer	  cells	  [10-­‐14].	  Initially	  delineated	  in	  the	  context	  of	  neurotransmission,	  extracellular	  ATP	  now	  has	  emerged	  as	  an	  important	  messenger	  in	  a	  number	  of	  signaling	  paradigms	   [15,	   16].	   It	   facilitates	   cell-­‐to-­‐cell	   communication	   in	   both	   autocrine	   and	  paracrine	  manners	  in	  various	  pathological	  conditions	  [10,	  15].	  In	  the	  context	  of	  cancer,	  extracellular	  ATP	  has	   recently	   emerged	   as	   an	   important	  damage-­‐associated	  molecular	  pattern	   (DAMP)	   [17],	   modulating	   both	   chemo-­‐attraction	   and	   activation	   of	   innate	  immune	  cells	  in	  a	  paracrine	  manner	  [12,	  18,	  19].	  On	  the	  other	  hand,	  autocrine	  signaling	  elicited	   by	   extracellular	  ATP	   can	   also	   facilitate	   pro-­‐cancerous	   processes	   e.g.	   increased	  proliferation	   and	   migration/invasion.	   Thus,	   depending	   on	   the	   signaling	   context	   and	  target	   cells	   involved,	   extracellular	   ATP	   can	   exert	   both	   pro-­‐	   and	   anti-­‐cancerous	   effects	  [15,	   16,	   20].	   Two	   mutually-­‐exclusive	   pathways	   have	   been	   demonstrated	   to	   facilitate	  trafficking	   of	   extracellular	   ATP	   after	   treatment	   with	   anticancer	   therapy	   [17]	   i.e.	   the	  classical	   secretory	   pathway	   (in	   case	   of	   photodynamic	   therapy)	   and	   the	   pannexin	  channels-­‐based	   secretion	   (in	   case	  of	   chemotherapy	  and/or	   targeted	   therapy)	   [18,	  21].	  After	   release	  or	   secretion,	   extracellular	  ATP	   tends	   to	   signal	   through	   the	  P2	  purinergic	  receptors	  on	  the	  surface	  of	  (target)	  cells	  [15].	  	  Interestingly,	   two	   decades	   ago	   some	   studies	   had	   reported	   that	   exogenous	   addition	   of	  extracellular	   ATP	   can	   improve	   ciliary	   beat	   frequency	   (CBF)	   in	   epithelial	   cells	   derived	  from	  frog	  palate	  and	  esophagus	  [22,	  23].	  The	  modulation	  of	  CBF	  was	  further	  shown	  to	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occur	   through	   activation	   of	   purinergic	   receptors	   present	   on	   the	   cilium	   [3,	   24,	   25].	  Consistent	   with	   these	   findings,	   mutant	   mice	   lacking	   purinergic	   receptors	   showed	   a	  significant	   reduction	   in	   CBF	   [26].	   Collectively,	   these	   findings	   hinted	   towards	   a	   bi-­‐directional	   link	   between	   primary	   cilia	   and	   extracellular	   ATP	   or	   purinergic	   receptor	  signaling,	  that	  had	  not	  been	  probed	  in	  the	  context	  of	  cancer	  cells	  so	  far.	  	  Following	  the	  above	  cues,	  we	  aimed	  to	  investigate	  to	  what	  extent	  and	  how	  cilia-­‐inducing	  chemotherapeutic	  drugs	  (hereafter	  referred	  to	  as	  ciliogenic	  drugs)	  promote	  ciliogenesis	  in	   pancreatic	   cancer	   cells	   through	   the	   extracellular	   ATP-­‐purinergic	   receptor	   signaling	  pathway.	  Here	  we	  show	  that	   in	  CFPAC-­‐1	  pancreatic	  ductal	  cancer	  cells	   that	  were	  used	  for	   the	   original	   screening	   for	   ciliogenic	   chemotherapeutics,	   several	   ciliogenic	  compounds	  exert	  their	  cilium-­‐promoting	  effects	  at	  least	  in	  part	  through	  the	  extracellular	  ATP-­‐purinergic	  receptor	  signaling	  pathway.	  	  
3.3.	  Results	  
3.3.1.	   Ciliogenic	   chemotherapeutic	   drugs	   induce	   secretion	   of	   ATP	   in	   pancreatic	  
cancer	  cells	  	  First	  of	  all,	  we	  wanted	  to	  assess	  whether	  extracellular	  ATP	  levels	  in	  fact	  correlate	  with	  re-­‐expression	  of	  the	  primary	  cilium	  in	  cancer	  cells	  by	  ciliogenic	  chemotherapeutic	  drugs.	  To	  this	  end,	  we	  first	  investigated	  to	  what	  extent	  these	  drugs	  cause	  release/secretion	  of	  ATP	   in	   the	   extracellular	   medium.	   To	   address	   this,	   human	   pancreatic	   cancer	   cells	  (CFPAC-­‐1)	  were	  treated	  with	  a	  panel	  of	  22	  drugs	  that	  were	  previously	  shown	  to	  induce	  ciliogenesis	   in	   these	   cells	   [9].	   The	   drug	   esomeprazole,	   which	   is	   incapable	   of	   inducing	  cilia	  [9],	  was	   included	  as	  negative	  control.	   Interestingly,	  6	  out	  of	  22	  drugs	  significantly	  increased	   the	   levels	   of	   extracellular	   ATP	   as	   compared	   to	   untreated	   control	   cells	   (Fig	  3.1A).	   These	   results	   were	   reconfirmed	   in	   another	   pancreatic	   cancer	   cell	   line	   model	  PANC-­‐1	   for	   a	   selection	   of	   compounds	   (Fig	   3.S1).	   Although	   most	   other	   ciliogenic	  compounds	   also	   induced	   a	   certain	   degree	   of	   ATP	   secretion/release,	   it	   was	   not	  statistically	   significant.	   Interestingly,	   a	   correlation	   analysis	   showed	   that	   drug-­‐induced	  re-­‐expression	   of	   primary	   cilia	   positively	   correlates	   (significantly)	   with	   increased	  secretion/release	  of	  ATP	  in	  these	  cancer	  cells	  (Fig	  3.1B).	  These	  observations	  confirmed	  that	   certain	   potent	   ciliogenic	   drugs	   also	   tend	   to	   cause	   increased	   release/secretion	   of	  ATP.	  	  



























3.3.2.	  Exogenous	  ATP	  induces	  primary	  cilia	  in	  pancreatic	  cancer	  cells	  The	   above	   observations	   spurred	   us	   to	   assess	   whether	   exogenous	   ATP	   can	   in	   fact	  modulate	   ciliogenesis.	   Therefore,	   we	   exposed	   untreated	   CFPAC-­‐1	   cells	   to	   increasing	  concentrations	  of	  exogenously	  added	  ATP	  and	  visualized	  the	  primary	  cilium	  by	  confocal	  microscopy.	   A	   significant	   increase	   in	   the	   percentage	   of	   ciliated	   cells	   was	   observed	  already	  at	  nanomolar	  concentrations	  of	  exogenously	  added	  ATP.	  At	  higher	  micromolar	  concentrations	  the	  increase	  was	  less	  pronounced	  but	  still	  significant	  (Fig	  3.2A	  and	  3.2B).	  A	  similar	  effect	  was	  seen	  in	  PANC-­‐1	  cells	  (Fig	  3.S2A	  and	  3.S2B).	  These	  results	  show	  that	  
Figure	   3.1.	   Ciliogenic	   chemotherapeutics	   tend	   to	   induce	   extracellular	   ATP	   in	   cancer	   cells.	  Quantitative	   and	   correlative	   analysis	   of	   extracellular	   ATP	   upon	   exposure	   of	   CFPAC-­‐1	   cells	   to	   a	  panel	  of	   ciliogenic	  drugs	   (black	  bars	  and	  dots)	   and	  a	  non-­‐ciliogenic	  drug	   (blue	  bar	  and	  dot)	   at	  2	  micromolar	   concentration	   for	   96	   hours.	   (A)	   The	   drugs	   are	   ranked	   in	   ascending	   order	   of	   their	  potency	  to	  release	  extracellular	  ATP	  into	  the	  culture	  medium	  as	  assessed	  by	  the	  measurement	  of	  bioluminescence	  based	  on	  luciferin-­‐luciferase	  conversion	  principle.	  The	  red	  dotted	  line	  represents	  the	  basal	  level	  of	  extracellular	  ATP	  in	  the	  medium	  (represented	  as	  relative	   luminescence	  units	  or	  RLUs).	   (B)	   Regression	   analysis	   between	   extracellular	   ATP	   and	   cilia	   induction.	   Correlation	   was	  calculated	  by	  using	  Pearson	  correlation	  coefficient	  analysis.	  Data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005.	  	  
	   93	  






















3.3.3.	   Degradation	   of	   drug-­‐induced	   extracellular	   ATP	   suppresses	   ciliogenesis	   in	  
pancreatic	  cancer	  cells	  To	   corroborate	   the	   link	   between	   secreted	   ATP	   and	   cilium	   induction,	  we	   assessed	   the	  ability	   of	   two	   potent	   ciliogenic	   and	   ATP-­‐releasing	   compounds	   (dexamethasone	   and	  gefitinib)	   to	   induce	   ciliogenesis	   in	   the	   presence	   of	   apyrase,	   a	   known	   ATP	   degrading	  enzyme.	   The	   non-­‐ciliogenic	   compound	   Esomeprazole,	   which	   also	   displayed	   a	   lack	   of	  ability	  to	  induce	  ATP	  secretion,	  was	  used	  as	  a	  negative	  control.	  To	  this	  end,	  we	  applied	  an	   immunofluorescence	   microscopy-­‐based	   phenotypic	   imaging	   strategy	   in	   a	   96-­‐well	  
Figure	   3.2.	   	   Effect	   of	  
exogenous	   ATP	   on	   cilia	  
induction	   in	   CFPAC-­‐1	  
cells.	   (A)	   Quantitative	  analysis	   of	   ciliogenesis	  upon	   treatment	   of	   cells	  with	   exogenous	   ATP	   at	  increasing	   concentrations,	  as	   assessed	   by	   confocal	  fluorescence	   microscopy.	  (B)	  Representative	  images	  of	   cells	   showing	   the	   effect	  of	   exogenous	   ATP	   on	  ciliation.	   Nuclei	   were	  stained	   with	   DAPI	   (blue)	  and	  cilia	  with	  an	  antibody	  against	   the	   cilium	  marker	  acetylated	  tubulin	  (green).	  All	   images	   were	   captured	  using	   Olympus	   Fluoview	  confocal	  microscope	  using	  a	   40X	   objective	   lens.	   Data	  are	   presented	   as	   mean	   ±	  SEM,	   *p	   ≤	   0.05,	   **p	   ≤	  0.005,	  ***p	  ≤	  0.0005.	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3.3.4.	  Pannexin	  channels	  mediate	  the	  secretion	  of	  extracellular	  ATP	  by	  ciliogenic	  
drugs	  Beyond	  the	  above	  discussed	  effects	  which	  confirm	  that	  drug-­‐induced	  ATP	  release	  affects	  ciliogenesis,	   chemotherapeutic	   drugs	   tend	   to	   also	   modulate	   the	   proliferation	   and	  
Figure	   3.3.	   	   Effect	   of	   apyrase-­‐
mediated	   extracellular	   ATP	  
degradation	   on	   ciliogenesis	   in	  
CFPAC-­‐1	   cells	   exposed	   to	  
ciliogenic	  drugs.	  	  (A)	  Quantification	  of	  the	  effect	  of	  apyrase	  treatment	  on	  ciliogenesis.	  	  (B)	   Representative	   images	  showing	  the	  effect	  of	  apyrase	  on	  ciliogenesis	   of	   cells	   exposed	   to	  the	   indicated	  drugs.	  Nuclei	  were	  stained	   with	   DAPI	   (blue)	   and	  cilia	  with	  an	  antibody	  against	  the	  cilium	  marker	  acetylated	  tubulin	  (green).	   All	   images	   were	  captured	  using	  Nikon	  C2	  Eclipse	  Ni-­‐E	  confocal	  microscope	  using	  a	  60X	   objective	   lens.	   Data	   are	  presented	   as	   mean	   ±	   SEM,	   *p	   ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005.	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survival	   of	   cancer	   cells	   –	   processes	   that	   have	   ability	   to	  modulate/exploit	   extracellular	  ATP.	   To	   this	   end,	   we	   deemed	   it	   crucial	   to	   analyze	   the	   overall	   correlation	   between	  secreted/released	  ATP	  and	  drug-­‐induced	  effects	  on	  proliferation/survival.	  We	  observed	  an	  overall	  reduction	  in	  cellular	  proliferation	  following	  ciliogenic	  drug	  treatment,	  which	  interestingly	   correlated	   with	   an	   increase	   in	   the	   secretion/release	   of	   ATP	   (Fig	   3.4A)	  thereby	  exposing	  a	  negative	  correlation	  between	  proliferation	  and	  extracellular	  ATP	  in	  this	   system.	   On	   the	   other	   hand,	   although	   most	   of	   the	   ciliogenic	   drugs	   compromised	  cellular	  survival	  to	  a	  certain	  extent,	  no	  statistically	  significant	  correlation	  was	  observed	  between	  cellular	  survival	  and	  ATP	  secretion	  (Fig	  3.4B),	  suggesting	  the	  possibility	  of	  the	  existence	  of	  an	  active	  ATP	  secretion	  pathway.	  	  	  
	  	  	  	  	  	  
Figure	  3.4.	  Effect	  of	  secreted	  ATP	  on	  proliferation	  and	  survival	  of	  CFPAC-­‐1	  pancreatic	  cancer	  
cells.	   (A)	   Quantitative	   analysis	   of	   cell	   proliferation	   upon	   secretion	   of	   ATP	   by	   exposure	   of	   cells	   to	  ciliogenic	   chemotherapeutic	   drugs	   (black	   bars	   and	   dots)	   and	   a	   non-­‐ciliogenic	   drug	   (blue	   bar	   and	  dot).	   Changes	   in	   proliferation	  were	  measured	   by	   a	   BrdU	   incorporation	   assay.	   Lower	   panel	   shows	  correlative	   analysis	   between	   cell	   proliferation	   and	   secreted	   ATP.	   (B)	   Quantitative	   analysis	   of	   cell	  viability	   upon	  exposure	  of	   cells	   to	   ciliogenic	   chemotherapeutic	   drugs	   and	   a	  non-­‐ciliogenic	  drug	   as	  measured	   by	  MTS	   assay.	   Lower	   panel	   displays	   the	   correlation	   between	   cell	   survival	   and	   secreted	  ATP	   in	   treated	   cells.	   Correlation	   was	   calculated	   by	   using	   Pearson	   correlation	   coefficient	   analysis.	  Data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005.	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Although	  the	  cellular	  survival	  assay	  suggested	  that	  at	  least	  some	  extracellular	  ATP	  in	  our	  set-­‐up	   might	   be	   passively	   released,	   the	   lack	   of	   a	   statistically	   significant	   correlation	  between	   survival	   and	  ATP	   release	   (Fig	   3.4B)	   prompted	   us	   to	   explore	  whether	   ATP	   is	  secreted	  by	  the	  studied	  pancreatic	  cancer	  cells	  in	  an	  active	  manner;	  and	  to	  what	  extent	  this	   is	   crucial	   for	   ciliogenesis.	   To	   investigate	   the	   involvement	   of	   the	   two	   main	   ATP	  secretion	   mechanisms	   [17]	   we	   treated	   cells	   with	   well-­‐established	   small	   molecule	  inhibitors	  each	  targeting	  different	  players	  in	  putative	  ATP	  secretion	  pathway	  
	  	  	  	  	  	  	  
Figure	   3.5.	   	   Effect	   of	   inhibition	   of	   different	   intracellular	   trafficking	   pathways	   on	   the	  
concentration	   of	   extracellular	   ATP	   in	   CFPAC-­‐1	   cells	   treated	   with	   ciliogenic	   drugs.	   (A)	  Quantification	   of	   extracellular	   ATP	   in	   cells	   treated	   with	   pannexin	   channel	   blocker	   (mefloquine),	  vesicular	   transport	   inhibitor	   (latrunculin	   B),	   inhibitor	   of	   microtubule-­‐dependent	   transport	  (nocodazole).	   (B)	   Quantification	   of	   the	   effect	   of	   mefloquine	   on	   ciliogenesis	   in	   CFPAC1	   cells.	   (C)	  Representative	   images	   showing	   the	   effect	   of	   pannexin	   channel	   blockade	  on	   ciliogenesis	   in	  CFPAC-­‐1	  cells	  exposed	  to	  a	  selection	  of	  ciliogenic	  drugs.	  Nuclei	  were	  stained	  with	  DAPI	  (blue)	  and	  cilia	  with	  an	  antibody	  against	  the	  cilium	  marker	  acetylated	  tubulin	  (green).	  All	  images	  were	  captured	  using	  Nikon	  C2	  Eclipse	  Ni-­‐E	  confocal	  microscope	  using	  a	  60X	  objective	  lens.	  Data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005.	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Vesicular	   transport	   mediated	   by	   actin	   was	   inhibited	   by	   the	   actin	   polymerization	  inhibitor	   latrunculin	   B;	   and	   pannexin-­‐based	   release	   was	   inhibited	   by	   the	   pannexin	  channel	   inhibitor	   mefloquine.	   Latrunculin	   B	   pre-­‐treatment	   failed	   to	   reduce	   drug-­‐induced	  ATP	  secretion	  (Fig	  3.5A),	  thereby	  ruling	  out	  a	  major	  role	  of	  vesicular	  and/or	  	  secretory	   anterograde	   transport	   in	   ATP	   secretion	   in	   this	   set-­‐up.	   However,	   when	  pannexin	   channels	   were	   blocked	   with	   mefloquine,	   a	   significant	   reduction	   in	   the	  extracellular	  ATP	  was	  observed,	   indicating	   the	   involvement	  of	   this	  mechanism	   in	  ATP	  secretion	   induced	   by	   certain	   drugs	   (Fig	   3.5A).	   The	   role	   of	   pannexins-­‐based	   ATP	  secretion	   in	  our	  set-­‐up	  was	   further	  corrobrated	  by	   the	  observation	   that	  CFPAC-­‐1	  cells	  pre-­‐treated	   with	   mefloquine	   and	   subsequently	   exposed	   to	   ciliogenic	   drugs	   showed	   a	  significant	  reduction	  in	  the	  percentage	  of	  ciliated	  cells	  (Fig	  3.5B	  and	  3.5C).	  	  
3.3.5.	  P2	  purinergic	  receptors	  are	  involved	  in	  drug-­‐induced	  ciliogenesis	  As	   mentioned	   previously,	   extracellular	   ATP	   tends	   to	   largely	   signal	   through	   the	   P2	  purinergic	   receptors.	   Since	   the	   increased	   extracellular	   ATP	   had	   a	   positive	   effect	   on	  ciliogenesis,	  we	  decided	  to	  probe	  the	  involvement	  of	  the	  extracellular	  ATP-­‐P2	  purinergic	  receptor	  link	  in	  the	  induction	  of	  primary	  cilia	  in	  CFPAC-­‐1	  cells	  by	  ciliogenic	  	  
Figure	  3.6.	  	  
P2	   purinergic	   receptor	  
blockade	   reduces	  
ciliogenesis.	  	  (A)	   Effect	   of	   suramin,	   a	  blocker	   of	   P2	   purinergic	  receptors	   on	   ciliogenesis	  in	  CFPAC-­‐1	  cells	  exposed	  to	  ciliogenic	  drugs.	  	  (B)	   Representative	  images	   of	   CFPAC-­‐1	   cells	  showing	   the	   effect	   of	  suramin	   on	   ciliation	   in	  untreated	   and	   treated	  cells.	  Nuclei	  were	  stained	  with	   DAPI	   (blue)	   and	  cilia	   with	   an	   antibody	  against	  the	  cilium	  marker	  acetylated	   tubulin	  (green).	   All	   images	   were	  captured	   using	  Nikon	   C2	  Eclipse	   Ni-­‐E	   confocal	  microscope	   using	   a	   60X	  objective	   lens.	   Data	   are	  presented	   as	   mean	   ±	  SEM,	   *p	   ≤	   0.05,	   **p	   ≤	  0.005,	  ***p	  ≤	  0.0005.	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  drugs.	   To	   this	   end,	   we	   exposed	   cells	   treated	   with	   representative	   ciliogenic	   drugs	   to	  suramin,	  a	  pan-­‐P2	  receptor	  inhibitor,	  and	  examined	  to	  what	  extent	  this	  interferes	  with	  ciliogenesis.	   Indeed,	   a	   significant	   suppression	   of	   ciliogenesis	   was	   observed	   in	   cells	  treated	  with	   the	  drugs	  when	  suramin	  was	  present	   (Fig	  3.6A	  and	  3.6B).	  Thus,	  our	  data	  show	  that	  both	  degrading	  ATP	  (thus	  removing	  the	  ligand)	  or	  inhibiting	  its	  main	  receptor	  exert	   the	   same	   effect,	   suggesting	   that	   the	   extracellular	   ATP-­‐P2	   purinergic	   receptor	  signaling	  arc	  is	  involved	  in	  the	  induction	  of	  primary	  cilia	  in	  pancreatic	  cancer	  cells	  by	  a	  subset	  of	  ciliogenic	  drugs.	  	  	  
3.4.	  Discussion	  In	  a	   recent	  study	  we	  had	  shown	  that	  various	  commonly	  used	  chemotherapeutic	  drugs	  restore	   ciliogenesis	   in	   cancer	   cells	   [9].	   Since	   the	   cilium	   uses	   the	   same	   structural	  elements	   as	   the	   centrosome	   that	   is	   required	   for	   cell	   division	   and	   proliferation,	  ciliogenesis	  is	  believed	  to	  put	  a	  brake	  on	  the	  proliferation	  of	  cells,	  including	  many	  cancer	  cells.	   This	   is	   also	   the	   reason	   behind	   cilium	   induction	   being	   regarded	   as	   a	   novel	  therapeutic	   mechanism	   [9].	   Here,	   we	   demonstrate	   that	   certain	   drugs	   promote	  ciliogenesis,	  at	   least	   in	  part,	   through	  a	  hitherto	  unrecognized	  autocrine/paracrine	   loop	  involving	  the	  extracellular	  ATP-­‐purinergic	  receptor	  signaling	  pathway.	  We	  found	  that	  a	  subset	  of	  ciliogenic	  compounds	  stimulate	  ATP	  release,	  which	  positively	  correlates	  with	  their	   ciliogenic	   ability.	   Consistent	   with	   previous	   studies	   [18,	   21],	   using	   chemical	  inhibitors	  targeting	  different	  potential	  players	  in	  ATP-­‐secretion	  pathways	  we	  found	  that	  specific	  ciliogenic	  drugs	  stimulate	  the	  active	  secretion	  of	  ATP	  mainly	  through	  pannexin	  channels.	  This	  active	  ATP	  secretion	  pathway	  might	  co-­‐exist	  with	  some	  passive	  release	  of	  ATP,	  at	  least	  in	  the	  case	  of	  certain	  ciliogenic	  drugs	  that	  induce	  cell	  death	  in	  a	  fraction	  of	  the	   cancer	   cells.	   Extracellular	   ATP	   in	   turn	   promotes	   ciliogenesis	   as	   revealed	   by	   the	  treatment	   of	   cells	   with	   varying	   concentrations	   of	   exogenous	   ATP,	   by	   blocking	   P2	  purinergic	  receptors,	  which	  are	  known	  to	  mediate	  many	  effects	  of	  extracellular	  ATP	  [15]	  and	  by	  co-­‐treatment	  with	  the	  ATP-­‐degrading	  enzyme	  apyrase.	  	  Thus,	  a	  picture	  emerges	  in	  which	  the	  extracellular	  ATP	  may	  act	  in	  both	  an	  autocrine	  manner	  (ATP	  secreted	  by	  a	  live	   cell	   that	   acts	   on	   the	   same	   cell)	   and	   a	   paracrine	   manner	   (ATP	   released	   from	  dead/dying	   cells	   or	   secreted	   by	   live	   cells	   that	   acts	   on	   other	   live	   cells)	   to	   induce	  ciliogenesis	   in	   pancreatic	   cancer	   cells.	   Figure	   3.7	   illustrates	   the	   involvement	   of	   this	  autocrine/paracrine	  loop	  of	  extracellular	  ATP	  in	  ciliogenesis.	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This	   involvement	   of	   the	   extracellular	   ATP-­‐purinergic	   receptor	   pathway	   in	   the	   cilium-­‐inducing	  effect	  of	  certain	  chemotherapeutic	  drugs	  is	  of	  particular	  interest	  in	  view	  of	  the	  emerging	   central	   role	   of	   purinergic	   signaling	   in	   many	   cellular	   events	   including	  inflammation	   and	  wound	  healing	   [28-­‐30].	  Our	  observation	  of	   a	   statistically	   significant	  negative	   correlation	   between	   extracellular	   ATP	   levels	   and	   overall	   proliferation	   of	  pancreatic	   cancer	   cells	   is	   particularly	   intriguing	   in	   view	   of	   the	   divergent	   effects	   of	  extracellular	  ATP	  on	  cell	  proliferation	  [15,	  31-­‐33]	  and	  suggest	  that	  the	  mitigating	  effects	  of	  extracellular	  ATP-­‐induced	  ciliogenesis	  on	  proliferation	  may	  at	  least	  partially	  account	  for	  this	  discrepancy.	  This	  notion	  needs	  proper	  molecular	  analysis	  and	  warrants	  further	  examination	  in	  a	  tumor	  context	  in	  vivo,	  to	  what	  extent	  this	  newly	  delineated	  function	  of	  extracellular	   ATP-­‐purinergic	   signaling	   contributes	   to	   the	   anticancer	   effects	   of	   the	  studied	  drugs	  in	  pancreatic	  and	  other	  cancers.	  
	  	  While	  we	  have	  provided	  evidence	   for	   the	   role	  of	   autocrine/paracrine	   signaling	  by	   the	  extracellular	  ATP	  in	  drug-­‐induced	  ciliogenesis;	  it	  should	  be	  considered	  that	  this	  pathway	  may	  not	  be	  the	  only	  existing	  mechanism.	  The	  action	  of	  chemotherapeutic	  drugs	  tends	  to	  be	   pleiotropic,	   consisting	   of	   both	   on-­‐target	   as	  well	   as	   off-­‐target	   therapeutic	   effects.	   In	  view	   of	   the	   complexity	   of	   cilia-­‐inducing	   signaling	   it	   is	   likely	   that	   other	   signaling	  
Figure	   3.7.	   Overview	   of	   the	   proposed	   autocrine/paracrine	   loop	   model	   of	   extracellular	   ATP-­‐mediated	   ciliogenesis	   by	   ciliogenic	   chemotherapeutics	   through	   activation	   of	   the	   pannexin	  pathway	  and	  purinergic	  signaling.	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pathways	  also	  play	  a	  major	  role.	  Moreover,	  considering	  that	  extracellular	  ATP	  also	  has	  a	  crucial	  role	  in	  the	  modulation	  of	  inflammation	  [17,	  34-­‐37],	  and	  as	  a	  large	  number	  of	  anti-­‐inflammatory	   drugs	   have	   been	   reported	   to	   induce	   primary	   cilia	   in	   cancer	   cells	   [9],	   it	  would	   be	   interesting	   to	   investigate	   the	   relationship	   between	   ciliogenesis	   and	  inflammation	   and	   the	   role	   of	   extracellular	   ATP	   in	   this	   context.	   Further	   elucidation	   of	  these	  and	  other	  pathways	  will	  be	  of	  interest	  to	  fully	  exploit	  the	  cilium-­‐inducing	  property	  of	  common	  chemotherapeutics	  in	  a	  more	  clinical	  setting.	  	  	  	  
3.5.	  Materials	  and	  Methods	  
3.5.1.	  Reagents	  and	  Drugs	  Esomeprazole,	   Pargyline,	   Leflunomide,	   Clofibrate,	   Ciprofloxacin,	   Ketorolac,	   Paroxetine,	  Dobutamine,	   Tranilast,	   Loperamide,	   Xylazine,	   Capsaicin,	   Papaverine,	   Oxymetazoline,	  Dexamethasone,	   Docetaxel,	   Topotecan,	   Paclitaxel	   were	   purchased	   from	   Sigma.	  Almotriptan	   Malate	   and	   Sirolimus	   were	   purchased	   from	   Selleckchem,	   Gefitinib	   from	  Invivogen,	  Cefprozil	  Monohydrate	  from	  Abcam	  and	  Imexon	  from	  MicroSource	  Discovery	  Systems	  Inc.;	  ATP,	  Apyrase,	  Suramin,	  Nocodazole	  and	  Mefloquine	  were	  purchased	  from	  Sigma;	  Latrunculin	  B	  was	  purchased	  from	  Abcam.	  	  
3.5.2.	  Cell	  culture	  and	  drug	  treatments	  	  Both	  the	  pancreatic	  cancer	  cells	  CFPAC-­‐1	  and	  PANC-­‐1	  were	  obtained	  from	  ATCC.	  CFPAC-­‐1	  cells	  were	  cultured	  in	  RPMI-­‐1640	  medium	  (Life	  Technologies)	  whereas	  PANC-­‐1	  cells	  were	  maintained	  in	  DMEM	  medium	  (Life	  Technologies).	  Both	  media	  were	  supplemented	  with	   10%	   FBS	   (Life	   Technologies)	   and	   incubated	   at	   37°C	   in	   5%	   CO2.	   For	   drug	  treatments,	   cells	   were	   seeded	   in	   96-­‐well	   plates	   at	   a	   density	   of	   10,000	   cells	   per	   well	  containing	   200ul	   of	   culture	  medium	   supplemented	  with	   10%	   FBS	   and	   incubated	   in	   a	  humidified	   incubator	   at	   37°	   C	   and	   5%	   CO2	   for	   48	   hours.	   This	   was	   followed	   by	  refreshment	   of	   the	   medium	   with	   culture	   medium	   containing	   2%	   FBS.	   Assays	   were	  performed	  by	   treating	   the	  cells	  with	  drugs	  as	   indicated:	   for	   induction	  of	  primary	  cilia,	  the	  cells	  were	  treated	  with	  ciliogenic	  drugs.	  Hydrolysis	  of	  ATP	  was	  achieved	  by	  treating	  cells	  with	  Apyrase.	  Purinergic	  receptor	  signaling	  in	  cells	  was	  blocked	  by	  treatment	  with	  Suramin.	   Disruption	   of	   the	   secretory	   pathway	   was	   carried	   out	   by	   Latrunculin	   B	  treatment.	  Mefloquine	  was	  used	  to	  block	  the	  pannexin	  pathway.	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3.5.3.	  Immunofluorescence	  and	  automated	  imaging	  for	  primary	  cilia	  	  	  To	   stain	  primary	  cilia,	   chemotherapeutics-­‐treated	  and	  untreated	  cells	  were	  chemically	  fixed	  with	  4%	  Formaldehyde	  (Merck),	  permeabilized	  with	  0.1%	  Triton	  X100	  (Merck)	  in	  DPBS,	  blocked	  with	  1%	  BSA	  (Applichem)	  in	  DPBS,	  and	  incubated	  with	  1:1000	  dilution	  of	  anti-­‐acetylated	  tubulin	  antibody	  (Sigma)	  for	  1	  hour	  followed	  by	  incubation	  with	  1:1000	  dilution	  of	   a	   fluorescent	   secondary	  antibody	   (Life	  Technologies,	  AlexaFluor	  488)	   for	  1	  hour.	   Nuclei	   were	   stained	   with	   Hoechst-­‐33258	   (Calbiochem).	   Images	   were	   acquired	  using	  an	  IN	  Cell	  Analyzer	  (GE	  Healthcare)	  at	  20X	  magnification	  and	  were	  analyzed	  using	  IN	   Cell	   Developer	   software.	   In	   order	   to	   minimize	   the	   signal-­‐to-­‐noise	   ratio,	   20	  randomized	  fields	  per	  well	  were	  imaged	  at	  a	  single	  plane	  of	  focus.	  	  	  
3.5.4.	  Confocal	  microscopy	  	  CFPAC-­‐1	  and	  PANC-­‐1	  cells	  were	  seeded	  on	  glass	  coverslips	  in	  12-­‐well	  plates	  containing	  1	   ml	   culture	   medium	   per	   well	   and	   allowed	   to	   grow	   to	   30%	   confluency.	   This	   was	  followed	   by	   replacement	   of	   culture	   medium	   with	   medium	   containing	   2%	   FBS	   and	  treatment	  of	   cells	  with	  drugs	   as	  previously	   indicated.	  To	  visualize	   the	  primary	   cilium,	  treated	  and	  untreated	  cells	  were	  fixed	  with	  4%	  formaldehyde,	  permeabilized	  with	  0.1%	  Triton	  X100	  in	  DPBS,	  blocked	  with	  1%	  BSA	  in	  DPBS,	  incubated	  with	  1:1000	  dilution	  of	  anti-­‐acetylated	  tubulin	  antibody	  for	  1	  hour,	  followed	  by	  incubation	  with	  1:1000	  dilution	  of	   fluorescent	   secondary	   antibody	   for	   1	   hour.	   The	   coverslips	   were	  mounted	   on	   glass	  slides	   and	   stained	   for	   nuclei	   with	   DAPI	   (Vector	   Laboratories,	   Vectashield).	   Images	   of	  primary	  cilia	  were	  captured	  by	  acquiring	  Z-­‐stacks	  using	  Olympus	  FluoView-­‐FV	  1000	  or	  Nikon	  C2	  Eclipse	  Ni-­‐E	  confocal	  laser	  scanning	  microscope	  using	  60X	  oil	  immersion	  lens.	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3.5.6.	  Proliferation	  assay	  	  Proliferation	  assay	  was	  performed	  by	  measuring	  BrdU	  incorporation	  using	  5-­‐Bromo-­‐2-­‐deoxy-­‐uridine	  Labeling	  and	  Detection	  Kit	  III	  (Cat	  No.	  11444611001)	  in	  accordance	  with	  the	  manufacturer's	  protocol.	  	  
3.5.7.	  Cell	  viability	  assay	  The	   viability	   of	   cells	   in	   drug	   treated	   cultures	   was	   determined	   by	   measuring	   the	  bioreduction	  of	  MTS	  tetrazolium	  compound	  using	  the	  CellTiter96	  AQueous	  One	  Solution	  Cell	   Proliferation	   Assay	   kit	   (Promega).	   The	   assay	   was	   performed	   by	   following	   the	  protocol	  provided	  with	  the	  kit.	  	  
3.5.8.	  Statistical	  analysis	  	  Statistical	  analysis	  of	  data	  was	  performed	  using	  GraphPad	  Prism	  version	  6	  for	  Mac	  OS	  X	  (GraphPad	  Software,	  San	  Diego,	  California,	  USA).	  All	  data	  are	  expressed	  as	  mean	  ±SEM.	  Significance	  level	  of	  Student's	  t-­‐test	  was	  set	  at	  p	  <	  0.05.	  	  
















Figure	   3.S1.	   Ciliogenic	   chemotherapeutics	  
induce	   extracellular	   ATP	   in	   pancreatic	  
cancer	  cell	  line	  PANC-­‐1.	  Quantitative	  analysis	  of	   ATP	   secretion	   upon	   exposure	   of	   PANC-­‐1	  cells	   to	   a	   selection	   of	   ciliogenic	   drugs	   (black	  bars)	  and	  a	  non-­‐ciliogenic	  drug	  (blue	  bar)	  at	  2	  micromolar	  concentration	  for	  96	  hours	  (A)	  as	  assessed	   by	   the	   measurement	   of	  bioluminescence	   based	   on	   luciferin-­‐luciferase	  conversion	   principle.	   Data	   are	   presented	   as	  mean	   ±	   SEM,	   *p	   ≤	   0.05,	   **p	   ≤	   0.005,	   ***p	   ≤	  0.0005.	  	  





















Figure	   3.S2.	   Effect	   of	   exogenous	   ATP	  
on	  cilia	   induction	  in	  PANC-­‐1	  cells.	  (A)	  Quantitative	   analysis	   of	   ciliogenesis	   in	  cells	   treated	   with	   increasing	  concentrations	   of	   exogenous	   ATP,	   as	  assessed	   by	   confocal	   fluorescence	  microscopy.	   (B)	   Representative	   images	  showing	  the	  effect	  of	  exogenous	  ATP	  on	  ciliation	   in	   PANC-­‐1	   cells.	   Nuclei	   were	  stained	  with	   DAPI	   (blue)	   and	   cilia	   with	  an	   antibody	   against	   the	   cilium	   marker	  acetylated	   tubulin	   (green).	   All	   images	  were	   captured	   using	  Olympus	   Fluoview	  confocal	   microscope	   using	   a	   40X	  objective	   lens.	   Data	   are	   presented	   as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005.	  	  
Figure	   3.S3.	   Apyrase-­‐mediated	  
degradation	  of	  extracelluar	  ATP	  
in	  pancreatic	  cancer	  cells	  PANC-­‐
1	   exposed	   to	   ciliogenic	   drugs.	  (A)	   Quantitative	   analysis	   of	   the	  effect	   of	   apyrase	   treatment	   on	  ciliogenesis.	   (B)	   Representative	  images	   showing	   the	   effect	   of	  apyrase	   on	   ciliogenesis	   in	   cells	  treated	   with	   indicated	   drugs.	  Nuclei	   were	   stained	   with	   DAPI	  (blue)	   and	   cilia	   with	   an	   antibody	  against	   the	   cilium	   marker	  acetylated	   tubulin	   (green).	   Data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005.	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Identification	  of	  kinase	  inhibitors	  as	  modulators	  of	  
ciliogenesis	  in	  cancer	  cells	  
	  
4.1.	  Introduction	  	  Most	  mammalian	  cells	  have	  an	  elongated	  protruding	  structure	  called	  the	  primary	  cilium	  that	   is	   crucial	   for	   the	   ability	   of	   the	   cell	   to	   sense	   signals	   from	   the	   extracellular	  environment.	   Accumulating	   evidence	   points	   towards	   a	   possible	   link	   between	   these	  structures	  and	  cancer	  development	  [1].	  However,	  the	  precise	  role	  of	  cilia	  in	  this	  context	  is	   not	   yet	   known.	   It	   is	   unclear	   whether	   cilia	   regress	   or	   promote	   the	   progression	   of	  cancers.	  A	  number	  of	  reports	  have	  documented	  the	  loss	  of	  cilia	  in	  different	  cancer	  types	  that	   include	   breast,	   prostate	   and	   pancreatic	   cancers	   [2-­‐4].	   On	   the	   other	   hand,	   several	  studies	   have	   provided	   evidence	   that	   presence	   of	   cilia	   is	   necessary	   for	   the	   survival	   of	  certain	  types	  of	  cancers	  like	  basal	  cell	  carcinoma	  (BCC),	  medulloblastoma	  and	  a	  subset	  of	   glioblastomas	   [5,	   6].	   Cilia	   might	   thus	   act	   as	   unique	   organelles	   that	   can	   play	   a	  paradoxical	  role	  of	  either	  mediating	  or	  curbing	  oncogenesis	  [7,	  8].	  Therefore,	  depending	  on	  the	  cancer	   type,	   targeting	   the	  cilium	  by	  agonists	  or	  antagonists	   to	  either	  restore	  or	  suppress	   ciliogenesis	   can	   be	   considered	   as	   a	   novel	   therapeutic	   approach	   to	   treat	  cancers.	   In	   our	  previous	  work,	  we	  have	  developed	  a	   cell-­‐based	   screening	   approach	   to	  identify	  compounds	  that	  have	  the	  ability	  to	  modulate	  cilium	  expression	  in	  cells	  [9].	  Here,	  in	  view	  of	  the	  reported	  role	  of	  kinases	  in	  the	  regulation	  of	  ciliogenesis	  and	  their	  widely	  applied	   use	   in	   the	   oncology	   field,	   we	   have	   used	   this	   approach	   to	   screen	   a	   library	   of	  kinase	  inhibitors	  to	  identify	  cilium	  modulators.	  Our	  results	  show	  that	  kinase	  inhibitors	  may	   either	   stimulate	   or	   repress	   ciliogenesis	   in	   cancer	   models.	   Key	   examples	   include	  Herbimycin	   A	   and	   Kenpaullone,	   which	   suppress	   ciliogenesis	   in	   cilia-­‐dependent	  glioblastoma	   cells	   and	   attenuate	   their	   cell	   growth	   and	   proliferation,	   and	   EGFR/ErbB-­‐2/ErbB-­‐4	   Inhibitor	   (CAS	   881001-­‐19-­‐0)	   and	   Src	   Kinase	   Inhibitor	   I,	   which	   enhance	  ciliogenesis	   in	   poorly	   ciliated	   pancreatic	   cancer	   cells.	   These	   findings	   provide	   novel	  insights	  in	  the	  role	  of	  kinases	  in	  the	  regulation	  of	  ciliogenesis.	  They	  expand	  our	  arsenal	  of	  tools	  to	  modulate	  ciliogenesis	  in	  cancer	  cells	  depending	  on	  the	  cilium-­‐dependence	  of	  the	   tumor	   type,	   and	   they	   advance	   the	   concept	   that	  modulation	   of	   ciliogenesis	  may	  be	  used	  as	  a	  therapeutic	  strategy	  to	  combat	  different	  types	  of	  cancers.	  	  
	  




















4.2.	  Results	  	  	  	  
4.2.1.	   Identification	   of	   cilium	   modulators	   from	   a	   compound	   screen	   of	   kinase	  
inhibitors.	  	  To	   identify	   potential	  modulators	   of	   ciliogenesis,	  we	   employed	   a	   96-­‐well	   format	   screening	  strategy	   previously	   developed	   by	   us	   [9],	   which	   evaluates	   the	   changes	   in	   percentage	   of	  ciliated	   cells	   in	   CFPAC-­‐1	   cells	   by	   immunofluorescence	   microscopy-­‐based	   visualization	   of	  
Figure	   4.1.	   Identification	   of	   cilium	  modulators	   in	   a	   kinase	   inhibitor	   library	   using	   the	   IN	  Cell	  
Analyzer.	   (A)	   Ciliogenic	   potential	   of	   160	   compounds	  of	   the	   kinase	   inhibitor	   library	   as	   revealed	  by	  assessing	   the	   percentage	   of	   ciliated	   CFPAC-­‐1	   cells	   (acetylated	   tubulin	   staining)	   using	   the	   IN	   Cell	  Analyzer	   8	   days	   after	   compound	   treatment	   (1	  micromolar).	   Compounds	   are	   ranked	   in	   descending	  order	   of	   their	   potency	   to	   increase	   the	   percentage	   of	   ciliated	   cells	   relative	   to	   vehicle	   control	   (pink	  dotted	   line).	   (B)	   List	   of	   cilium	   suppressors	   (blue	   bars)	   and	   enhancers	   (green	   bars)	   based	   on	   the	  criterion	   to	   reduce	   the	   percentage	   of	   ciliated	   cells	   by	  more	   than	   3	   times	   the	   standard	   deviation	   as	  compared	  to	  control	  cells	  and	  ranked	  according	  to	  their	  effect.	  Data	  are	  presented	  as	  mean	  ±	  S.D.	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	  compared	  to	  control.	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primary	  cilia	  stained	  with	  an	  antibody	  specific	  to	  the	  ciliary	  component	  acetylated	  tubulin.	  Using	   this	   strategy	   we	   screened	   a	   library	   of	   160	   kinase	   inhibitors	   (Figure	   4.1A).	   All	  compounds	  were	  screened	  in	  triplicate.	  Compounds	  (hits)	  were	  considered	  	  
	  
INHIBITOR	  NAME	   CAS	  NUMBER	  
Cilia	  suppressors	   	  Chk2	  Inhibitor	  II	   516480-­‐79-­‐8	  Casein	  Kinase	  I	  Inhibitor,	  D4476	   301836-­‐43-­‐1	  Bcr-­‐abl	  Inhibitor	   778270-­‐11-­‐4	  Herbimycin	  A,	  Streptomyces	  sp.	   70563-­‐58-­‐5	  	  Kenpaullone	   142273-­‐20-­‐9	  cFMS	  Receptor	  Tyrosine	  Kinase	  Inhibitor	   870483-­‐87-­‐7	  Aloisine,	  RP106	   496864-­‐15-­‐4	  MK2a	  Inhibitor	   41179-­‐33-­‐3	  ERK	  Inhibitor	  II,	  FR180209	   1177970-­‐73-­‐8	  SU9516	   666837-­‐93-­‐0	  Lck	  Inhibitor	   213743-­‐31-­‐8	  IRAK-­‐1/4	  Inhibitor	   509093-­‐47-­‐4	  
Cilia	  inducers	   	  PKCbII/EGFR	  Inhibitor	   145915-­‐60-­‐2	  DNA-­‐PK	  Inhibitor	  V	   404009-­‐46-­‐7	  STO-­‐609	   52029-­‐86-­‐4	  Sphingosine	  Kinase	  Inhibitor	   1177741-­‐83-­‐1	  IGF-­‐1R	  Inhibitor	  II	   196868-­‐63-­‐0	  AG	  1024	   65678-­‐07-­‐1	  DNA-­‐PK	  Inhibitor	  II	   154447-­‐35-­‐5	  Aminopurvalanol	  A	   220792-­‐57-­‐4	  	  AGL	  2043	   22617-­‐28-­‐8	  ERK	  Inhibitor	  II,	  FR180204	   865362-­‐74-­‐9	  GTP-­‐14564	   34823-­‐86-­‐4	  	  	  DNA-­‐PK	  Inhibitor	  III	   404009-­‐40-­‐1	  LY	  294002	   154447-­‐36-­‐6	  PKCb	  Inhibitor	   257879-­‐35-­‐9	  Indirubin	  Derivative	  E804	   854171-­‐35-­‐0	  PP1	  Analog	  II,	  1NM-­‐PP1	   221244-­‐14-­‐0	  MEK	  1/2	  Inhibitor	   305350-­‐87-­‐2	  Rapamycin	   53123-­‐88-­‐9	  PI-­‐103	   371935-­‐74-­‐9	  Src	  Kinase	  Inhibitor	  I	   179248-­‐59-­‐0	  JAK	  Inhibitor	  I	   457081-­‐03-­‐7	  EGFR/ErbB-­‐2/ErbB-­‐4	  Inhibitor	  	   881001-­‐19-­‐0	  MNK1	  Inhibitor	   522629-­‐08-­‐9	  	  as	   cilia	   suppressors	  or	  enhancers	  based	  on	   their	  ability	   to	   reduce	  or	   respectively	   increase	  the	  percentage	  of	  ciliated	  cells	  by	  more	  than	  3	  times	  the	  standard	  deviation	  as	  compared	  to	  control	   cells.	   The	   hits	   based	   on	   low	   cell	   count	   were	   considered	   unreliable	   and	   hence	  
Table	  4.1.	  List	  of	  cilia-­‐modulating	  kinase	  inhibitors	  identified	  from	  the	  library	  screen	  and	  their	  Unique	  numerical	  identifier	  numbers	  (CAS	  numbers).	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excluded	   from	   further	  evaluation.	  Based	  on	   these	   criteria,	  12	  potential	   cilium	  suppressors	  and	   23	   cilium	   enhancers	   (Figure	   4.1B)	   were	   identified	   from	   the	   initial	   screen.	   Table	   4.1	  shows	  the	  unique	  numerical	  identifier	  (CAS	  Number)	  of	  each	  identified	  hit.	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4.2.2.	  Confirmation	  of	  cilium	  modulation	  by	  confocal	  microscopy	  Out	  of	  the	  12	  cilia	  suppressors	  and	  23	  cilia	  enhancers	  identified	  in	  the	  initial	  screen,	  we	  selected	  the	  5	  most	  potent	  suppressors	  from	  each	  category	  for	  confirmation	  of	  their	  cilio-­‐modulatory	   effect	   by	   a	   more	   robust	   confocal	   microscopy	   technique,	   which	   allows	   the	  elimination	   of	   false	   positives.	   Three	   out	   of	   5	   potential	   repressors	   and	   all	   5	   selected	  enhancers	   significantly	   modulated	   cilium	   expression	   (Figure	   4.2A	   and	   4.2B).	   The	   two	  most	   potent	   suppressors	   (Herbimycin	   A,	   Kenpaullone)	   and	   enhancers	   (EGFR/ErbB-­‐2/ErbB-­‐4	  inhibitor,	  Src	  Kinase	  Inhibitor	  I)	  of	  cilia	  were	  selected	  for	  further	  testing.	  	  
4.2.3.	   Herbimycin	   A	   and	   Kenpaullone	   suppress	   ciliogenesis	   and	   attenuate	   cell	  
proliferation	   in	   cilium-­‐dependent	   glioblastoma	   cells.	  We	  next	   evaluated	   the	  most	  potent	  cilia	  suppressors	  Herbimycin	  A	  and	  Kenpaullone	  for	  their	  ability	  to	  suppress	  cilia	  in	   a	   glioblastoma	   cell	   line	   model	   GL2664,	   the	   growth	   of	   which	   is	   dependent	   on	   the	  primary	  cilium	  and	  hence	  is	  richly	  ciliated	  in	  the	  basal	  condition	  (Figure	  4.3).	  Both	  the	  compounds	  Herbimycin	  A	  and	  Kenpaullone	  significantly	  inhibited	  ciliogenesis	  in	  this	  cell	  line	  and	  reduced	  the	  percentage	  of	  ciliated	  cells	  from	  approximately	  70%	  to	  5%	  or	  less	  (Figure	   4.3).	   This	   result	   highlights	   the	   potential	   of	   these	   compounds	   as	   potent	   cilium	  suppressors	   in	   highly	   ciliated	   and	   cilium-­‐dependent	   cancer.	   Both	   compounds	  significantly	  attenuated	  the	  growth	  of	   the	  cilium-­‐dependent	  GL2664	  glioblastoma	  cells	  but	  not	  of	  the	  CFPAC-­‐1	  pancreatic	  cancer	  cells,	  which	  are	  relatively	  poorly	  ciliated	  and	  the	  growth	  of	  which	  is	  known	  to	  be	  repressed	  by	  cilium	  expression	  	  (Figure	  4.4A).	  This	  result	   was	   further	   substantiated	   by	  measurement	   of	   cell	   proliferation	   based	   on	   BrdU	  incorporation	   in	   cells	   treated	   with	   the	   compounds.	   Both	   compounds	   significantly	  reduced	   BrdU	   incorporation	   in	   glioblastoma	   cells	   but	   not	   of	   pancreatic	   cancer	   cells	  (Figure	   4.4B).	   As	   revealed	   by	   FACS	   analysis	   both	   compounds	   caused	   a	   shift	   in	   the	  percentage	   of	   cells	   in	   the	   G0-­‐G1	   phase	   to	   those	   in	   the	   G2-­‐M	   phase	   of	   the	   cell	   cycle	  of	  
Figure	  4.2.	  (on	  page	  108)	  Reconfirmation	  of	  the	  cilium	  modulatory	  effect	  of	  the	  10	  best	  hits	  by	  
confocal	  microscopy	   of	   CFPAC-­‐1	   cells.	   (A)	  Quantitative	  analysis	  of	   the	  effect	  of	   the	  best	  5	  cilium	  suppressors	   and	   enhancers	   from	   Figure	   4.1	   on	   the	   percentage	   of	   ciliation	   in	   CFPAC-­‐1	   cells	   as	  determined	  by	  confocal	  microscopy.	  200-­‐300	  cells	  were	  counted	  from	  at	  least	  three	  different	  regions	  of	  the	  well	  to	  perform	  the	  quantification.	  All	  data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	  compared	  to	  control.	  (B)	  Images	  of	  primary	  cilia	  in	  compound-­‐treated	  CFPAC-­‐1	  cells	  as	  visualized	  by	  confocal	  microscopy.	  Cilia	  suppressors	  and	  enhancers	  are	  indicated	  by	  red	  and	  black	  font	  colors	  respectively.	   Cilia	  were	  stained	  with	  anti-­‐acetylated	  tubulin	  antibody	  (green)	  and	  nuclei	  were	  counterstained	  with	  DAPI	  (blue).	  Scale	  bar	  represents	  10	  μm.	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glioblastoma	   cells,	   whereas	   CFPAC-­‐1	   pancreatic	   cancer	   cells	   were	   unaffected	   (Figure	  4.4C).	   These	   findings	   highlight	   the	   potential	   of	   Herbimycin	   A	   and	   Kenpaullone	   to	  attenuate	  the	  growth	  of	  glioblastoma	  cells	  that	  are	  dependent	  on	  cilia	  for	  their	  survival	  and	  growth.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  4.3.	  Effect	  of	  Herbimycin	  A	  and	  Kenpaullone	  on	  ciliogenesis	  in	  GL2664	  glioblastoma	  
cells.	  Quantification	  of	  the	  percentage	  of	  ciliated	  cells	  after	  treatment	  of	  cells	  with	  Herbimycin	  A	  and	  Kenpaullone.	  Data	  was	  obtained	  by	  counting	  200-­‐300	  cells	  from	  three	  different	  regions	  of	  the	  well	  and	  is	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	  compared	  to	  control.	  Representative	   confocal	   microscopy	   images	   show	   the	   effect	   of	   Herbimycin	   A	   and	   Kenpaullone	  treatment	  on	  glioblastoma	  cells.	  Scale	  bar	  in	  the	  images	  represents	  10	  μm.	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4.2.4.	   EGFR/ErbB-­‐2/ErbB-­‐4	   inhibitor	   and	   Src	   Kinase	   Inhibitor	   I	   attenuate	   cell	  
proliferation	  in	  poorly	  ciliated	  pancreatic	  cancer	  cells	  	  To	   assess	   the	   ability	   of	   cilia	   enhancers	   to	   inhibit	   the	   proliferation	   of	   other	   poorly	   ciliated	  cells	   that	   benefit	   from	   cilium	   loss,	   we	   treated	   CFPAC-­‐1	   pancreatic	   cancer	   cells	   with	  EGFR/ErbB-­‐2/ErbB-­‐4	   inhibitor	   and	   Src	   Kinase	   Inhibitor	   I	   and	  measured	   cell	   proliferation	  
Figure	  4.4.	  Effect	  of	  Herbimycin	  A	  and	  Kenpaullone	  on	  cell	  proliferation	  of	  cilium-­‐dependent	  and	  
cilium-­‐independent	  cancer	  cell	   lines.	  (A)	  Effect	  of	  indicated	  compounds	  on	  the	  growth	  of	  GL2664	  and	  CFPAC-­‐1	   cancer	   cells	   as	   assessed	   by	   Incucyte	   live	   cell	   imaging	   and	   analysis.	   Data	   was	   obtained	   by	  calculating	  the	  mean	  value	  of	  confluence	  from	  6	  different	  wells	  of	  each	  condition.	  The	  panel	  on	  the	  right	  shows	  representative	   images	  of	  control	  and	  compound-­‐treated	  GL2664	  cells	  as	  captured	  by	  Incucyte	  at	  different	  time	  points.	  (B)	  Effect	  of	  the	  indicated	  compounds	  on	  proliferation	  of	  GL2664	  and	  CFPAC-­‐1	  cells	  as	  measured	  by	  BrdU	  incorporation	  assay.	  (C)	  Assessment	  of	  changes	  in	  cell	  cycle	  profile	  as	  determined	  by	  FACS	  analysis	  of	  GL2664	  and	  CFPAC-­‐1	  cells	  treated	  with	  indicated	  compounds.	  Data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	  compared	  to	  control.	  	  
	   116	  














4.3.	  Discussion	  	  Venturing	  into	  the	  hitherto	  unexplored	  area	  of	  cancer	  therapy	  based	  on	  cilium	  modulation,	  we	  have	  screened	  a	  library	  of	  160	  kinase	  inhibitors	  for	  potential	  modulators	  of	  ciliogenesis	  
Figure	  4.5.	  Effect	  of	  cilium	  enhancers	  EGFR/ErbB-­‐2/ErbB-­‐4	  inhibitor	  and	  Src	  Kinase	  Inhibitor	  
I	   on	   cell	   proliferation	   of	   poorly	   ciliated	   pancreatic	   cancer	   cells.	   (A)	   Effect	   of	   indicated	  compounds	  on	  proliferation	  of	  CFPAC-­‐1	  pancreatic	  cancer	  cells	  as	  assessed	  by	  BrdU	  incorporation	  assay.	   (B)	   Assessment	   of	   cell	   cycle	   profile	   by	   FACS	   analysis	   of	   CFPAC-­‐1	   cells	   treated	   with	   the	  indicated	  compounds.	  Data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	   ***p	  ≤	  0.0005	  as	  compared	   to	   control.	   (C)	   Effect	   of	   indicated	   compounds	   on	   the	   growth	   of	   L3.6	   pancreatic	   cancer	  spheroids.	  The	  volume	  was	   calculated	  as	   a	  mean	  of	  at	   least	  6	  spheroids	   for	   each	  condition.	  Lower	  panel	  displays	  representative	  images	  of	  untreated	  and	  treated	  spheroids	  at	  different	  time	  intervals.	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and	   identified	   two	   classes	   of	   compounds:	   cilium	   suppressors	   and	   cilium	   enhancers.	   A	  deeper	   look	   into	   the	   molecular	   targets	   and	   modes	   of	   action	   of	   the	   identified	   cilium	  suppressors	  and	  inducers	  provides	  interesting	  clues	  into	  some	  of	  the	  possible	  mechanisms	  that	   might	   be	   involved	   in	   their	   differential	   effect	   on	   ciliogenesis.	   Herbimycin	   A	   is	   a	  pleiotrphic	   inhibitor	   that	   among	   others	   inhibits	   Hsp90	   [10,	   11],	   which	   is	   a	   heat	   shock	  protein	   that	   is	   associated	   with	   microtubules	   of	   the	   cilium	   and	   is	   important	   for	   the	  stabilization	   of	   tubulin	   [12,	   13].	   Hence,	   the	   suppression	   of	   ciliogenesis	   by	  Herbimycin	   A	  might	   in	  part	  be	  attributed	  to	  the	  destabilization	  of	  microtubules	  potentially	   involving	  an	  HDAC6-­‐HSP90	  interplay	  [14].	  Kenpaullone	  is	  an	  inhibitor	  of	  GSK-­‐3β,	  an	  important	  protein	  involved	  in	  the	  maintenance	  of	  cilia	  [15,	  16].	  It	  also	  inhibits	  several	  CDKs,	  suggesting	  that	  Kenpaullone	  may	  also	  suppress	  ciliogenesis	  by	  the	  regulation	  of	  the	  cell	  cycle.	  Interestingly,	  both	   compounds	   cause	   a	   shift	   in	   the	   percentage	   of	   cells	   in	   the	   G0-­‐G1	   phase,	   which	   is	  typically	   associated	   with	   cilium	   expression,	   towards	   those	   in	   the	   G2-­‐M	   phase,	   which	  usually	  are	  devoid	  of	  cilia	  as	  the	  structural	  elements	  of	  the	  cilium	  are	  used	  for	  chromosome	  segregation.	  To	  what	  extent	  changes	  in	  cell	  cycle	  are	  cause	  or	  consequence	  or	  work	  hand-­‐in-­‐hand	  with	  alterations	  in	  ciliogenesis	  remains	  unknown.	  With	   respect	   to	   cilia	   enhancers,	   the	   ciliogenic	   effect	   of	   EGFR/ErbB-­‐2/ErbB-­‐4	   Inhibitor	   is	  likely	  attributed	  to	  its	  ability	  to	  inhibit	  EGFR,	  which	  is	  known	  to	  activate	  MAPK	  signaling,	  a	  negative	   regulator	   of	   ciliogenesis	   [17,	   18].	   Therefore,	   it	   is	   plausible	   that	   suppression	   of	  hyperactive	  MAPK	  signaling	  through	  inhibition	  of	  EGFR	  activity	  leads	  to	  the	  enhancement	  of	   ciliogenesis.	   Interestingly,	   it	   has	   also	   been	   shown	   that	   EGFR	   is	   a	   part	   of	   protein	  complexes	   that	   are	   involved	   in	   the	   localization	   of	   a	   sensory	   protein	   to	   the	   cilium	   [19].	  However,	  it	  is	  not	  yet	  known	  if	  it	  is	  also	  involved	  in	  the	  localization	  of	  structural	  proteins	  that	   are	   required	   for	   the	   formation	   of	   cilium.	   Src	  Kinase	   Inhibitor	   I	   is	   known	   to	   directly	  bind	  and	  phosphorylate	  NEDD9,	  a	  protein	  involved	  in	  the	  inhibition	  of	  ciliogenesis	  [20,	  21].	  The	  activated	  NEDD9	  in	  turn	  activates	  HDAC6	  via	  AURKA	  to	  inhibit	  ciliogenesis	  [22].	  Thus,	  inhibition	  of	  Src	  Kinase	  activity	  may	  promote	  ciliogenesis	  by	   inhibiting	  NEDD9-­‐mediated	  disassembly	   of	   the	   cilium.	   Previous	   studies	   have	   show	   that	   Src	   Kinase	   inhibition	   has	  therapeutic	  effects	  in	  polycystic	  kidney	  disease	  [23,	  24].	  Recently,	  a	  study	  has	  shown	  that	  an	  actin	   regulatory	  protein	  MIM	  (Missing-­‐in	  Metastasis)	   is	  present	  at	   the	  basal	  body	  and	  promotes	   ciliogenesis	   by	   antagonizing	   src-­‐dependent	   activation	   of	   another	   protein	  cortactin	   [25].	   Therefore,	   inhibition	   of	   Src	   Kinase	   may	   promote	   ciliogenesis	   by	   positive	  regulation	  of	  MIM.	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In	   view	   of	   earlier	   findings	   that	   various	   cancer	   types	   show	   distinct	   and	   opposite	  dependencies	   and	   growth	   (dis)advantages	   linked	   to	   the	   primary	   cilium	   [7,	   8],	   the	   two	  classes	   of	   compounds	  may	   find	   other	   applications	   depending	   on	   the	   tumor	   type	   (Figure	  4.6).	  Cilium	  inhibitors	  may	  have	  therapeutic	  potential	  mainly	  in	  cilium-­‐dependent	  cancers	  like	   glioblastomas,	   basal	   cell	   carcinomas,	   medulloblastomas,	   whereas	   cilium	   enhancers	  could	  be	  used	  to	  treat	  cancers	  like	  pancreatic,	  breast,	  prostate	  cancers	  and	  melanomas	  that	  benefit	   from	   the	   loss	   of	   the	   cilium	   (Figure	   4.6).	   Our	   findings	   may	   also	   have	   broader	  implications	   as	   they	   can	   also	   be	   expanded	   to	   develop	   therapeutic	   strategies	   for	   the	  treatment	  of	  other	  cilium-­‐related	  disorders	  and	  ciliopathies.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4.4.	  Materials	  and	  methods	  
4.4.1.	  Cell	  culture	  	  CFPAC-­‐1	   and	   L3.6	   pancreatic	   cancer	   cell	   lines	   were	   obtained	   from	   ATCC.	   The	   GL2664	  glioblastoma	   cell	   line	   was	   attained	   from	   the	   laboratory	   of	   Angiogenesis	   and	  
Figure	   4.6.	  Overview	   of	   the	   therapeutic	   strategy	   to	   treat	   cancers	   with	   different	   cilium	  
dependencies.	  Two	  classes	  of	  compounds	  were	  identified	  in	  our	  screen:	  cilium	  suppressors	  and	  cilium	   enhancers.	   Cilium	   suppressors	   can	   be	   used	   as	   potential	   therapeutic	   agents	   against	  cancers	   that	   are	   dependent	   on	   the	   cilium,	  whereas	   cilia	   inducers	   can	   be	   used	   as	   therapeutics	  against	  cancer	  cells	  that	  are	  dependent	  on	  the	  loss	  of	  the	  cilium.	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Neurovascular	   Link	   (KU	   Leuven,	   Belgium).	   CFPAC-­‐1	   and	   L3.6	   cells	  were	  maintained	   in	  RPMI-­‐1640	  medium	  (Life	  Technologies)	  supplemented	  with	  10%	  FBS	  (Life	  Technologies).	  The	  medium	  for	  L3.6	  cells	  was	  supplemented	  with	  4mM	  L-­‐Glutamine	  (Life	  Technologies).	  GL2664	   cells	   were	   cultured	   in	   DMEM	   high	   glucose	   medium	   (Life	   Technologies)	  supplemented	  with	   10%	  FBS	   and	   4mM	  L-­‐Glutamine.	   All	   the	   cell	   lines	  were	   grown	   at	   a	  temperature	  of	  37°C	  in	  a	  humidified	  incubator	  with	  5%	  levels	  of	  CO2.	  	  
4.4.2.	  Screening	  of	  protein	  kinase	  inhibitor	  library	  A	   library	   comprising	   of	   a	   panel	   of	   160	  well-­‐	   characterized,	   cell	   permeable,	   potent	   and	  reversible	   protein	   kinase	   inhibitors	   (Calbiochem)	   was	   procured	   from	   Center	   for	   Drug	  Design	  and	  discovery	  (CD3)	  (Leuven,	  Belgium).	  The	  compounds	  were	  dissolved	  in	  DMSO	  and	   stored	   as	   10mM	   stock	   solutions	   before	   addition	   to	   culture	   medium	   at	   a	   final	  concentration	  of	  1	  μM.	  The	  library	  was	  screened	  according	  to	  the	  methodology	  developed	  by	  us	  previously	   [9]	  based	  on	  CFPAC-­‐1	  pancreatic	  cancer	  cells	  grown	   in	  96-­‐well	   format	  followed	  by	  immunofluorescence	  based	  imaging	  and	  analysis	  using	  IN	  Cell	  Analyzer	  and	  IN	   Cell	   Developer	   respectively,	   to	   assess	   changes	   in	   the	   percentage	   of	   ciliated	   cells	   by	  staining	   of	   cilium	   with	   anti-­‐acetylated	   tubulin	   antibody	   (Sigma,	   Cat	   No.	   T6793-­‐.5ML)	  followed	  by	  a	  fluorescent	  secondary	  antibody	  (Life	  Technologies,	  AlexaFluor	  488,	  Cat	  No.	  A21145).	  	  
4.4.3.	  Immunofluorescence	  confocal	  microscopy	  	  CFPAC-­‐1	   and	   GL2664	   cells	   were	   seeded	   on	   glass	   coverslips	   placed	   in	   12-­‐well	   plates	  containing	  1ml	  of	  culture	  medium	  per	  well.	  When	  cells	  were	   fully	  confluent,	   the	  culture	  medium	   was	   replaced	   with	   fresh	   medium	   containing	   2%	   FBS	   and	   treated	   with	  compounds	   for	  24	  hours	  and	   fixed	  with	  4%	  Formaldehyde	  (Merck),	  permeabilized	  with	  0.1%	  Triton	  X100	  (Merck)	  in	  DPBS,	  blocked	  with	  1%	  BSA	  (Applichem)	  in	  DPBS,	  incubated	  with	  anti-­‐acetylated	  tubulin	  antibody	  (1:1000)	  dilution	  for	  1	  hour,	  followed	  by	  incubation	  with	  a	  fluorescent	  secondary	  antibody	  for	  1	  hour.	  Nuclei	  were	  stained	  with	  DAPI	  (Vector	  Laboratories,	  Vectashield,	  Cat.	  No.	  H-­‐1500).	  Nikon	  C2	  Eclipse	  Ti-­‐E	  confocal	  laser	  scanning	  microscope	  was	  used	  to	  capture	  images	  of	  cilia	  as	  Z-­‐stacks	  using	  a	  60X	  oil	  immersion	  lens.	  Compounds	  selected	  for	  confirmation	  experiments	  and	  functional	  assays	  were	  purchased	  from	  Calbiochem.	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4.4.4.	  Cell	  growth	  assay	  Cell	  growth	  assays	  were	  performed	  in	  96-­‐well	  plates	  for	  a	  period	  of	  5	  days	  using	  Incucyte	  (Essen	   Bioscience),	   a	   live	   cell	   imaging	   system	   that	   captures	   bright	   phase	   images	   at	   an	  interval	  of	  every	  2	  hours	  from	  4	  separate	  regions	  per	  well	  using	  a	  20X	  lens.	  Assay	  plates	  were	   maintained	   at	   37°C	   in	   an	   incubation	   chamber	   throughout	   the	   run.	   The	   Incucyte	  software	   was	   used	   to	   plot	   the	   growth	   curves	   by	   calculating	  mean	   confluence	   from	   six	  wells	  of	  the	  96-­‐well	  plate	  for	  each	  condition.	  	  
4.4.5.	  BrdU	  incorporation	  assay:	  	  BrdU	  incorporation	  assay	  to	  measure	  cell	  proliferation	  was	  performed	  using	  5-­‐Bromo-­‐2-­‐deoxy-­‐uridine	  Labeling	  and	  Detection	  Kit	  III	  (Cat.	  No.	  11444611001,	  Roche)	  following	  the	  manufacturer	  protocol.	  	  
4.4.6.	  Tumor	  spheroid	  assay:	  Tumor	  spheroid	  assay	  based	  on	  L3.6	  pancreatic	  cancer	  cells	  was	  performed	  as	  described	  in	  [9].	  	  
4.4.7.	  Cell	  cycle	  analysis	  	  GL2664	  and	  CFPAC-­‐1	  cells	  were	  plated	  in	  6-­‐well	  plates	  at	  a	  density	  of	  300,000	  cells/well	  and	   allowed	   to	   reach	   60%	   confluence	   before	   the	   start	   of	   compound	   treatment	   for	   48	  hours.	   Post	   treatment,	   cells	   were	   harvested	   by	   trypsinization,	   fixed	   with	   4%	  Formaldehyde,	  permeabilized	  with	  0.1%	  Triton	  X100,	  followed	  by	  staining	  with	  Vybrant	  DyeCycle	  Green	  Stain	  (Cat.	  No.	  V35004,	  ThermoFisher	  Scientific).	  Data	  was	  obtained	  using	  BD	  FACSCanto	  Flow	  Cytometer	   (Becton	  Dickinson)	  by	  measuring	  at	   least	  10,000	  events	  per	  sample.	  Data	  was	  analyzed	  using	  FlowJo	  software	  (Becton	  Dickinson).	  	  
4.4.8.	  Statistical	  analysis	  	  Statistical	   analysis	   was	   performed	   using	   GraphPad	   Prism	   version	   6	   for	   Mac	   OS	   X	  (GraphPad	   Software,	   San	   Diego,	   California,	   USA).	   Data	   are	   expressed	   as	   mean	   ±S.D.	   or	  ±SEM.	   Differences	   between	   two	   groups	   were	   calculated	   using	   the	   t-­‐test.	   Statistical	  significance	  was	  set	  at	  p	  value	  of	  <	  0.05.	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Identification	   and	   functional	   testing	   of	   novel	   small	  
molecule	   compounds	   that	   reverse	   SREBP1-­‐mediated	  
suppression	   of	   the	   primary	   cilium:	   application	   to	  
models	  of	  cancer	  and	  ciliopathies	  	  
5.1.	  Introduction	  The	   primary	   cilium	   is	   a	   single,	   slender	   eyelash-­‐like	   structure	   that	   grows	   at	   the	   apical	  surface	  of	   the	   cell.	   It	   is	   a	  microtubule-­‐based	  organelle	   that	   is	  present	  on	  almost	   every	  cell	   type	   in	  mammals.	   Primary	   cilia	   function	   as	   sensors	   of	   extracellular	   signals.	   They	  capture	   signals	   from	   their	   immediate	   surroundings	   and	   transduce	   them	   into	   the	   cell,	  which	  is	  then	  informed	  of	  how	  to	  adapt	  and	  develop	  itself.	  Thus,	  a	  primary	  cilium	  acts	  as	  an	  antenna	  that	  serves	  as	  a	  communication	  device	  between	  the	  cell	  and	  the	  extracellular	  environment.	   To	   this	   end	   a	   large	   diversity	   of	   receptors,	   proteins,	   or	   channels	   can	   be	  present	  on	  the	  same	  cilium.	  Many	  different	  signal	  transduction	  systems	  may	  exist	  on	  a	  single	  primary	   cilium	   to	   facilitate	  diverse	   signaling	  processes	   that	   are	   instrumental	   in	  tissue	   development.	   These	   include	   Hedgehog,	   Wnt	   and	   PDGFRα	   pathways	   that	   are	  pivotal	  for	  embryonic	  growth	  and	  development.	  	  Being	   a	   hub	   of	   cellular	   signaling,	   structural	   integrity	   of	   the	   cilium	   and	   ciliary	  components	   becomes	   cardinally	   important.	   Abrogation	   of	   the	   cilium	   or	   loss	   of	   ciliary	  function	   leads	  to	  profound	  effects	  that	  compromise	  normal	  development	  and	  health	  of	  an	  organism	  [1].	  Ciliary	  dysfunction	  results	  in	  specific	  disorders	  called	  ciliopathies	  that	  include	  Polycystic	  Kidney	  Disease	   (PKD),	  Primary	  Cilia	  Dyskinesia	   (PCD),	  Bardet-­‐Biedl	  Syndrome	   (BBS),	   Joubert	   Syndrome	   (JBTS),	   Meckel	   Syndrome	   (MKS),	   Kartagener	  Syndrome	  etc.	  Interestingly,	  there	  is	  increasing	  evidence	  that	  the	  primary	  cilium	  is	  also	  involved	  in	  other	  much	  more	  common	  human	  diseases	  like	  cancer	  [2].	  In	  fact,	  emerging	  evidence	  implicates	  a	  decrease,	  loss,	  distortion	  or	  ablation	  of	  primary	  cilia	  in	  a	  number	  of	   cancers	   [3-­‐5]	   like	   prostate	   cancer,	   pancreatic	   cancer,	   breast	   cancer,	  melanoma	   etc.	  Although	   the	   exact	  mechanisms	   underlying	   cilium	   loss	   in	   cancer	   development	   remain	  unknown,	   evidence	   from	   our	   team	   has	   shown	   that	   aberrant	   lipid	   metabolism	   and	  particularly	   constitutive	   activation	   of	   the	   lipogenic	   transcription	   factor	   SREBP1	   may	  play	   an	   important	   role	   in	   cilium	   repression	   [6].	  As	   to	   the	   role	  of	   cilium	   loss	   in	   cancer	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cells,	  it	  is	  commonly	  assumed	  that	  the	  cilium	  puts	  a	  break	  on	  cell	  proliferation	  as	  it	  uses	  the	   same	   structural	   components	   as	   required	   for	   chromosome	   segregation.	   Moreover,	  cilium	  loss	  may	  contribute	  to	  distorted	  cellular	  signaling	  that	  is	  a	  hallmark	  of	  cancer	  [7-­‐9].	   Hence,	   the	   primary	   cilium	   and	   particularly	   the	   mechanisms	   that	   govern	   primary	  ciliogenesis	  may	  be	  interesting	  novel	  targets	  for	  antineoplastic	  therapy.	  	  In	   the	   present	   study,	   we	   have	   developed	   a	   chemical	   screening	   platform	   based	   on	  SREBP1c-­‐mediated	   cilium	   suppression	   in	   MDCK	   kidney	   cells	   to	   identify	   novel	  compounds	   that	   can	   revive	  primary	  cilium	   in	  cancer	   cells.	  This	   screening	  method	  was	  further	   applied	   to	   screen	   a	   library	   of	   1300	   small	   molecules,	   which	   revealed	   8	  compounds	  that	  had	  the	  ability	  to	  potently	  induce	  cilia	  in	  several	  cancer	  models	  and	  to	  rescue	  ciliary	  length	  in	  a	  ciliopathy	  model.	  By	  virtue	  of	  their	  ability	  to	  induce	  cilia,	  these	  compounds	   attenuated	   cell	   proliferation	   in	   melanoma,	   breast	   and	   prostate	   cancer	  models.	  These	  findings	  provide	  a	  solid	  groundwork	  to	  support	  the	  feasibility	  of	  using	  a	  new	  concept	  of	  cilium	  restoration	  as	  a	  strategy	  to	  treat	  cancers	  and	  ciliopathies.	  	  
5.2.	  Results	  
5.2.1.	   Development	   of	   a	   screening	   strategy	   based	   on	   normal	   kidney	   cells	   with	  
forced	  SREBP-­‐induced	  cilium	  repression	  In	   view	   of	   our	   previous	   studies	   showing	   that	   aberrant	   activation	   of	   the	   lipogenic	  transcription	  factor	  SREBP1	  mediates	  primary	  cilium	  repression	  in	  various	  models	  [6],	  we	   developed	   a	   compound	   screening	   approach	   using	   normal	   kidney	   cells	   (MDCK)	  transduced	  with	  an	  SREBP1c	  gene-­‐encoding	  adenovirus	  to	  identify	  chemical	  compounds	  with	   the	   ability	   to	   re-­‐induce	   the	   cilium.	   Transduction,	   seeding	   and	   culture	   conditions	  were	  thoroughly	  optimized	  for	  consistency	   in	  cilium	  repression	  (down	  to	  20%	  ciliated	  cells	   in	   the	   culture)	   and	   formation	   of	   flat	  monolayers	   amenable	   for	   automated	   image	  acquisition	   by	   high	   content	   analysis	   using	   the	   IN	   Cell	   Analyzer.	   The	   acquired	   images	  were	   analyzed	   by	   the	   IN	   Cell	   Developer	   software	   followed	   by	   statistical	   analysis	   to	  identify	   the	   compounds	   that	   were	   able	   to	   reverse	   the	   SREBP-­‐induced	   repression	   of	  primary	  cilium.	  Figure	  5.1	   illustrates	  the	  schematic	  workflow	  of	  the	  screening	  process.	  Using	  this	  model	  we	  screened	  a	  library	  of	  1300	  unknown	  compounds	  (CISTIM	  Library).	  This	  library	  was	  composed	  of	  compounds	  that	  were	  non-­‐cytotoxic	  and	  easily	  soluble	  in	  aqueous	   solutions.	   Initially	   102	   hits	   were	   selected	   based	   their	   ability	   to	   increase	   the	  percentage	  of	  ciliated	  cells	  by	  at	  least	  3-­‐fold	  the	  standard	  deviation	  compared	  to	  vehicle-­‐
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5.2.2.	  Confirmation	  of	  8	  ciliogenic	  compounds	  from	  the	  CISTIM	  Library	  by	  confocal	  
fluorescence	  microscopy	  The	  20	  hits	  from	  the	  InCell	  Analyzer	  screen	  were	  tested	  for	  their	  ability	  to	  induce	  cilium	  expression	  in	  LNCaP	  cells,	  a	  prostate	  cancer	  cell-­‐line	  that	  is	  lipogenic	  and	  poorly	  ciliated	  (Figure	  5.2A).	   	  8	  of	  the	  20	  compounds	  potently	   induced	  ciliogenesis	  and	  were	  selected	  for	   further	   studies	   (Figure	   5.2A).	   Since	   we	   cannot	   reveal	   the	   identity	   of	   these	  compounds,	  we	  labeled	  them	  C1	  to	  C8.	  All	  8	  of	  these	  compounds	  were	  reconfirmed	  by	  confocal	   microscopy	   to	   re-­‐induce	   cilium	   expression	   in	   adSREBP1c-­‐transduced	   MDCK	  cells	  (Figure	  5.2B	  and	  5.2C).	  All	  compounds	  increased	  the	  percentage	  of	  ciliated	  cells	  by	  more	  than	  2-­‐fold	  as	  compared	  to	  untreated	  control.	  The	  ability	  of	   these	  compounds	  to	  reverse	  the	  SREBP1c-­‐mediated	  repression	  of	  ciliogenesis	  marks	  their	  prospective	  use	  as	  possible	  re-­‐inducers	  of	  the	  primary	  cilium	  in	  lipogenic	  cancers.	  	  
	  
	  
Figure	   5.1.	   A	   schematic	   overview	   of	   the	   screening	   strategy	   of	   the	   CISTIM	   library	   using	   the	  adSREBP1c-­‐transduced	  MDCK	  cell	  line	  model.	  	  


































Figure	   5.2.	  Selection	   of	   the	   8	  most	   potent	   ciliogenic	   compounds	   and	   reconfirmation	   in	  
adSREBP1c-­‐transduced	  MDCK	   cells	   by	   confocal	  microscopy.	   	   (A)	  Scatter	  diagram	  showing	  the	   ability	   of	   compounds	   to	   increase	   the	   percentage	   of	   ciliated	   cells	   in	   LNCaP	   cultures.	   The	  orange	   dot	   indicates	   the	  %	   of	   ciliated	   cells	   in	   untreated	   control	   cultures.	   Green	   dots	   indicate	  compounds	   selected	   for	   further	   analysis.	   (B)	   MDCK	   cells	   were	   infected	   with	   SREBP1c	  adenovirus	   (adSREBP1c)	   and	   treated	   with	   the	   compounds	   selected	   in	   (A)	   for	   8	   days.	   The	  percentage	  of	  ciliated	  cells	  was	  quantified	  by	  counting	  100-­‐300	  cells	  from	  at	  least	  three	  regions	  of	  the	  well	  using	  ImageJ	  software.	  Data	  are	  presented	  as	  mean	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	  compared	  to	  control.	  (C)	  Confocal	  fluorescence	  microscopy	  images	  of	  primary	  cilia	  in	   adSREBP1c-­‐transduced	  MDCK	   cells	   treated	  with	   the	   compounds	   selected	   in	   (A).	   Cilia	  were	  stained	  using	   an	   antibody	  against	   acetylated	   tubulin	   (red)	   and	  nuclei	  were	   stained	  with	  DAPI	  (blue).	   	   Images	   were	   captured	   using	   a	   Bio-­‐Rad	   Radiance	   confocal	   microscope	   through	   a	   40X	  objective	  lens	  at	  2.3X	  zoom.	  The	  scale	  bar	  represents	  5	  μm.	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5.2.3.	   Confirmation	   of	   cilium	   induction	   in	   multiple	   lipogenic	   cancer	   cell	   line	  
models	  These	  8	  selected	  compounds	  were	  further	  tested	  for	  their	  ability	  to	  induce	  ciliogenesis	  in	   several	   other	   lipogenic	   cancer	   cell	   lines:	   WM2664	   (melanoma),	   SKBR3	   (breast	  cancer),	  A549	  (lung	  cancer),	  which	  all	  show	  an	  inherently	  low	  expression	  of	  ciliogenesis	  even	  at	  high	  confluency	  (2-­‐12	  %	  of	  the	  cell	  population).	  The	  compounds	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   5.3.	   Determination	   of	   the	   ciliogenic	   potential	   of	   selected	   compounds	   in	   different	  
lipogenic	  cancer	  cell	  line	  models	  by	  confocal	  microscopy.	  	  (A)	  Quantification	  of	  the	  percentage	  of	  ciliated	   cancer	   cells	   in	   various	   cancer	   cell	   lines	   treated	  with	   ciliogenic	   compounds	   for	   8	   days.	   (B)	  Graphs	  showing	  the	  effect	  of	  compounds	  on	  the	  percentage	  of	  ciliated	  cells	  and	  cilium	  length	  in	  the	  pancreatic	  cancer	  cell	  line	  model	  Panc1.	  	  Both	  the	  percentage	  of	  ciliated	  cells	  and	  changes	  in	  cilium	  length	   were	   analyzed	   and	   quantified	   by	   using	   ImageJ	   software.	   All	   data	   are	   presented	   as	   mean	  (n=100–300	   cells)	   ±	   SEM,	   *p	   ≤	   0.05,	   **p	   ≤	   0.005,	   ***p	   ≤	   0.0005	   as	   compared	   to	   control.	  Representative	   images	   in	   the	   lower	   panel	   show	   the	   effect	   of	   compound	   C2	   on	   cilium	   induction	   in	  Panc1	   cells.	   Cilia	   are	   stained	   in	   red	   (acetylated	   tubulin)	   and	   nuclei	   (DAPI)	   in	   blue.	   The	   scale	   bar	  represents	  10	  μm.	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  potently	  induced	  ciliogenesis	  in	  these	  models,	  with	  discernable	  cilia	  in	  up	  to	  60%	  of	  the	  cell	   population	   (Figure	   5.3A).	   The	   relative	   potency	   of	   the	   various	   compounds	   varied,	  however,	  from	  cell	  line	  to	  cell	  line.	  In	  addition	  to	  their	  ability	  to	  significantly	  increase	  the	  percentage	  of	  ciliated	  cells,	  the	  compounds	  were	  also	  able	  to	  increase	  the	  average	  cilium	  length	   in	   another	   lipogenic	   cancer	   cell-­‐line	   PANC-­‐1	   (pancreatic	   cancer),	   which	   is	   an	  attractive	   model	   to	   assess	   changes	   in	   terms	   of	   both	   percentage	   of	   ciliated	   cells	   and	  cilium	   length	   (Figure	  5.3B).	  Up	   to	  a	  5-­‐fold	   increase	  was	  observed	   in	   the	  percentage	  of	  ciliated	   cells	  whereas	   the	   average	   cilium	   length	  was	   enhanced	   by	   up	   to	   3-­‐fold	   by	   the	  ciliogenic	  compounds.	  	  










































Figure	  5.4.	  Rescue	  of	  primary	  cilia	  by	  ciliogenic	  compounds	  in	  1p36	  ciliopathy	  models.	  (A)	  LLC-­‐CL4	   cells	   in	   with	   the	   Rer1p	   protein	   was	   knocked	   down	   using	   siRNAs	   was	   used	   a	   1p36	  ciliopathy	  model	  and	  was	   treated	  with	  selected	   compounds	   to	  assess	   their	  ability	   to	   restore	  the	  cilium	   length	   as	   assessed	   by	   immunofluorescent	   confocal	   microscopy	   with	   antibodies	   against	  acetylated	  tubulin	  to	  reveal	  cilia	  (red)	  and	  DAPI	  to	  stain	  nuclei	  (blue).	  (B)	  1p36	  patient	  fibroblasts	  were	  treated	  with	  compound	  2	  and	  cilia	  were	  stained	  as	   in	  A	  (yellow	  arrows).	  N=3,	  Error	  Bars	  =	  +/-­‐	  SEM,	  P-­‐value:	  *	  =	  ≤	  0.05,	  **	  =	  ≤	  0.005,	  ***	  =	  ≤	  0.0005.	  The	  scale	  bar	  represents	  10	  μm.	  	  






























Figure	   5.5.	  Structure	   Activity	   Relationship	   (SAR)	   assay	   for	   each	   family	   of	   ciliogenic	   compounds.	  MDCK	   cells	   were	   transduced	   with	   SREBP1c	   adenovirus	   (AdSREBP1c)	   (black	   bar)	   or	   with	   GFP	   control	  adenovirus	   (adGFP)	   (orange	   bar).	   AdSREBP1c	   cells	   were	   treated	   with	   equal	   concentrations	   of	   parent	  compounds	  and	   their	   analogs	   (grey	  bars).	   After	  8	   days,	   cilia	  were	   stained	  and	  quantified	  as	   in	  Figure	  1.	  Changes	  in	  ciliation	  are	  expressed	  as	  relative	  ratio	  of	  ciliation	  with	  respect	  to	  untreated	  adSREBP	  control.	  The	  solid	  black	  line	  represents	  the	  percentage	  of	  ciliated	  cells	  in	  untreated	  AdSREBP1c	  cells	  and	  was	  set	  at	  1.	   The	   dotted	   orange	   line	   represents	   the	   relative	   ciliation	   in	   AdGFP	   cells	   and	   the	   thin	   black	   dotted	   line	  represents	  the	  level	  of	  ciliation	  achieved	  by	  the	  parent	  compound	  in	  each	  family	  of	  compounds.	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5.2.5.	  Structure	  Activity	  Relationship	  (SAR)	  studies	  reveal	  analogs	  that	  are	  better	  
inducers	  of	  ciliogenesis	  as	  compared	  to	  respective	  parent	  compounds	  Structure	  Activity	  relationship	  (SAR)	   is	  an	  approach	  to	  study	  the	  relationship	  between	  the	  molecular	  structure	  of	  a	  compound	  and	  it’s	  biological	  activity.	  This	  study	  is	  critical	  to	  identify	  analogs	  with	  greatest	  potency	  and	  minimum	  side	  effects,	  and	  to	  establish	  which	  features	  of	  the	  molecular	  structure	  are	  important	  for	  its	  function.	  We	  have	  tested	  a	  panel	  of	  analogs	  for	  every	  compound	  and	  identified	  the	  most	  potent	   inducers	  of	  ciliogenesis.	  For	  compounds	  C2,	  C5	  and	  C7,	   the	  original	  parent	  compounds	  picked	   from	  the	   library	  screen	  were	   found	   to	  be	  most	  potent	   (Figure	  5.5).	   	  For	   the	  remaining	  compounds,	   the	  following	   analogs	   were	   identified	   as	   the	   most	   potent	   cilia	   inducers:	   analog	   1.01	   of	  compound	  C1,	  analog	  3.06	  of	  compound	  C3,	  analog	  4.04	  of	  compound	  C4,	  analog	  6.10	  of	  compound	   C6	   and	   analog	   8.01	   of	   compound	   C8	   (Figure	   5.5).	   We	   also	   identified	  compounds	  that	  were	   less	  active	  than	  the	  parent	  compounds.	  This	  provides	   important	  information	  on	  the	  functional	  aspects	  of	  the	  structures.	  Analogs	  that	  were	  inactive	  and	  hence	   least	   potent	   in	   terms	   of	   induction	   of	   ciliogenesis	  were	   analogs	   1.08,	   2.03,	   3.10,	  4.11,	  5.06,	  6.03,	  7.06	  and	  8.05	  for	  parent	  compounds	  C1	  to	  C8	  respectively	  (Figure	  5.5).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5.6.	  Comparative	  assessment	  of	  the	  ability	  of	  active	  and	  inactive	  analogs	  to	  rescue	  cilia	  
in	  a	  ciliopathy	  model.	  Effect	  of	  the	  selection	  of	  analogs	  on	  rescue	  of	  ciliary	  length	  in	  LLC-­‐CL4	  Rer1p	  knockdown	  (KD)	  model.	  	  The	  panel	  on	  the	  right	  shows	  representative	  images	  of	  LLC-­‐CL4	  cells	  treated	  with	  the	  analogs.	  Cilia	  are	  stained	   in	  red	  and	  nuclei	  in	  blue.	  Data	  are	  presented	  as	  mean	  (n=100-­‐300	  cells)	  ±	  SEM,	  *p	  ≤	  0.05,	  **p	  ≤	  0.005,	  ***p	  ≤	  0.0005	  as	  compared	  to	  control.	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Next,	  we	  compared	  the	  ability	  of	  these	  ciliogenic	  and	  corresponding	  inactive	  analogs	  to	  rescue	   primary	   cilia	   in	   the	   previously	   described	   Rer1p	   knockdown	   1p36	   ciliopathy	  model.	  As	   expected,	   analogs	  C2	  and	  C6.10	   cause	  a	   resurgence	  of	   cilia	   in	  LLC-­‐CL4	   cells	  that	  have	  shorter	  cilia	  due	  to	  knockdown	  of	  Rer1p	  gene	  (Figure	  5.6).	  As	  opposed	  to	  the	  active	  analogs,	  neither	  of	  the	  inactive	  analogs	  C2.03	  or	  C6.03	  was	  able	  to	  rescue	  the	  cilia	  in	  these	  cells	  (Figure	  5.6).	  Pairs	  of	  active	  and	  inactive	  compounds	  are	   interesting	  tools	  for	  further	  functional	  studies.	  	  
5.2.6.	  Ciliogenic	  compounds	  reduce	  the	  proliferative	  potential	  of	  cancer	  cells	  To	   test	   whether	   ciliogenic	   compounds	   affect	   the	   proliferation	   of	   cancer	   cells,	   we	  comparatively	  assessed	  the	  activity	  of	  ciliogenic	  analogs	  with	  their	  inactive	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5.7.	  Effect	  of	  ciliogenic	  compounds	  and	  their	  inactive	  counterparts	  on	  the	  proliferative	  
potential	  of	  cancer	  cells.	  A	  selection	  of	  active	  and	  inactive	  analogs	  were	  comparatively	  assessed	  on	  spheroid	   formation	   of	   LNCaP	   prostate	   cancer	   cells.	   Data	   are	   presented	   as	   the	  mean	   of	   at	   least	   6	  spheroids	  ±	  SEM,	  *p	  <	  0.0005	  as	  compared	  to	  control.	  The	  lower	  panel	  shows	  representative	  images	  of	  spheroids	  treated	  with	  vehicle	  control	  and	  with	  the	  indicated	  analogs	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counterparts	   on	   the	   proliferative	   ability	   of	   LNCaP	   (Prostate	   cancer)	   cells	   grown	   as	  spheroids,	  which	  allows	  the	  monitoring	  of	  growth	  over	  a	  longer	  period	  of	  time	  and	  in	  a	  condition	   that	   more	   closely	   reflects	   the	   in	   vivo	   situation.	   As	   observed	   in	   Figure	   5.7,	  ciliogenic	   analogs	   C2	   and	   C6.10	   significantly	   reduced	   spheroid	   growth,	   which	   was	  measured	  as	   the	  percentage	   increase	   in	   spheroid	  volume.	   In	   contrast,	   their	   respective	  inactive	  analogs	  C2.03	  and	  C6.03	  failed	  to	  reduce	  proliferation	  (Figure	  5.7).	  This	  result	  indicates	   that	   reduction	   in	   spheroid	   growth	   is	   associated	   with	   the	   ability	   of	   the	  compound	  to	  induce	  the	  primary	  cilium	  in	  cancer	  cells.	  	  	  
5.2.7.	   Ciliogenic	   compounds	   stimulate	   Rab11	   vesicle	   trafficking	   to	   the	   primary	  
cilium	  To	   further	   assess	   how	   ciliogenic	   compounds	   induce	   ciliogenesis,	   we	   explored	   the	  changes	   in	   localization	  of	   the	  endosomal-­‐recycling	  marker	  Rab11	   in	  pancreatic	   cancer	  cell	  line	  PANC-­‐1.	  	  Rab11-­‐positive	  vesicles	  have	  been	  shown	  to	  play	  an	  important	  role	  in	  the	  delivering	  of	  cargo	  to	  the	  growing	  primary	  cilium	  [13,	  14].	  In	  previous	  studies,	  our	  team	  has	  shown	  that	  distortion	  of	  ciliogenesis	  by	  SREBP1	  is	  accompanied	  by	  a	  marked	  dispersion	   of	   Rab11	   positive	   vesicles	   away	   from	   the	   base	   of	   the	   cilium.	   Figure	   5.8	  confirms	   that	   Rab11	   is	   diffusely	   dispersed	   in	   the	   cytoplasm	   of	   poorly	   ciliated	   control	  cells.	   Treatment	   with	   the	   inactive	   analog	   C2.03	   does	   not	   affect	   Rab11	   distribution.	  However,	  in	  cells	  treated	  with	  ciliogenic	  compound	  C2,	  Rab11	  is	  redirected	  to	  the	  base	  of	   the	   cilium.	   This	   result	   shows	   that	   ciliogenesis,	   at	   least	   by	   this	   compound	   C2	   is	  accompanied	  by	  a	  normalization	  of	  Rab11-­‐mediated	  vesicle	  trafficking	  to	  the	  base	  of	  the	  cilium.	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5.3.	  Discussion	  Building	  up	  on	   the	  previous	  work	  of	  our	  group	   that	  aberrant	  activation	  of	  SREBP1c	   is	  frequently	   observed	   in	   many	   human	   cancers,	   and	   that	   constitutively	   active	   SREBP1c	  suppresses	  the	  formation	  of	  the	  primary	  cilium	  [6],	  we	  aimed	  to	  explore	  and	  establish	  a	  new	  concept	  in	  the	  treatment	  of	  common	  human	  diseases	  based	  on	  reversal	  of	  SREBP1c-­‐mediated	   suppression	   of	   the	   primary	   cilium.	   In	   this	   project	   we	   have	   successfully	  developed	   and	   established	   a	   semi-­‐high	   throughput	   screening	  method	  based	   on	  MDCK	  cells	   that	  overexpress	  SREBP1c	   to	  mimick	   the	   lipogenic	  phenotype	  of	   cancer	  cells.	  We	  have	   also	   demonstrated	   the	   usefulness	   of	   this	   method	   as	   a	   tool	   to	   screen	   potent	  
Figure	   5.8.	   	   Induction	   of	   primary	   cilia	   by	   compound	   C2	   is	   accompanied	   by	   the	  
accumulation	   of	   Rab11	   at	   the	   ciliary	   base.	   (A)	   Panc1	   cells	   were	   treated	   with	  compound	   C2	   or	   its	   inactive	   analog	   2.03	   for	   4	   days	   followed	   by	   staining	   for	   Rab11	  (green),	   acetylated	   tubulin	   (red)	  and	  DAPI	  (blue).	   (B)	  Magnification	  of	  representative	  regions	  marked	  with	  yellow	  square	  inserts	  in	  merged	  images	  shown	  in	  (A).	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ciliogenic	  modulators.	  Using	  this	  strategy	  we	  have	  identified	  8	  novel	  compounds	  that	  are	  cilia	   enhancers.	   These	   compounds	   have	   the	   ability	   to	   restore	   ciliogenesis	   in	   several	  cancer	   cell	   line	   models	   and	   in	   a	   ciliopathy	   model.	   For	   selected	   compounds	   we	   have	  shown	   that	   they	   block	   the	   growth	   of	   cancer	   cells	   in	   a	   spheroid	   assay	   in	   a	   manner	  associated	   with	   their	   ciliogenic	   ability,	   as	   would	   be	   expected	   for	   an	   inducer	   of	  ciliogenesis	   [15].	   To	   what	   extent	   growth	   inhibition	   is	   a	   cause	   or	   consequence	   of	  ciliogenesis	   remains	   to	   be	   determined.	   This	   is	   one	   of	   the	   first	   reports	   on	   the	   use	   of	  pharmacological	  compounds	  to	  rescue	  cilia	  in	  cells	  that	  have	  lost	  them	  due	  to	  a	  diseased	  condition.	  These	  compounds	  might	  serve	  as	  potential	  candidates	  for	  the	  development	  of	  drugs	   not	   only	   against	   cancer	   and	   ciliopathies,	   but	   also	   against	   other	   cilium-­‐related	  human	  diseases	  in	  general.	  Hence	  our	  findings	  open	  a	  whole	  new	  area	  of	  research	  and	  provide	  a	   framework	   for	   future	  development	  of	   therapies	  based	  on	  a	  novel	  concept	  of	  restoring	   cilia	   in	   diseased	   cells.	   As	   a	   future	   perspective,	   further	   optimization	   and	  validation	  of	  these	  ciliogenic	  compounds	  have	  to	  be	  performed	  by	  identification	  of	  their	  pharmacophores	  and	  their	  respective	  molecular	  targets.	  This	  knowledge	  will	  aid	  in	  the	  streamlining	   of	   mechanisms	   and	   pathways	   involved	   in	   the	   induction	   of	   ciliogenesis.	  However,	  challenges	  exist	  in	  further	  characterization	  of	  the	  mechanisms	  by	  which	  these	  compounds	   induce	  cilia.	  This	   is	  partly	  because	  of	   the	   incomplete	  understanding	  of	   the	  processes	   involved	   in	   ciliogenesis,	   which	   warrant	   further	   exploration.	   These	   facts	  together	  with	  our	   findings	  offer	  an	   interesting	  yet	   complex	   challenge	   for	   the	   future	  of	  cilia-­‐based	  drug	  therapy.	  	  
5.4.	  Materials	  and	  methods	  
5.4.1.	  Cell	  lines	  	  All	   cell	   lines	   were	   obtained	   from	   ATCC.	   MDCK	   cells	   were	   cultured	   in	   DMEM/F12	  medium,	   LNCaP	   cells	   in	   RPMI-­‐1640.	   SKBR3	   cells	   in	   McCoy's	   5a,	   WM2664,	   A549	   and	  PANC-­‐1	  in	  DMEM,	  and	  LLC-­‐CL4	  cells	   in	  MEM-­‐α.	  All	  media	  were	  from	  Life	  Technologies	  and	   were	   supplemented	   with	   10%	   FBS.	   Fibroblasts	   derived	   from	   1p36	   ciliopathy	  patients	  were	  maintained	  in	  DMEM/F12	  medium	  supplemented	  with	  10%	  FBS.	  All	  cell	  lines	  were	  incubated	  at	  37°C	  in	  a	  humidified	  incubator	  with	  5%	  levels	  of	  CO2.	  
	  
5.4.2.	  Screening	  of	  CISTIM	  compound	  library	  	  MDCK	  cells	  were	  used	  as	  a	  ciliogenesis	  model	   for	  compound	  screening.	  The	  cells	  were	  pre-­‐infected	   with	   30	   p.f.u./cell	   of	   adenovirus	   encoding	   SREBP1c	   [10,	   11]	   to	   repress	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ciliogenesis	   followed	   by	   seeding	   in	   96-­‐well	   plates	   at	   a	   density	   of	   10,000	   cells/well	  containing	   200	   μl	   culture	   medium	   supplemented	   with	   10%	   FBS.	   The	   plates	   were	  incubated	   at	   37°C	   and	   5%	   CO2	   in	   a	   humidified	   incubator	   till	   cell	   confluency	   reached	  30%	  after	  which	  medium	  was	  refreshed	  with	  200ul	  of	   culture	  medium	  containing	  2%	  FBS	   to	   reduce	   complexation	  of	   compound	  with	   serum	  proteins.	   The	  CISTIM	   library	  of	  1300	   compounds	  was	   provided	   by	   the	   Center	   for	   Innovation	   and	   Stimulation	   of	  Drug	  Discovery	   (CISTIM),	   (Leuven,	   Belgium).	   The	   compounds	   were	   stored	   as	   10mM	   stock	  solutions	  in	  dimethyl	  sulfoxide	  (DMSO)	  and	  were	  added	  to	  the	  culture	  medium	  to	  a	  final	  concentration	   of	   10μM.	   After	   4	   days,	  medium	  was	   replaced	   and	   fresh	   compound	  was	  added.	   After	   a	   total	   of	   8	   days	   of	   incubation,	   cells	   were	   chemically	   fixed	   and	  immunostained	   for	   cilia	   using	   an	   antibody	   against	   acetylated	   tubulin	   (Sigma,	   Cat	   No.	  T6793-­‐.5ML).	  	  A	  fluorescent	  secondary	  antibody	  (Life	  Technologies,	  AlexaFluor,	  Cat	  No.	  A21145)	  was	  used	  against	   the	  primary	  antibody	   followed	  by	  counterstaining	  of	  nuclei	  with	  Hoechst-­‐33258	  (Cat	  No:	  382061,	  Calbiochem).	  Images	  of	  cilia	  were	  acquired	  at	  20X	  magnification	   in	   a	   single	   plane	   of	   focus	   using	   an	   INCell	   High	   Content	   Analyzer	   (GE	  Healthcare).	   20	   random	   fields	   were	   imaged	   per	   well	   to	   minimize	   error.	   Cilia	   were	  defined	   as	   structures	   that	   appeared	   as	   fluorescent	   spots	   in	   the	   image.	   Percentage	   of	  ciliated	  cells	  was	  determined	  using	  INCell	  Developer	  software	  by	  counting	  both	  cilia	  and	  nuclei.	  All	   compounds	  were	   tested	   in	   three-­‐fold.	  Compounds	  were	  considered	  positive	  when	   they	   increased	   the	   percentage	   of	   ciliated	   cells	   by	   at	   least	   3	   standard	   deviations	  compared	   to	  vehicle	   (DMSO)	   treated	  cells.	   	  Toxicity/cytostatic	  effect	  was	  estimated	  by	  comparing	  nuclei	  count	  to	  vehicle	  control.	  	  
5.4.3.	  Confocal	  microscopy	  	  The	   cilium	   modulating	   effect	   of	   selected	   compounds	   was	   confirmed	   by	   confocal	  fluorescence	  microscopy	  using	  the	  cell	  lines	  mentioned	  previously.	  Cells	  were	  plated	  on	  glass	   coverslips	   in	   12-­‐well	   plates	   and	   were	   grown	   in	   low	   serum	   medium	   (2%	   FCS).	  Treatment	  was	  started	  when	  cell	  cultures	  reached	  a	  confluency	  of	  approximately	  30%.	  Cells	   were	   treated	   with	   the	   indicated	   compounds	   for	   8	   days	   with	   medium	   and	  compound	  refreshment	  on	  the	  4th	  day.	  Cells	  were	  fixed	  in	  formaldehyde,	  permeabilized	  with	  0.1%	  Triton	  X100,	  blocked	  with	  1%	  BSA,	   incubated	  with	  1:1000	  dilution	  of	   anti-­‐acetylated	  tubulin	  antibody	  (Sigma,	  Cat	  No.	  T6793-­‐.5ML)	  for	  1h	  followed	  by	  incubation	  with	  1:1000	  dilution	  of	  a	  fluorescent	  secondary	  antibody	  (Life	  Technologies,	  AlexaFluor,	  Cat.	   No.	   A21145)	   for	   1h.	   Nuclei	   were	   stained	   with	   DAPI	   (Vector	   Laboratories,	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Vectashield,	   Cat.	   No.	   H-­‐1500).	   Images	   of	   primary	   cilia	   were	   captured	   by	   acquiring	   Z-­‐stacks	   using	   a	   Bio-­‐Rad	   confocal	   laser	   scanning	  microscope	   using	   a	   40X	   oil	   immersion	  lens.	   	   Images	  were	  analyzed	   for	   cilia	  percentage	  and	  cilium	   length	  by	   ImageJ	   software	  (Rasband,	   W.S.,	   ImageJ,	   U.	   S.	   National	   Institutes	   of	   Health,	   Bethesda,	   Maryland,	   USA,	  http://imagej.nih.gov/ij/,	  1997-­‐2016).	  	  
5.4.4.	  BrdU	  assay	  and	  tumor	  spheroid	  assay	  for	  cell	  proliferation	  	  For	  WM2664	  and	  SKBR3	  cell	   lines,	  a	  5-­‐Bromo-­‐2	  deoxy-­‐uridine	  Labeling	  and	  Detection	  Kit	   III	   (Cat	   No.	   11444611001,	   Roche)	   was	   used	   to	   measure	   cell	   proliferation	   after	  treatment	  of	  the	  cells	  with	  compounds	  for	  8	  days.	  	  To	   compare	   the	   effect	   of	   ciliogenic	   and	   inactive	   analogs	   on	   prostate	   cancer	   cell	  proliferation,	   tumor	  spheroids	  were	   formed	  on	  agarose-­‐coated	  (1%)	  96-­‐well	  plates	  by	  seeding	   LNCaP	   prostate	   cancer	   cells	   at	   a	   density	   of	   5000	   cells	   in	   200ul	   per	   well	   of	  culture	  medium.	  The	  plate	  was	  then	  kept	  undisturbed	   in	  an	   incubator	  at	  37°C	  and	  5%	  CO2	  for	  4	  days	  to	  facilitate	  spheroid	  formation.	  Treatment	  with	  compounds	  was	  started	  when	  the	  cells	  aggregated	  to	  form	  spheroids.	  Compounds	  and	  50%	  of	  the	  medium	  were	  refreshed	   every	   4th	   day.	   Images	   were	   captured	   at	   the	   start	   of	   treatment	   with	   5X	  objective	  mounted	  on	  an	  inverted	  light	  microscope.	  	  Imaging	  was	  done	  every	  4	  days	  for	  a	  period	  of	  12	  days	   from	   the	   start	   of	   treatment.	  The	   images	  were	   analyzed	  by	   ImageJ	  software	  to	  calculate	  the	  differences	  in	  the	  volume	  of	  spheroids	  at	  different	  time	  points.	  	  
5.4.5.	  siRNA-­‐mediated	  knockdown	  assay	  	  In	   order	   to	   explore	   the	   ability	   of	   compounds	   to	   rescue	   cilia	   in	   a	   ciliopathy	  model,	  we	  performed	   a	   siRNA-­‐mediated	   knockdown	   of	   the	   Rer1p	   gene	   in	   LLC-­‐CL4	   cells	   [12]	  followed	   by	   treatment	   with	   compounds	   or	   DMSO	   vehicle.	   The	   cells	   were	   transfected	  prior	   to	   seeding	   (reverse	   transfection)	  using	   lipofectamine	   (Thermo	  Fisher	   Scientific).	  Compound	  treatment	  was	  started	  24	  hours	  after	  seeding	  and	  continued	  for	  a	  period	  of	  2	  days.	   Following	   treatment,	   cells	   were	   fixed	   and	   stained	   for	   confocal	   microscopy	   to	  visualize	  cilia.	  Changes	  in	  cilium	  length	  were	  measured	  by	  Image	  J	  software.	  	  
5.4.6.	  Structure	  Activity	  Relationship	  (SAR)	  studies	  	  To	  test	  the	  structure-­‐function	  relation	  of	  novel	  compounds,	  analogs	  of	  selected	  positive	  compounds	  were	  obtained	   from	  CD3/CISTIM.	  Activity	  of	  compounds	  was	  tested	   in	   the	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fluorescence	  microscopy-­‐based	  ciliogenesis	  assay	   in	  96-­‐well	  plate	   format	  as	  described	  above.	  	  
5.4.7.	  Statistical	  analysis	  Statistical	  analysis	  was	  done	  using	  GraphPad	  Prism	  version	  6	   for	  Mac	  OS	  X	  (GraphPad	  Software,	  San	  Diego,	  California,	  USA).	  Data	  are	  expressed	  as	  mean	  ±	  SEM.	  Student's	  t-­‐test	  was	  used	   to	  assess	  differences	  between	   two	  groups.	  Values	  of	  p	   less	   than	  <	  0.05	  were	  considered	  to	  be	  statistically	  significant.	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General	  Discussion	  	  	   Primary	   cilia	   are	   elongated	   microtubule-­‐based	   organelles	   present	   on	   the	   external	  surface	   of	   most	   mammalian	   cells.	   They	   serve	   as	   antenna	   of	   the	   cell	   to	   detect	  extracellular	   signals	   and	   translate	   them	   into	   intracellular	   pathways	   that	   regulate	   cell	  development	   and	  homeostasis.	  The	   importance	  of	   cilia	  has	  been	   clearly	  demonstrated	  by	  a	  connection	  between	  cilia	  and	  a	  group	  of	  numerous	  diseases	  termed	  as	  ciliopathies.	  Mounting	   evidence	   from	   recent	   years	   points	   towards	   a	   compelling	   link	   between	   cilia	  and	  cancers.	  However,	   the	  exact	  role	  of	   the	  cilium	  in	  tumorigenesis	  remains	  debatable	  and	  open	  to	  exploration.	  A	  general	  agreement	  exists	  that	  the	  cilium	  provides	  a	  natural	  braking	   mechanism	   to	   control	   cell	   division	   because	   it	   shares	   the	   same	   molecular	  machinery	   that	   is	   required	   for	   cell	  division.	  Loss	  of	   the	   cilium	   thus	   releases	   the	  brake	  mechanism	   leading	   to	   unrestricted	   cell	   division.	   On	   the	   other	   hand,	   several	   reports	  provide	  evidence	  that	  some	  types	  of	  cancers	  are	  dependent	  on	  the	  presence	  of	  cilia	  for	  their	   survival	   and	   growth.	   Therefore,	   primary	   cilia	   can	   either	   inhibit	   or	   facilitate	  tumorigenesis	  depending	  on	  the	  cancer	  type.	  Hence,	  either	  re-­‐expression	  or	  inhibition	  of	  the	  cilium	  offers	  an	  attractive	  and	  novel	  therapeutic	  approach	  to	  treat	  a	  wide	  variety	  of	  cancers.	   Unfortunately,	   only	   few	   small	   molecule	   cilium	   regulators	   are	   known	   so	   far.	  Several	   screens	   of	   compounds	   have	   been	   reported,	   several	   of	   which	   using	   flagellated	  algae	  as	  an	  experimental	  model	  [1-­‐3].	  In	  this	  research	  project,	  we	  aimed	  to	  identify	  small	  molecule	  cilium	  modulators	  using	  human	  cancer	  cells	  or	  other	  mammalian	  cell	  models	  to	  screen	  several	  libraries	  of	  pharmacological	  and	  small	  molecule	  compounds	  to	  identify	  and	   test	  modulators	  of	   ciliogenesis	   for	   their	   therapeutic	   effect	   on	  different	   cancer	   cell	  line	  models	  and	  in	  a	  ciliopathy	  model.	  	  To	  begin	  with,	  we	  aimed	   to	   identify	   compounds	   that	   could	   re-­‐express	  primary	   cilia	   in	  cancer	  cells.	  Our	  immediate	  goal	  in	  chapter	  2	  was	  to	  develop	  and	  establish	  a	  screening	  method	  based	  on	  cancer	  cells	  in	  which	  the	  primary	  cilium	  is	  lost.	  This	  was	  achieved	  by	  using	  pancreatic	  cancer	  cells	  CFPAC-­‐1	  as	  a	  platform	  to	  develop	  a	  high	  content	  (IN	  Cell)	  analysis	  and	  semi-­‐automated	  immunofluorescence	  microscopy-­‐based	  screening	  method	  that	   identifies	   the	   presence	   of	   the	   cilium	   based	   on	   antibody	   staining	   of	   the	   ciliary	  component	   acetylated	   tubulin.	   This	   cell	   line	  was	   selected	  because	  of	   its	   relatively	   low	  ciliation	  percentage,	  its	  ability	  to	  grow	  as	  a	  flat	  monolayer	  and	  the	  clinical	  need	  for	  novel	  therapeutic	   agents	   for	   pancreatic	   cancer.	   Using	   this	  method	  we	   screened	   a	   library	   of	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1600	   commonly	   known	   drugs	   to	   identify	   inducers	   of	   ciliogenesis.	   Through	   this	  screening	  we	  showed	  that	  a	  diverse	  set	  of	  drugs	  are	  capable	  of	  inducing	  primary	  cilia	  in	  this	  and	  other	  cancer	  cell	  models	  including	  breast	  cancer	  and	  lung	  cancer.	  Classification	  based	   on	   their	   putative	   targets	   revealed	   ciliogenic	   activity	   of	   modulators	   of	   steroid	  receptors,	  neurotransmitters,	  ion	  channels,	  microtubules,	  tyrosine	  kinase	  receptors	  etc.	  	  We	   also	   showed	   that	   re-­‐expression	   of	   cilia	   through	   these	   drugs	   hampered	   the	  proliferative	  potential	  of	  cancer	  cells	  and	  causes	  cell	  cycle	  arrest	  in	  G0-­‐G1	  phase,	  which	  is	  known	  to	  promote	  ciliogenesis.	  Although	   for	  certain	  drugs	   it	   is	   likely	   that	   increased	  ciliogenesis	   is	   a	   consequence	   of	   cell	   cycle	   arrest,	   for	   others	   we	   have	   shown	   that	   the	  reduction	  in	  proliferation	  was	  mediated	  at	  least	  in	  part	  by	  the	  expression	  of	  the	  cilium,	  as	   demonstrated	   by	   abolition	   of	   the	   cilium	   by	   chloral	   hydrate,	   which	   restored	   the	  proliferative	   potential	   of	   drug-­‐treated	   cancer	   cells.	   Our	   findings	   reveal	   hitherto	  unknown	   activities	   of	   old	   compounds	   and	   fit	   in	   the	   concept	   of	   drug	   repurposing,	   a	  strategy	   that	   redirects	   existing	   drugs	   for	   a	   new	   indication	   or	   purpose,	   thereby	  decreasing	  the	  time-­‐frame	  and	  costs	  of	  making	  a	  drug	  available	  in	  the	  market.	  	  In	   chapter	  3,	  we	  built	   on	   the	  newly	   identified	   compounds	  described	   in	  Chapter	  2	   and	  explored	   whether	   there	   are	   any	   common	   underlying	   mechanisms	   through	   which	   the	  diverse	  ciliogenic	  drugs	  might	  induce	  cilia	  in	  cancer	  cells.	  Since	  several	  ciliogenic	  drugs	  from	   our	   screen	   have	   been	   reported	   to	   release	   ATP	   from	   cells	   and	   because	   of	   the	  availability	   of	   expertise	   in	   our	   research	   consortium	   to	   investigate	  ATP-­‐related	   effects,	  we	  aimed	  to	  investigate	  to	  what	  extent	  these	  ciliogenic	  drugs	  secrete	  ATP	  from	  cells	  and	  whether	  the	  secreted	  ATP	  is	  involved	  in	  the	  promotion	  of	  ciliogenesis.	  Using	  cultures	  of	  pancreatic	  cancer	  cells	  as	  experimental	  model	  we	  have	  experimentally	  shown	  that	  most	  of	  these	  drugs	  induce	  secretion	  of	  ATP	  from	  these	  cells,	  and	  that	  this	  secretion	  positively	  correlates	   with	   their	   ciliogenic	   ability.	   Using	   a	   panel	   of	   chemical	   inhibitors	   against	  different	  ATP-­‐secretion	  pathways	  we	  showed	   that	  ATP	   is	  mainly	   released	   through	   the	  pannexin	  channels,	  although	  passive	  release	  by	  a	  small	  fraction	  of	  dying	  cells	  cannot	  be	  excluded.	  Treatment	  with	   the	  ATP-­‐degrading	   enzyme	  Apyrase	   suppressed	   ciliogenesis	  in	  drug-­‐treated	  cells,	  corroborating	  the	  importance	  of	  the	  released	  ATP	  in	  the	  ciliogenic	  activity	  of	  the	  selected	  drugs.	  Ciliogenesis	  was	  suppressed	  when	  drug-­‐treated	  cells	  were	  exposed	   to	   Suramin,	   providing	   evidence	   for	   the	   involvement	   of	   purinergic	   receptor	  signaling	  in	  this	  process.	  Also,	   it	  has	  been	  shown	  previously	  that	  extracellular	  ATP	  can	  modulate	   ciliary	   beat	   frequency	   (CBF)	   through	   activation	   of	   purinergic	   receptors	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present	  on	   the	  cilium	  [4-­‐6].	  Our	   findings	  point	   to	   the	  existence	  of	  a	  hitherto	  unknown	  autocrine/paracrine	   loop	   involving	   the	  extracellular	  ATP-­‐purinergic	  signaling	  pathway	  in	  the	  induction	  of	  ciliogenesis	  at	  least	  by	  a	  selection	  of	  the	  drugs	  identified	  in	  Chapter	  2.	  Several	  other	  mechanisms	  may	  be	   involved	  in	  parallel	  or	  may	  be	  exploited	  by	  some	  of	  the	   other	   drugs.	   These	   include	   changes	   in	   cAMP,	   intracellular	   calcium	   and	   others	   as	  discussed	   in	   chapter	   2	   and	   as	   summarized	   in	   figure	   2.8.	   Also	   changes	   in	   intracellular	  trafficking	   are	   likely	   to	   play	   a	   key	   role	   as	   shown	   in	   Chapter	   5.	   To	   what	   extent	   these	  mechanisms	  are	  interlinked	  and	  vary	  in	  different	  cell	  types	  remains	  to	  be	  investigated.	  In	  any	  case,	   the	  ATP-­‐purinergic	  signaling	   loop	   that	  we	   identified	  here	  should	  be	   taken	  into	  consideration	  in	  future	  therapeutic	  approaches	  targeting	  the	  restoration	  of	  primary	  cilium	  in	  specific	  disease	  contexts.	  	  	  Using	  the	  same	  screening	  platform	  as	  described	  in	  Chapter	  2,	  we	  screened	  a	   library	  of	  160	  well-­‐characterized	  kinase	  inhibitors	  (Chapter	  4).	  Our	  choice	  of	  selecting	  a	  library	  of	  kinase	   inhibitors	  was	   influenced	  by	   reports	   in	   literature	   that	   a	  number	  of	   kinases	   are	  involved	  in	  ciliogenesis	  and	  in	  view	  of	  the	  fact	  that	  kinases	  are	  known	  to	  play	  a	  vital	  role	  in	  oncogenesis	  [7-­‐11].	  Interestingly	  this	  led	  to	  the	  identification	  of	  cilium	  enhancers	  as	  well	  as	  cilium	  suppressors.	  This	  finding	  is	  of	  particular	  interest	  in	  view	  of	  the	  ambiguous	  role	   of	   cilia	   in	   cancer,	   depending	   on	   the	   cancer	   type.	   In	   fact,	   although	   the	   cilium	   is	  thought	   to	  put	  a	  break	  on	   cancer	   cell	  proliferation	  and	  apparently	   tends	   to	  get	   lost	   in	  many	  tumor	  types	  including	  pancreas,	  breast	  and	  prostate	  cancer,	  it	  has	  been	  reported	  that	   cancers	   like	   basal	   cell	   carcinoma	   (BCC),	   medulloblastoma	   and	   a	   subset	   of	  glioblastomas	  are	  dependent	  on	  primary	  cilia	  for	  their	  growth	  and	  progression.	  This	  is	  most	   likely	  related	  to	   the	  dependency	  of	   these	  cell	   lines	  on	  Hedgehog	  signaling,	  which	  (unless	   constitutively	   activated	   through	   mutations	   in	   downstream	   actors	   such	   as	   Gli	  transcription	  factors)	  is	  dependent	  on	  the	  primary	  cilium	  [12].	  Hence	  we	  tested	  two	  of	  the	  most	  potent	  suppressors	  of	  ciliogenesis,	  Herbimycin	  A	  and	  Kenpaullone,	  on	  cilium-­‐dependent	   cancer	   models	   such	   as	   the	   glioblastoma	   cell	   line	   GL2664,	   which	   is	   well	  ciliated	   in	   the	   basal	   condition.	   Both	   the	   compounds	   were	   able	   to	   potently	   suppress	  ciliogenesis	   in	   this	   model	   and	   reduced	   their	   proliferative	   potential.	   Conversely,	   we	  tested	  the	  most	  potent	  cilium	  enhancers,	  EGFR/ErbB-­‐2/ErbB-­‐4	  Inhibitor	  and	  Src	  Kinase	  Inhibitor	   I	   on	   poorly	   ciliated	   pancreatic	   cancer	   cells	   and	   showed	   that	   they	   enhanced	  ciliogenesis	   and	   also	   attenuated	   their	   proliferation.	   With	   respect	   to	   the	   mechanisms	  involved	  in	  the	  suppression	  of	  the	  cilium,	  and	  based	  on	  the	  knowledge	  of	  the	  molecular	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targets	   of	   Herbimycin	   A	   and	   Kenpaullone,	   it	   can	   be	   speculated	   that	   microtubule	  stabilizing	  proteins	  and	  GSK-­‐3β-­‐mediated	  pathways	  are	  involved	  in	  the	  observed	  effects	  on	   the	   cilium.	   The	   cilium	   enhancer	   EGFR/ErbB-­‐2/ErbB-­‐4	   Inhibitor	   may	   exert	   its	  ciliogenic	   effect	   by	   negative	   regulation	   of	   MAPK	   signaling	   and	   by	   regulating	   calcium	  influx	   into	   the	   cell.	   Src	   Kinase	   Inhibitor	   I	   likely	   maintains	   ciliogenesis	   by	   inhibiting	  NEDD9-­‐mediated	   HDAC6	   disassembly	   of	   the	   cilium.	   Also,	   it	   promotes	   the	   ciliogenic	  activity	  of	  MIM	  (Missing-­‐in-­‐Metastasis)	  protein,	  which	  is	  localized	  to	  the	  basal	  body.	  To	  what	   extent	   also	   here	   secreted	   ATP	   and/or	   changes	   in	   intracellular	   trafficking	   are	  involved	  remains	  to	  be	  investigated.	  Also	  further	  research	  is	  needed	  to	  delineate	  the	  role	  of	  ciliogenesis	  in	  the	  antineoplastic	  effects	  of	  the	  kinase	  inhibitors.	  	  	  In	  the	  last	  part	  of	  this	  thesis	  project	  (Chapter	  5)	  we	  pursued	  the	  more	  ambitious	  plan	  of	  searching	   for	   novel	   small	  molecule	   compounds	   that	   can	   induce	   ciliogenesis.	   Based	   on	  our	   previous	   findings	   that	   aberrant	   activation	   of	   the	   lipogenic	   transcription	   factor	  SREBP1	  contributes	  to	  the	  suppression	  of	  the	  cilium	  in	  cancer	  cells,	  we	  designed	  a	  new	  screening	   method	   based	   on	   SREBP1-­‐mediated	   forced	   suppression	   of	   primary	   cilia	   in	  normal	  MDCK	   kidney	   cells	   to	  mimic	   the	   lipogenic	   cancer	   phenotype.	  We	   applied	   this	  strategy	   to	   screen	   a	   library	   of	   1300	   small	   molecules	   to	   identify	   compounds	   that	   are	  capable	   of	   reversing	   SREBP1-­‐mediated	   cilium	   suppression.	   From	   our	   screen	   we	  identified	   8	   such	   compounds,	   whose	   chemical	   structures	   cannot	   be	   revealed	   for	  intellectual	   property	   reasons.	  We	   confirmed	   that	   these	   compounds	   effectively	   induce	  cilia	  in	  a	  panel	  of	  lipogenic	  cancer	  cell	  lines.	   	  Interestingly,	  in	  a	  Rer1p	  gene	  knockdown	  model	  of	  1p36	  ciliopathy,	  some	  of	  our	  compounds	  had	  the	  ability	  to	  normalize	  the	  cilium	  length	   to	   that	   of	   unaffected	   healthy	   cells.	   Hence,	   future	   studies	   should	   also	   focus	   on	  identifying	   the	   effect	   of	   ciliary	   length	   on	   the	   severity	   of	   the	   disease.	   In	   our	   quest	   to	  identify	  more	  potent	  analogs	  of	  the	  selected	  ciliogenic	  compounds	  and	  to	  gain	  insight	  in	  the	   structure-­‐activity	   relationship	   (SAR)	   of	   these	   compounds	   we	   compared	   the	  ciliogenic	  potential	  of	   the	  parent	   compounds	  with	   their	   respective	  analogs.	  This	   study	  revealed	   both	   more	   active	   as	   well	   as	   less	   active	   analogs	   that	   we	   used	   as	   pairs	   in	   a	  comparative	  study	  of	   their	  effect	  on	  the	  proliferation	  of	   lipogenic	  prostate	  cancer	  cells	  and	   their	   capability	   to	   restore	   ciliogenesis,	   also	   in	   the	   previously	   described	   ciliopathy	  model.	   Such	   studies	   may	   reveal	   important	   clues	   and	   insights	   regarding	   the	  pharmacophores	   responsible	   for	   ciliogenesis,	   which	   can	   aid	   in	   pinpointing	   the	  mechanisms	   through	   which	   these	   compounds	   exert	   their	   cilia-­‐inducing	   effects.	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Knowledge	   of	   essential	   and	   less	   important	  moieties	   of	   these	  molecules	  will	   also	   help	  identify	   potential	   sites	   for	   addition	   of	   labels	   that	   can	   help	   in	   the	   identification	   of	   the	  targets	  to	  which	  these	  molecules	  bind,	  which	  is	  one	  of	  the	  key	  questions	  that	  remain	  to	  be	   addressed.	   Using	   such	   pairs	  we	   have	   also	   provided	   evidence	   that	   at	   least	   some	   of	  these	  novel	   ciliogenic	   compounds	   restore	   ciliogenesis	   by	  normalizing	   the	   intracellular	  trafficking	   of	  Rab11-­‐positive	   vesicles	   towards	   the	  base	   of	   the	   cilium,	   a	   process	   that	   is	  distorted	   by	   cancer	   cells	   by	   the	   action	   of	   SREBP1	   [13].	   	   To	   what	   extent	   also	   other	  mechanisms	  as	  those	  referred	  to	  in	  other	  chapters	  of	  this	  thesis	  manuscript	  are	  involved	  remains	  to	  be	  explored.	  	  Overall,	  our	  results	  reveal	  that	  many	  small	  molecule	  compounds	  affect	  the	  expression	  of	  the	  primary	  cilium.	  These	  include	  many	  commonly	  used	  drugs,	  such	  as	  glucocorticoids,	  ion	  channel	  modulators	  and	  kinase	   inhibitors,	   revealing	  hitherto	  unrecognized	  actions	  of	   these	   compounds.	   To	   what	   extent	   these	   cilio-­‐modulatory	   effects	   contribute	   to	   the	  therapeutic	  actions	  or	  even	  side	  effects	  of	   these	  compounds	  remains	  to	  be	  determined	  and	   represents	   an	   interesting	   area	   of	   further	   investigation.	   We	   also	   succeeded	   in	  identifying	   several	   new	   ciliogenic	   compounds	   that	   have	   the	   ability	   to	   normalize	   cilia	  both	   in	   cancer	   cells	   and	   ciliopathy	   models.	   These	   findings	   open	   up	   a	   new	   research	  avenue	  with	  potentially	   important	   therapeutic	  applications.	  Future	  efforts	  will	  have	   to	  be	  directed	  towards	  the	  identification	  of	  the	  structural	  elements	  that	  are	  responsible	  for	  the	   cilio-­‐modulatory	   effects	   of	   these	   compounds	   and	   to	   identify	   the	  molecular	   targets	  and	   important	   players	   in	   the	   complex	   web	   of	   molecular	   interactions	   that	   regulate	  ciliogenic	   pathways.	   Further	   optimization	   and	   validation	   studies	   in	   vivo	   will	   be	  necessary	   to	   firmly	   establish	   the	   concept	   of	   cilium-­‐targeting	   drug	   therapies.	   Although	  the	  generation	  of	  accurate	  in	  vivo	  models	  to	  study	  cilia-­‐related	  disorders	  is	  a	  challenge,	  in	   the	   last	   few	  years	   several	   reliable	   in	  vivo	  models	   to	   study	   the	   relationship	  between	  cilium	  biology	  and	  disease	  have	  become	  available.	  The	  choice	  of	  the	  appropriate	  model	  depends	  on	  the	  type	  of	  ciliopathy	  or	  study.	  For	   instance,	   to	   investigate	  the	  therapeutic	  potential	   of	   ciliogenic	   compounds	   against	   ciliopathies	   arising	   from	   defects	   in	   ciliary	  motility	  (for	  e.g.	  PCD),	  ciliated	  unicellular	  organisms	  like	  trypanosoma	  serve	  as	  efficient	  models.	   To	   test	   compounds	   against	  more	   complex	   diseases	   that	   display	  more	   diverse	  clinical	  manifestations	  (for	  e.g.	  MKS,	  BBS),	  multicellular	  organisms	  like	  mouse,	  zebrafish,	  xenopus	   etc.	   are	   more	   attractive	   models	   because	   of	   their	   similarity	   with	   humans	   in	  terms	   of	   morphology,	   physiology	   and	   genetics.	   Zebrafish	   and	   xenopus	   have	   unique	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features	   such	   as	   ease	   of	   breeding,	   transparency	   and	   well-­‐defined	   developmental	  changes	  related	  to	  cilium	  defects	  that	  make	  these	  models	  particularly	  interesting	  in	  this	  context.	   Recently,	  mutant	  mouse	  models	   have	  been	  developed	   against	   several	   notable	  ciliopathies	   like	   MKS,	   BBS	   and	   others	   [14].	   Mouse	   models	   with	   tagged	   cililary	  components	  that	  facilitate	  the	  visualization	  of	  cilia	  have	  also	  become	  available	  and	  can	  be	  crossed	  with	  specific	  cancer	  models	  [15].	  These	  organisms	  are	  ideal	  models	  to	  study	  the	   in	   vivo	  effect	   of	   the	   ciliogenic	   compounds	   that	   we	   have	   identified	   in	   this	   project.	  Depending	   on	   the	   disease-­‐specific	   mechanism	   of	   cilium	   distortion,	   different	   small	  molecules	   may	   be	   most	   suitable	   and	   fine-­‐tuning	   of	   the	   treatment	   regimens	   will	   be	  important	   to	   limit	   effects	   on	  healthy	   cells.	   	   In	   view	  of	   the	   importance	  of	   cilia	   in	  many	  physiological	  processes	  and	  pathologies,	  having	  small	  molecules	  available	  that	  have	  the	  ability	   to	   normalize	   or	   otherwise	  modulate	   cilia	  might	   find	   important	   applications	   in	  clinical	  practice.	  The	  future	  will	  tell.	  	  
References	  1.	   Wu	  VM,	  Chen	  SC,	  Arkin	  MR	  and	  Reiter	  JF.	  Small	  molecule	  inhibitors	  of	  Smoothened	  ciliary	  localization	  and	  ciliogenesis.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  USA.	  2012;	  109(34):13644-­‐13649.	  2.	   Avasthi	  P,	  Marley	  A,	  Lin	  H,	  Gregori-­‐Puigjane	  E,	  Shoichet	  BK,	  von	  Zastrow	  M	  and	  Marshall	  WF.	  A	  chemical	  screen	   identifies	   class	   a	   g-­‐protein	   coupled	   receptors	   as	   regulators	   of	   cilia.	   ACS	  Chemical	  Biology.	   2012;	  7(5):911-­‐919.	  3.	   Engel	  BD,	  Ishikawa	  H,	  Feldman	  JL,	  Wilson	  CW,	  Chuang	  PT,	  Snedecor	  J,	  Williams	  J,	  Sun	  Z	  and	  Marshall	  WF.	  A	  cell-­‐based	  screen	  for	  inhibitors	  of	  flagella-­‐driven	  motility	  in	  Chlamydomonas	  reveals	  a	  novel	  modulator	  of	  ciliary	  length	  and	  retrograde	  actin	  flow.	  Cytoskeleton	  (Hoboken).	  2011;	  68(3):188-­‐203.	  4.	   Weiss	   T,	   Gheber	   L,	   Shoshanbarmatz	   V	   and	   Priel	   Z.	   Possible	   Mechanism	   of	   Ciliary	   Stimulation	   by	  Extracellular	  Atp	  -­‐	  Involvement	  of	  Calcium-­‐Dependent	  Potassium	  Channels	  and	  Exogenous	  Ca2+.	  Journal	  of	  Membrane	  Biology.	  1992;	  127(3):185-­‐193.	  5.	   Masyuk	  AI,	  Gradilone	  SA,	  Banales	  JM,	  Huang	  BQ,	  Masyuk	  TV,	  Lee	  SO,	  Splinter	  PL,	  Stroope	  AJ	  and	  LaRusso	  NF.	  Cholangiocyte	  primary	  cilia	  are	  chemosensory	  organelles	  that	  detect	  biliary	  nucleotides	  via	  P2Y(12)	  purinergic	   receptors.	   American	   Journal	   of	   Physiology-­‐Gastrointestinal	   and	   Liver	   Physiology.	   2008;	  295(4):G725-­‐G734.	  6.	   Lieb	  T,	  Frei	  CW,	  Frohock	  JI,	  Bookman	  RJ	  and	  Salathe	  M.	  Prolonged	  increase	  in	  ciliary	  beat	  frequency	  after	  short-­‐term	  purinergic	  stimulation	   in	  human	  airway	  epithelial	  cells.	   Journal	  of	  Physiology-­‐London.	  2002;	  538(2):633-­‐646.	  7.	   Egeberg	   DL,	   Lethan	   M,	   Manguso	   R,	   Schneider	   L,	   Awan	   A,	   Jorgensen	   TS,	   Byskov	   AG,	   Pedersen	   LB	   and	  Christensen	  ST.	  Primary	  cilia	  and	  aberrant	  cell	  signaling	  in	  epithelial	  ovarian	  cancer.	  Cilia.	  2012;	  1(1):15.	  8.	   Buschhorn	   HM,	   Klein	   RR,	   Chambers	   SM,	   Hardy	   MC,	   Green	   S,	   Bearss	   D	   and	   Nagle	   RB.	   Aurora-­‐A	   over-­‐expression	  in	  high-­‐grade	  PIN	  lesions	  and	  prostate	  cancer.	  Prostate.	  2005;	  64(4):341-­‐346.	  9.	   White	   MC	   and	   Quarmby	   LM.	   The	   NIMA-­‐family	   kinase,	   Nek1	   affects	   the	   stability	   of	   centrosomes	   and	  ciliogenesis.	  BMC	  Cell	  Biology.	  2008;	  9:29.	  10.	   Cajanek	   L	   and	   Nigg	   EA.	   Cep164	   triggers	   ciliogenesis	   by	   recruiting	   Tau	   tubulin	   kinase	   2	   to	   the	  mother	  centriole.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  USA.	  2014;	  111(28):E2841-­‐2850.	  11.	   Xu	  Q,	  Zhang	  Y,	  Wei	  Q,	  Huang	  Y,	  Hu	  J	  and	  Ling	  K.	  Phosphatidylinositol	  phosphate	  kinase	  PIPKIgamma	  and	  phosphatase	  INPP5E	  coordinate	  initiation	  of	  ciliogenesis.	  Nature	  Communications.	  2016;	  7:10777.	  12.	   Toftgard	  R.	  Two	  sides	  to	  cilia	  in	  cancer.	  Nature	  Medicine.	  2009;	  15(9):994-­‐996.	  13.	   Gijs	  HL,	  Willemarck	  N,	  Vanderhoydonc	  F,	  Khan	  NA,	  Dehairs	  J,	  Derua	  R,	  Waelkens	  E,	  Taketomi	  Y,	  Murakami	  M,	  Agostinis	  P,	  Annaert	  W	  and	  Swinnen	  JV.	  Primary	  cilium	  suppression	  by	  SREBP1c	  involves	  distortion	  of	  vesicular	  trafficking	  by	  PLA2G3.	  Molecular	  Biology	  of	  the	  Cell.	  2015;	  26(12):2321-­‐2332.	  14.	   Norris	   DP	   and	   Grimes	   DT.	   Mouse	   models	   of	   ciliopathies:	   the	   state	   of	   the	   art.	   Dis	   Model	   Mech.	   2012;	  5(3):299-­‐312.	  
	   149	  




































































	   151	  
Summary	  	  	   In	  this	  doctoral	  thesis	  project	  we	  have	  aimed	  to	  identify	  small	  molecules	  that	  modulate	  the	   formation	  of	   the	  primary	  cilium.	  This	   is	   a	  microtubule-­‐based	  cellular	  antenna	   that	  protrudes	   from	   many	   mammalian	   and	   human	   cells	   and	   that	   is	   distorted	   in	   many	  diseases,	   including	   so-­‐called	   ciliopathies	   but	   also	   in	  more	   common	   conditions	   such	   as	  cancer.	   To	   this	   end	   we	   have	   developed	   a	   microscopy-­‐based	   semi-­‐high	   throughput	  screening	  method	   and	   have	   used	   it	   to	   screen	   three	   chemical	   libraries:	   a	   repurposing	  library	   of	   FDA-­‐approved	   drugs,	   a	   library	   of	   kinase	   inhibitors	   and	   a	   library	   of	   novel	  compounds.	  Altogether	  we	  have	  identified	  more	  than	  100	  known	  and	  novel	  compounds	  that	   act	   either	   as	   enhancers	   or	   suppressors	   of	   ciliogenesis.	   Among	   the	   identified	  compounds	  are	  commonly	  used	  drugs	  including	  glucocorticoids,	  ion	  channel	  modulators	  and	   kinase	   inhibitors.	   Several	   of	   these	   compounds	   have	   the	   ability	   to	   normalize	   or	  modulate	   the	   primary	   cilium	   in	   various	   cancer	   models	   and	   to	   attenuate	   cancer	   cell	  proliferation.	  Some	  of	  these	  compounds	  also	  normalize	  the	  cilium	  in	  a	  ciliopathy	  model.	  These	   compounds	  may	   act	   through	  multiple	  mechanisms	   including	   the	   secreted	   ATP-­‐purinergic	   signaling	   axis	   and	   the	  modulation	   of	   intracellular	   vesicle	   trafficking.	   These	  findings	  are	  among	  the	  first	  on	  the	  identification	  and	  use	  of	  pharmacological	  compounds	  to	  modulate	  cilia	   in	  cells	   in	  a	  diseased	  context	  and	  provide	  a	   framework	  for	  the	  future	  development	  of	  novel	  cilium-­‐targeting	  therapies	  for	  cancer	  and	  ciliopathies.	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Samenvatting	  	  In	   de	   hier	   voorliggende	   doctoraatsthesis	   hebben	   we	   tot	   doel	   gesteld	   om	   chemische	  moleculen	  te	  identificeren	  die	  de	  vorming	  moduleren	  van	  het	  primaire	  cilium.	  Dit	  is	  een	  microtubule-­‐gebaseerde	   cellulaire	   antenne	   die	   uitsteekt	   vanaf	   het	   oppervlak	   van	   vele	  zoogdier-­‐	   en	   humane	   cellen	   en	   die	   verstoord	   is	   in	   heel	  wat	   aandoeningen	   gekend	   als	  ciliopathieën,	  maar	  ook	  in	  meer	  voorkomende	  ziektes	  zoals	  kanker.	  Hiertoe	  hebben	  we	  een	   op	   microscopie	   gebaseerde	   semi-­‐hoge	   doorvoer	   screeningsmethode	   ontwikkeld,	  waarmee	   we	   drie	   chemische	   bibliotheken	   gescreend	   hebben:	   een	   ‘repurposing’	  bibliotheek	  van	  FDA-­‐erkende	  geneesmiddelen,	  een	  bibliotheek	  van	  kinase	  inhibitoren	  en	  een	  bibliotheek	  van	  nieuwe	  chemische	  stoffen.	  Alles	  tezamen	  hebben	  we	  meer	  dan	  100	  gekende	  en	  nieuwe	  chemische	  moleculen	  geïdentificeerd	  die	  werken	  als	  promotoren	  of	  inhibitoren	   van	   de	   ciliogenese.	   Onder	   de	   geïdentificeerde	   moleculen	   bevinden	   zich	  veelgebruikte	   geneesmiddelen	   zoals	   glucocorticoïden,	   modulatoren	   van	   ionenkanalen	  en	  kinase-­‐inhibitoren.	  Verscheidene	  van	  deze	  moleculen	  zijn	  in	  staat	  het	  primaire	  cilium	  te	  normaliseren	  of	  te	  moduleren	  in	  verschillende	  kankermodellen	  en	  hun	  celproliferatie	  te	   remmen.	   Sommige	   van	   deze	   stoffen	   nomaliseren	   ook	   het	   cilium	   in	   een	  ciliopathiemodel.	   Deze	  moleculen	   werken	   via	   verschillende	  mechanismen,	   waaronder	  de	   gesecreteerde	   ATP-­‐purinergische	   signaaltransductieweg	   en	   de	   modulatie	   van	   het	  intracellulaire	   vesikelverkeer.	   Deze	   bevindingen	   zijn	   één	   van	   de	   eerste	  wat	   betreft	   de	  identificatie	   en	   het	   gebruik	   van	   farmacologische	   middelen	   om	   cilia	   te	   moduleren	   in	  cellen	  in	  een	  ziektetoestand	  en	  vormen	  het	  kader	  voor	  de	  toekomstige	  ontwikkeling	  van	  nieuwe	  op	  het	  cilium	  gerichte	  therapieën	  voor	  kanker	  en	  ciliopathieën.	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SUMMARY	  
	  11	  years	  of	  research	  and	  development	  (R&D)	  experience	  in	  the	  biotech	  industry	  and	  academia	  with	  a	  proven	  record	  of	  successful	  handling	  of	  complex	  and	  diverse	  projects.	  	  
	  
WORK	  EXPERIENCE	  	  
• May	  2010	  –	  September	  2016:	   	  Doctoral	  researcher	  in	  the	  Laboratory	  of	  Lipid	  Metabolism	   and	   Cancer,	   Dept.	   of	   Oncology,	   Faculty	   of	   Medicine,	   KU	   Leuven,	  Belgium.	  	  
• December	   2009	   -­‐	   May	   2010:	   Doctoral	   researcher	   in	   the	   Laboratory	   of	  Experimental	   Radiotherapy,	   Dept.	   of	   Oncology,	   Faculty	   of	   Medicine,	   KU	  Leuven,	  Belgium.	  	  




• Biomarker	  and	  small	  molecule	  drug	  discovery	  for	  cancers.	  
• High-­‐throughput	  screening	  of	  chemical	  compound	  libraries.	  
• Construction	  and	  serological	  screening	  of	  cDNA	  libraries.	  
• SAR	  (Structure-­‐Activity	  Relationship)	  assays	  and	  studies.	  
• Drug	  dose	  response	  assays.	  
• Development	  and	  optimization	  of	  cell-­‐based	  functional	  assays.	  
• Cell	  culture,	  molecular	  biology	  and	  microbiology	  techniques.	  
• siRNA	  knock-­‐down	  assays.	  
• Immunofluorescence	  techniques	  and	  confocal	  microscopy.	  
• Production	  of	  anti-­‐cancer	  monoclonal	  antibodies	  from	  transfected	  mammalian	  CHO	  cell-­‐lines	  by	  suspension	  cell	  fermentation	  technology.	  
• High	   Density	   Fermentation	   and	   Downstream	   Processing	   of	   genetically	  engineered	   Pichia	   pastoris	   and	   E.coli	   designed	   to	   produce	   therapeutic	  recombinant	  proteins.	  
• Pilot	   scale	   production	   of	   capsular	   polysaccharides	   by	   fermentation	   of	  Streptococcus	  pneumoniae	  in	  bioreactors.	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• Process	   development	   of	   vaccines	   against	   infectious	   bacterial	   and	   viral	  diseases.	  
• Direct	   and	   Indirect	   ELISA	   tests	   (to	   measure	   antigen	   content	   in	   vaccine	   test	  samples	  /	  IgG	  antibody	  concentration	  in	  serum	  samples).	  
	  
	  
PROJECTS	  HANDLED	  	  
In	  the	  Laboratory	  of	  Lipid	  Metabolism	  and	  Cancer,	  Department	  of	  Oncology,	  KU	  
Leuven:	  
	  
• Screened	   a	   repurposing	   library	  of	   1600	  FDA-­‐approved	  drugs.	   This	  work	  has	  led	   to	   the	   development	   and	   optimization	   of	   a	   screening	   method	   to	   identify	  cilia-­‐inducing	  compounds.	  Using	  this	  method,	  different	  classes	  of	  cilia	  inducers	  have	  been	   identified	  which	  might	  serve	  as	  potential	  drugs	  against	  pancreatic	  and	   other	   types	   of	   cancers.	   This	   research	   has	   been	   published	   in	   the	   journal	  'Oncotarget'.	  	  
• Screened	  a	  library	  of	  4500	  small	  molecules.	  This	  led	  to	  the	  identification	  of	  8	  novel	   ciliogenic	   compounds	   and	   several	   cilia	   inhibitors,	   which	   are	   potential	  candidates	  for	  the	  development	  of	  cancer	  therapeutics.	  	  	  
• Screened	  a	  library	  of	  160	  kinase	  inhibitors	  to	  study	  the	  effect	  on	  cilia	  induction	  in	   cancer	   cells.	  This	  work	  has	   led	   to	   the	   identification	  of	   several	   compounds	  that	  are	  effective	  against	  glioblastomas.	  	  	  
	  
	  
In	  the	  R&D	  department	  of	  Shantha	  Biotech,	  Hyderabad,	  India:	  	  
• Worked	   on	   Oral	   Cancer	   Project,	   which	   involved	   construction	   of	   oral	   tumor	  cDNA	   library	   and	   serological	   screening	   for	   novel	   antigens	   by	   SEREX	  technology.	  This	  work	  resulted	  in	  the	  identification	  of	  several	  proteins	  that	  are	  being	  evaluated	  for	  their	  utility	  as	  biomarkers	  to	  develop	  a	  diagnostic	  method	  for	  oral	  cancer.	  	  
• Worked	  on	  the	  Process	  Development	  of	  a	  multivalent	  pneumococcal	  capsular	  polysaccharide	   conjugate	   vaccine.	   This	   work	   involved	   the	   designing	   of	  experiments	   to	   isolate	   the	   antigenic	   polysaccharides	   from	   the	   capsules	   of	  Streptococcus	   pneumoniae	   and	   to	   conjugate	   toxoids	   to	   the	   isolated	  polysaccharides.	  	  
• Produced	   therapeutic	   recombinant	   proteins	   HBsAg	   (Hepatitis	   B	   surface	  antigen),	  HPV16L1	  (Human	  Papilloma	  Virus	  Antigen),	  tPA	  (tissue	  Plasminogen	  Activator),	  GCSF	  (Granulocyte	  Colony	  Stimulating	  Factor),	  by	   fermentation	  of	  genetically	  engineered	  bacteria	  and	  yeast	  in	  fermenters	  on	  a	  pilot	  scale.	  	  
• Involved	   in	   the	   production	   of	   anti-­‐cancer	   monoclonal	   antibodies	   from	  transfected	  CHO	  cell	  lines	  by	  fermentation	  technology.	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EDUCATIONAL	  QUALIFICATIONS	  	  
• Ph.D.	  in	  Biomedical	  Sciences,	  KU	  Leuven,	  Leuven,	  Belgium	  (2016).	  	  
• M.Sc.	  in	  Bioinformatics,	  Annamalai	  University,	  Tamil	  Nadu,	  India	  (2005)	  	  
• M.Sc.	  in	  Microbiology,	  Sri	  Krishnadevaraya	  University,	  A.P.,	  India	  (2003).	  	  
• B.Sc.	  in	  Microbiology,	  Sri	  Krishnadevaraya	  University,	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  India	  (2001).	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
PUBLICATIONS	  	  
• Identification	  of	  drugs	  that	  restore	  primary	  cilium	  expression	  in	  cancer	  cells	  -­‐	  
Khan	  NA,	  Willemarck	  N,	  Talebi	  A,	  Marchand	  A,	  Binda	  MM,	  Dehairs	   J,	  Rueda-­‐Rincon	  N,	  Daniels	  VW,	  Bagadi	  M,	  Raj	  DB,	  Vanderhoydonc	  F,	  Munck	  S,	  Chaltin	  P	  and	  Swinnen	  JV.	  (Oncotarget,	  February	  2016).	  	  
• Primary	   cilium	   suppression	   by	   SREBP1c	   involves	   distortion	   of	   vesicular	  trafficking	   by	   PLA2G3	   -­‐	   Gijs	  HL,	  Willemarck	  N,	   Vanderhoydonc	   F,	  Khan	   NA,	  Dehairs	  J,	  Derua	  R,	  Waelkens	  E,	  Taketomi	  Y,	  Murakami	  M,	  Agostinis	  P,	  Annaert	  W,	  Swinnen	  JV.	  (Molecular	  Biology	  of	  the	  Cell,	  June	  2015).	  	  
• p53	   attenuates	   AKT	   signaling	   by	   modulating	   membrane	   phospholipid	  composition	   -­‐	   Rueda-­‐Rincon	   N,	   Bloch	   K,	   Derua	   R,	   Vyas	   R,	   Harms	   A,	  Hankemeier	  T,	  Khan	  NA,	  Dehairs	  J,	  Bagadi	  M,	  Binda	  MM,	  Waelkens	  E,	  Marine	  JC,	  Swinnen	  JV.	  (Oncotarget,	  August	  2015).	  	  
• Drug-­‐induced	   ciliogenesis	   in	   pancreatic	   cancer	   cells	   is	   facilitated	   by	   the	  secreted	   ATP-­‐purinergic	   receptor	   signaling	   pathway	   -­‐	   Khan	   NA,	   Garg	   AD,	  Agostinis	  P,	  Swinnen	  JV.	  (Submitted).	  
	  
	  
POSTERS	  PRESENTED	  	  
• 'p53	   attenuates	   AKT	   signaling	   by	   modulating	   membrane	   phospholipid	  composition'	  presented	  at	  VIB	  conference	  "Metabolism	  in	  Cancer	  and	  Stromal	  Cells"	  held	  in	  Leuven	  (Belgium)	  in	  September	  2015.	  	  
• 'Identification	   of	   Ciliogenic	   Compounds	   using	   Pancreatic	   Cancer	   Cells	   as	   a	  Screening	  Model'	  presented	  at	  "Cilia	  2014"	  conference	  held	  at	  Institute	  Louis	  Pasteur,	  Paris	  (France)	  in	  November	  2014.	  	  
• 'p53	   regulates	   Akt/PKB	   signaling	   through	   stearoyl-­‐CoA	   desaturase	   (SCD1)-­‐mediated	   changes	   in	   membrane	   phospholipids'	   presented	   at	   Keystone	  Symposia	   "Tumor	   Metabolism"	   held	   in	   British	   Columbia	   (Canada)	   in	   March	  2014.	  	  
• 'Modulation	   of	   cancer	   membrane	   phospholipid	   composition	   by	   p53'	  	  presented	   at	   the	   conference	   "Cancer	   and	   Metabolism	   2013"	   held	   in	  Amsterdam	  (Netherlands)	  in	  June	  2013.	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• 'Superparamagnetic	   nanoparticles	   for	   targeted	   plasma	   membrane	   OMICS'	  presented	  at	  "Beatson	  International	  Cancer	  Conference	  -­‐	  Membrane	  Dynamics	  in	  Cancer	  2012"	  held	  in	  Glasgow,	  Scotland	  (UK)	  in	  July	  2012.	  	  	  
CONFERENCES	  ATTENDED	  	  
• "Cilia	   2014"	   organized	   at	   Institute	   Louis	   Pasteur,	   Paris,	   France	   in	  November	  2014.	  	  
• "Oncoforum	  2013"	   organized	   by	   Leuven	  Cancer	   Institute	   (LKI)	   and	  Doctoral	  School	  of	  Cancer,	  KU	  Leuven,	  Leuven,	  Belgium	  in	  May	  2013.	  	  
• "Cilia	  2012"	  organized	  by	  Ciliopathy	  Alliance	  at	   the	   Institute	  of	  Child	  Health,	  UCL,	  London,	  UK	  in	  May	  2012.	  	  
• "Entrepreneurship	  in	  Life	  Sciences"	  workshop	  organized	  by	  Flanders	  Institute	  of	  Biotechnology	  (VIB)	  and	  Vrije	  Universiteit	  Brussel	  (VUB)	  at	  Brussels	  in	  May	  2012.	  	  	  
MEMBERSHIPS	  AND	  AWARDS	  
	  
• Life	  Member	  of	  Association	  of	  Microbiologists	  of	  India	  (AMI).	  	  
• 2009	  -­‐2011:	  KU	  Leuven	  Ph.D.	  scholarship.	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